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Viral infection results in activation of the innate immune response that culminates in the 
production of the interferons and the establishment of an antiviral state through the 
expression of hundreds of interferon stimulated genes (ISGs). One such ISG is Viperin 
(RSAD2) that has broad antiviral activity against a range of RNA and DNA viruses. 
Previous work has established that viperin is antiviral against the hepatitis C virus, 
however the molecular mechanism(s) that underpin this antiviral activity are not well 
understood. It is thought that viperin interacts with the HCV NS5A protein and the host 
pro-viral host factor VAP-A within the HCV replication complex, although this has not 
formally been proven. Thus the main objective of this thesis was to investigate the 
localisation of viperin to the HCV replication complex at the cellular level and to identify 
additional viperin cellular interacting partners in the hope that we can further understand 
the biology of this enigmatic protein. 
 
We therefore used a cell biology approach to visualise viperin at or within the HCV 
replication complex. Expression of viperin tagged to the electron microscopy (EM) tag 
(APEX2) allowed us to precisely determine the localisation of viperin at the 
ultrastructural level by EM. We identified that in the presence of exogenous HCV non-
structural protein expression (and hence RC formation), viperin alters the formation of 
convoluted membranes that in-turn could have an impact on the establishment of 




In addition to viperin binding the HCV NS5A protein, it can also bind to host proteins 
(FPPS, VAP-A, TRAF6, and IRAK1) to modulate cellular function such as lipid 
metabolism and innate immune signalling. We hypothesised that viperin exerts such a 
diverse range of functions through interaction with as yet unidentified cellular proteins 
and we employed a yeast two-hybrid screen to identify novel interacting partners. The 
peroxisomal biogenesis factor 19 (PEX19) was identified as a genuine viperin interaction 
partner and furthermore showed that expression of viperin not only co-localised with 
peroxisomes but redirected them to a perinuclear localisation and association with lipid 
droplets. The reason for this is not immediately clear, however peroxisomes have recently 
been shown to be a scaffold for the innate immune adaptor molecule MAVS and are now 
recognised as important organelles in activation of the host cellular response to viral 
infection. Using a combination of deconvolution and super-resolution microscopy and 
EM using APEX2 tagged viperin we show that viperin localises to the LD in association 
with peroxisomes and the mitochondria. It is, therefore, possible that viperin may direct 
MAVS+ve peroxisomes to sites of innate immune signalling. Consistent with this 
hypothesis we have shown that viperin augments IFN- production for MAVS localised 
selectively on both mitochondria and the peroxisome, but not for each organelle 
individually. This implies that viperin may act as linker molecule for MAVS signalling 
from both organelles. 
 
In conclusion, we propose that viperin localises within the HCV replication complex to 
impart its antiviral effect. Furthermore, viperin interacts with PEX19 and recruits 




restrict viral infection. The work of this thesis contributes our understanding of the host-
virus relationship in control of HCV and the possibility of the development of innate 
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Abbreviation or symbol Term 
 g Acceleration gravity 





aa  Amino acids 
ATP  Adenosine triphosphate 
bp Base pair(s) 
BSA  Bovine serum albumin 
C Cytosine 
cDNA Complementary deoxyribonucleic acid 
CHC  Chronic hepatitis C 
CLDN Claudin 
CMV Cytomegalovirus  
DAA  Direct acting antiviral 
DAPI  4’, 6-Diamidino-2-pheylinodole 
dATP Deoxyadenosine triphosphate 
dCTP Deoxycytosine tripshosphate 
DDW Deionized distilled water 
DEPC Diethyl pyrocarbonate 
dGTP Deoxyguanosine triphosphate 
dH2O  Deionised water 
DMEM Dulbecco’s Modified Eagle Medium with HEPES 
DMSO  Dimethyl sulfoxide 
DMV  Double-membrane vesicle 




dNTP Deoxynucleotide triphosphate 
dsRNA  Double stranded RNA 
DTT  Dithiothreitol  
dTTP Deoxythymidine triphosphate 
EMCV  Encephalomyocarditis virus 
EDTA  Ethylenediamine tetraacetic acid 
ER  Endoplasmic reticulum 
FACS  Fluorescence-activated cell sorting 
FCS  Foetal calf serum 
FDA  Food and Drug Administration 
ffu  Focus forming units 
G Guanosine 
g Gram(s) 
GAG  Glycosaminoglycan 
GFP  Green fluorescent protein 
HCC  Hepatocellular carcinoma 
HCMV Human cytomegalovirus 
HCV  Hepatitis C virus 
HCVcc  Cell-culture propagated hepatitis C virus 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV  Human immunodeficiency virus 
hr Hour(s) 
HRP  Horse radish peroxidase 
Huh  Human hepatoma 
IFN- Interferon gamma 
IFN-α  Interferon alpha  
IFN-β Interferon beta 
IFN-λ Interferon lambda 
Ig Immunoglobulin(s) 
IRES  Internal ribosome entry site 




JAK Janus kinase 
kb  Kilobase 
kDa Kilodalton(s) 
kg(s) Kilogram(s) 
KO Knock out 
L-Agar LB + agar 
LB  Luria Bertani broth 
LD  Lipid droplet 
LDL  Low density lipoproteins 
LDLR  Low density lipoprotein receptor 
Luc  Luciferase 
LVP  Lipoviral particle 
M Mole 
mA Milliampere(s) 
MAVS Mitochondrial antiviral-signalling protein 
MCS  multiple cloning site 





MMV  Multi-membrane vesicle 
MOI  Multiplicity of infection 
mRNA Messenger ribonucleic acid 
MW  Molecular weight 
N/A Not applicable 
NANBH  Nnon-A, non-B hepatitis 
ng Nanogram(s) 
nM Nanomolar 
NPC1L1  Niemann-Pick C1 like 1 




nt (s) Nucleotide (s) 
OCLN  Occludin 
OD  Optical density 
ORF  Open reading frame 
OSBP Oxysterol-binding protein  
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PEG  Polyethylene glycol 
pg Picograms 
pH Negative logarithm of hydrogen ion activity 
PI4KIIIα  Phosphatidylinositol 4-kinase III alpha 
PI4P  Phosphatidylinositol 4-phosphate 
pmol Picomolar 
RC  Replication complex 
RdRp  RNA-dependent RNA polymerase 
RNA  Ribonucleic acid 
RNase Ribonuclease 
rpm  Revolutions per minute 
RT  Room temperature 
RT-PCR  Reverse transcriptase polymerase chain reaction 
SDS Sodium dodecyl sulfate 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
sec Second(s) 
SMV  Single-membrane vesicle 
SOC  Super optimal broth with catabolite repression 
SRB1  Scavenger receptor class B1 
ss Single stranded 
STAT Signal transducer and activator of transcription  





TAE  Tris, acetic acid, EDTA (TAE) buffer 
TBEV  Tick-borne encephalitis virus 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TYK2 Tyrosine kinase 2 
U/l Unit(s) per microliter 
UTR Untranslated region 
UV  Ultraviolet 
V  Volt(s) 
v/v  Volume per volume 
VAPA  Vesicle-associated membrane protein-associated 
protein A 
VLDL  Very low density lipoprotein 
w/v Weight per volume 
WHO  World Health Organization 
WT  Wild-type 









1.1 Hepatitis C Virus 
1.1.1 Discovery and Epidemiology 
Hepatitis C Virus (HCV) infection is a leading cause of acute and chronic liver disease 
worldwide. HCV was first categorised as non-A and non-B hepatitis virus (NANBH) 
(Feinstone et al., 1975) until the viral genome was isolated using molecular methods from 
NANBH plasma in 1989 (Choo et al., 1989). It is estimated that over 170 million people 
worldwide are infected with HCV (Organisation, 2014, Thomas, 2013). One of the major 
problems of HCV-infected patients is that approximately 80% of infected individuals will 
develop progressive chronic liver diseases such as fibrosis, liver cirrhosis, hepatic failure 
and/or hepatocellular carcinoma (Zhong et al., 2005). The World Health Organisation 
(WHO), estimates about 500,000 people die from HCV-related liver disease every year. 
In Australia, the prevalence of HCV infection has been estimated at 264,000 individuals 
and it is the most common cause of clinically significant liver disease (Razali et al., 2009, 
Razali et al., 2007). Approximately 8,000 new cases of HCV infection emerge each year 
(Razavi et al., 2014) resulting in increasing numbers of individuals with HCV-related 
chronic liver disease, which places a significant burden on the public health system 






HCV is a blood-borne virus and prior to 1992, the most common transmission route was 
blood transfusion or organ transplantation. However, the improvement of screening 
techniques in blood banks in 1992, effectively eliminated HCV infection via this route, 
although this type of transmission remains in developing countries due to the limitation 
of screening methods, un-screened blood components, or other inappropriate medical 
procedures (Sievert et al., 2011). Injecting drug use (IDU) with needle and syringe 
sharing is the major mode of transmission of HCV in developed countries. Other modes 
of HCV transmission include tattooing, piercing, sexual intercourse or vertical 
transmission from mother to baby, although the latter two are rare (Thomas, 2013, Dore 
et al., 2003, Mohan et al., 2010). 
 
1.1.3 Pathogenesis 
HCV is a noncytopathic virus, and therefore liver disease, particularly in the chronic liver 
phase is a result of both innate and adaptive immune responses to HCV infected 
hepatocytes such as immune-mediated cytolysis. The hepatocyte is the primary and main 
target of HCV replication. However, HCV infection is not restricted to hepatocytes as 
HCV RNA has been reported in a small percentage of different cell types including 
mononuclear cells such as macrophages, monocytes, dendritic cells (Goutagny et al., 
2003, Bouffard et al., 1992, Bain et al., 2001), B-cells (Sung et al., 2003), and gastric 
mucosa-associated lymphoid tissue (Tursi et al., 2002). The role of HCV replication at 





Acute HCV infection in most individuals often goes unrecognised as symptoms are 
usually absent or result in mild illness. Following acute infection, 20% of individuals 
successfully eliminate the virus, whereas the remaining 80% of patients will fail to 
develop an effective host antiviral response and subsequently will develop a chronic 
lifelong infection. Of those individuals who develop chronic infection, approximately 
20% will have progressive liver disease over a period of 25-30 years (Figure 1.1) 
(Freeman et al., 2001), culminating in liver cirrhosis, with 2% of individuals progressing 
to hepatocellular carcinoma (HCC) (Alter, 1995). The host immune response to HCV 
infection results in chronic hepatic inflammation including liver fibrosis and cirrhosis. 
Cirrhosis is the most progressive form of liver disease which occurs after long-term 
damage of the liver and is characterised by the replacement of normal liver tissue by 
extensive scarring. Alcohol consumption and co-infection with other viruses such as 
human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are co-factors which 
impact the rate of progression to advanced liver disease. 
 
1.1.4 Treatment 
Initial treatment for chronic hepatitis (CHC) was interferon- (IFN-) which became 
available in 1991; however response rates were poor with only 10-20% of individuals 
clearing the virus. IFN- is a cytokine which is able to induce an antiviral response. 
Using IFN- in combination with the guanine nucleotide analogue ribavirin improved the 
response rates to 40% (Foster, 2010). HCV treatment was revolutionised in 2001 by the 











enhanced the half-life of IFN-α and resulted in increased antiviral activity (Glue et al., 
2000). With a combination of PegIFN-α and ribavirin, a sustained virologic response 
(SVR, defined as undetectable HCV RNA in serum 6 months post-treatment) increased to 
an average of 40-50% in genotype 1 and 75-85% for genotype 2 and 3 infection (Manns 
et al., 2001, Fried et al., 2002, Hadziyannis et al., 2004). Such SVRs remain 
unsatisfactory especially in genotype 1 infected-individuals, which represents the most 
widely distributed genotype worldwide (Le Guillou-Guillemette et al., 2007). Another 
complicating factor for treatment decision is interleukin 28B (IL28B) genetic 
polymorphisms that are associated with HCV genotype 1. Genome-wide association 
studies (GWAS) identified IL28B polymorphism (on chromosome 19) as the most 
important factor in predicting interferon-based treatment response in HCV genotype 1 
(Ge et al., 2009, Tanaka et al., 2009, Rauch et al., 2010). The favourable homozygous 
SNP rs12979860 (C/C genotype) is also associated with higher spontaneous HCV 
clearance rates (Ge et al., 2009, Thomas et al., 2009).  
  
Interferon-based therapy is usually administered as a response-guided therapy for 24- or 
48- weeks depending on viral loads, genotypes, IL28B polymorphism and 
presence/absence of cirrhosis. Such prolonged therapy is associated with numerous side 
effects such as flu-like symptoms, fatigue, insomnia, rash, anorexia, weight loss and 
haemolytic anaemia (Feld and Hoofnagle, 2005, Sharma, 2010). However, most the 
concerning side effects of all are liver decompensation and significant depression leading 
to suicides, thus excluding many patients from treatment. Complicating this, SVRs can be 




resistance, obesity, heavy alcohol consumption and HIV co-infection (Thomas, 2013). 
These limitations redirected researchers to focus on the development of second 
generation anti-HCV drugs known as the direct-acting antivirals (DAAs).  
 
Direct-acting antiviral (DAAs) compounds are able to directly interfere with specific 
HCV viral proteins, thus arresting the viral life cycle (Gao et al., 2010, Jensen, 2011, 
Targett-Adams et al., 2011). The first generation DAAs approved by the US Food and 
Drug Administration (FDA) in 2011 were NS3/4A serine protease inhibitors [Boceprevir 
(Merck) and Telaprevir (Vertex Pharmaceuticals/ Johnson-Johnson)] for treatment of 
HCV genotype 1. These DAAs still require combination with pegylated IFN-α and 
ribavirin to yield satisfactory response (SVR rates to 70-80%) (Marks and Jacobson, 
2012) with lower SVRs reported from treatment-experienced or cirrhotic patients. IFN-α 
remains a key component owing to the development of antiviral resistance to DAAs 
when used in monotherapy (Aloia et al., 2012, Calle Serrano and Manns, 2012). Arrival 
of the NS5B polymerase inhibitor (Sofosbuvir, Gilead Sciences) and the second 
generation NS3-4A protease inhibitors (Simeprevir, Johnson & Johnson) in combination 
with pegylated IFN-α and ribavirin has significantly improved the SVRs for HCV 
genotype 1 (Keating, 2015) but has also seen HCV genotype 2 as the most resistant 
genotype to DAAs. To avoid the complications of interferon-based therapy, Sofosbuvir 
has now been used in combination with other NS5A inhibitors such as Ledipasvir 
(Harvoni), Daclatasvir and Velpatasvir (Epclusa). These DAAs have completely changed 
the landscape of HCV treatment, particularly with Epclusa, showing excellent pan-




very low level of drug resistance. The focus has now been shifted to improve the 
response rates in traditionally difficult to treat patients such as HIV co-infected and 
cirrhotic patients, with various combinations such as PrOD (Paritaprevir/ ritonavir/ 
ombitasvir/ dasabuvir) and elbasvir/grazoprevir (Zepatier). 
 
1.1.5 Classification and genotypes  
HCV is in the genus Hepacivirus, family Flaviviridae. The virus has now been classified 
into seven major genotypes (genotype 1-7) with numerous subtypes based on the 
phylogeny and the similarity of nucleotide sequence of the viral genome. The genotypes 
differ in nucleotide sequence by 30-35% from each other and subtypes differ from others 
by 15-25% (Simmonds et al., 2005, Smith et al., 2014). A worldwide distribution of HCV 
genotypes varies in geographical area (Figure 1.2). Genotypes 1-3, particularly 1a, 1b, 2a 
and 3a are widely distributed across the world including Australia (Dore et al., 2003). 
While genotypes 4-6 are mainly endemic to specific areas in Central Africa, the Middle 
East, South Africa and Asia (Bowden and Berzsenyi, 2006). HCV genetic diversity 
across the world has likely been influenced by historical and human migration. 
 
1.1.6 HCV genome and proteins 
HCV genome: HCV is a small-enveloped virus with a single-stranded, positive-sense 
RNA genome and as mentioned previously is a Hepacivirus within the Flaviviridae 
family. The HCV genome size is approximately 9.6 kb and comprises of a single open 











and is flanked by two highly conserved untranslated regions (5’UTR and 3’UTR) (Figure 
1.3) (Moradpour et al., 2007). The monocistronic plus-sense RNA genome of HCV is 
translated into a single polyprotein by host translational machinery using the HCV 
internal ribosomal entry site (IRES) in the 5’ UTR. The 5’ UTR contains 341 nucleotides; 
four highly structured domains and the internal ribosomal entry site (IRES) which 
controls the translation of the open reading frame into a single polyprotein. The IRES 
element mediates cap-independent translation initiation of HCV RNA by binding to the 
40s ribosomal subunit to form a stable pre-initiation complex. The 3’ UTR 
(approximately 225 nucleotides) which is essential for viral replication consists of three 
main regions including a variable region, a long polyuridine region (polyU/UC) and a 
highly conserved X region (Niepmann, 2013, Suzuki et al., 2007).  
 
The polyprotein is post-translationally processed by host cellular and viral proteases to 
produce 10 viral proteins: 3 structural proteins (core, envelope glycoproteins E1 and E2), 
a transmembrane protein belonging to the virioporin family (p7), and 6 non-structural 
proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) (Sharma, 2010, Sklan et al., 2009, 
Moradpour et al., 2007). A short summary of the function of HCV proteins is provided 
below. 
 
Core: The HCV core protein which forms the viral capsid is present in various sizes (17 
to 23 kDa) but the predominant form is the 21kDa form (Yasui et al., 1998). It is located 







Figure 1.3: HCV genome organisation and polyprotein processing. 
HCV is a 9.6 kb positive-strand RNA genome and consists of core and envelope glycoproteins E1 and E2; a transmembrane protein 
(p7); and non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B). The UTR at the 5' and 3' ends of the RNA are 
important to translation and replication of the viral RNA. Red arrowheads indicate cleavage sites of the HCV polyprotein precursor by 
signal peptidase. Pink arrowhead indicates C-terminal processing of the core protein by signal peptide peptidase. Diamonds represent 




signal peptidase (McLauchlan et al., 2002). It contains three distinct domains: an N-
terminal hydrophilic domain, a C-terminal hydrophobic domain and a signal peptide for 
targeting the nascent HCV polyprotein to the endoplasmic reticulum (ER) and bringing 
the translocation of E1 to the ER lumen (Lo et al., 1995). The immature form of the core 
protein (p23) is processed by an intramembrane protease and the signal peptide peptidase 
(SPP) to be mature form of the core protein (p21) (Weihofen et al., 2002, McLauchlan et 
al., 2002). The mature core protein (p21) is responsible for viral nucleocapsid formation 
and subsequently viral RNA packaging (Yasui et al., 1998). Moreover, it has been shown 
to associate with the lipid droplet after releasing from the ER membrane (McLauchlan et 
al., 2002, Boulant et al., 2006, Miyanari et al., 2007). Additionally, it has been shown to 
impact HCV pathogenesis by promoting the formation of lipid droplets which may 
enhance steatosis formation and possibly the development of HCC (Barba et al., 1997, 
Moriya et al., 1997, Moriya et al., 1998, Asselah et al., 2006). 
 
Envelope glycoproteins E1/E2: Both envelope proteins (E1 and E2) are highly 
glycosylated transmembrane proteins. E1 and E2 (30-35 kDa and 70-75 kDa, 
respectively) form non-covalent heterodimers which is the major integral component of 
the viral envelope (Goffard and Dubuisson, 2003). The E1 and E2 complex/heterodimer 
facilitates the attachment of the HCV virion to cell receptors which are necessary for 
HCV entry and fusion (Hsu et al., 2003, Moradpour et al., 2007, Suzuki et al., 2007).  
 
p7: p7 is a small polypeptide (63 amino acids) which is an integral membrane protein and 




connected by a cytoplasmic loop (Carrere-Kremer et al., 2002). It belongs to the 
viroporin family and has been documented to act as a cation channel which allows 
calcium ion flow from the ER into the cytoplasm (Griffin et al., 2003, Pavlovic et al., 
2003). The role of p7 in the virus life cycle is not well understood, but it is not required 
for viral replication (Jones et al., 2007, Steinmann et al., 2007). It has shown to be 
essential for infectivity (Sakai et al., 2003) and involved in viral particle assembly and 
release (Gentzsch et al., 2013). Although most of the researches up to date highlight the 
role of p7 in viral assembly and release, the molecular mechanism of p7 in the HCV life 
cycle is uncertain and remains to be clarified.  
 
NS2: NS2 (23 kDa) localises to the ER and contains cysteine autoprotease activity 
(Grakoui et al., 1993, Hijikata et al., 1993, Lorenz et al., 2006) which is located at the C-
terminal domain and cleaves NS2 from NS3 (Selby et al., 1994). It is dispensable for 
RNA replication and plays a central part but undefined role in viral particle assembly and 
possibly egress (Jirasko et al., 2008, Jones et al., 2007). It is demonstrated that NS2 
interacts with structural and non-structural proteins; E1, E2, p7, NS3 and NS5A and 
directs envelope proteins to lipid droplets which are the site of viral assembly (Popescu et 
al., 2011a). 
 
NS3/4A complex: NS3 is a multifunctional protein and contains seine protease activity at 
its N-terminus and a helicase/NTPase activity at the C-terminal domain (Yao et al., 
1999). The serine protease of NS3 is essential for HCV polyprotein cleavage of the 




and NS5A/NS5B. NS4A which forms a non-covalent complex with NS3 acts as a co-
factor of protease activity by stabilising the NS3/4A complex and is essential for its 
membrane association (Brass et al., 2008, Morikawa et al., 2011). The localisation of the 
NS3/4A complex is primarily on the ER membrane and in the replication complex (RC) 
(Wolk et al., 2000). In addition to its role in the viral life cycle, it also facilitates viral 
immune evasion by cleaving of adaptor proteins essential for innate immune signalling, 
Toll/interleukin-1 receptor domain-containing adaptor-inducing interferon-β (TRIF) and 
MAM-localised mitochondrial antiviral signalling protein (MAVS) (Li et al., 2005b, 
Meylan et al., 2005, Horner et al., 2011). Accordingly, the NS3/4A serine protease is one 
of the most popular targets for anti-HCV treatment and has been used as a target of the 
first and the second generation of DAAs (Morikawa et al., 2011, Lin et al., 2009). The 
other function of NS3/4A complex which is the RNA helicase activity unwinds double-
stranded RNA during viral replication in an ATP-dependent manner (Tai et al., 1996).  
 
NS4B: NS4B is a conserved hydrophobic membrane protein (27 kDa) and localises to 
ER (Hugle et al., 2001, Lundin et al., 2003). It modifies ER membrane to induce the 
membranous web formation, which represents the site of HCV RNA replication (Egger et 
al., 2002, Gosert et al., 2003). NS4B is composed of four transmembrane domains, 
flanked by amphipathic N-terminal helix which is responsible for remodelling of the ER 
membrane (Hugle et al., 2001, Lundin et al., 2003, Yu et al., 2006). NS4B interacts with 
other HCV non-structural proteins and also has a function in viral assembly (Gouttenoire 





NS5A: NS5A is a phosphorylated zinc-metalloprotein without any enzymatic activity 
which plays a crucial role in viral replication and assembly (Blight et al., 2000, Lohmann 
et al., 2001, Appel et al., 2008, Tellinghuisen et al., 2008a). It is composed of 3 domains 
(Tellinghuisen et al., 2004): domain 1 (D1), and domain 2 (D2) have been linked with 
RNA replication, whereas domain 3 (D3) is critical for virion assembly (Appel et al., 
2008, Tellinghuisen et al., 2008a, Tellinghuisen et al., 2008b, Kim et al., 2011). NS5A 
can be found in basally phosphorylated (p56) and hyperphosphorylated (p58) forms 
(Kaneko et al., 1994) and the phosphorylation status of NS5A affects the level of HCV 
replication (Appel et al., 2005, Appel et al., 2008, Blight et al., 2000). NS5A has been 
reported to interact with HCV RNA (Huang et al., 2005), and other HCV proteins such as 
core (Shimakami et al., 2004, Masaki et al., 2008) and interacts with a number of host 
cellular proteins such as Rab5a and the vesicle-associated membrane protein-associated 
protein A (VAP-A) (Coller et al., 2009, Hamamoto et al., 2005, Eyre et al., 2014). NS5A 
has shown to bind to the HCV core protein at the lipid droplet interface which may 
regulate HCV virus assembly (Shi et al., 2002, Goh et al., 2001). In addition, it was 
recently shown in live imaging studies that NS5A binds to HCV RNA and may facilitate 
the transfer of HCV from sites of replication to sites of virion assembly (Fiches et al., 
2016). Due to its multiple functions, it is a target of a number of new DAAs in 
development. 
 
NS5B: NS5B is an RNA-dependent RNA polymerase (RdRp) and has a central function 
in RNA synthesis of both positive and negative strand RNA (Behrens et al., 1996). Its C-




(Moradpour et al., 2004, Schmidt-Mende et al., 2001). NS5B is another target for the 
development of direct-acting antivirals (DAAs) (Di Marco et al., 2005, Pawlotsky, 2006). 
  
1.1.7 HCV virion/particles 
HCV viral particles are thought to be classical icosahedral symmetry and approximately 
40-70 nm in diameter. The virion is composed of an HCV RNA genome, core and the 
envelope glycoproteins, E1 and E2 (Bartenschlager et al., 2011). The viral nucleocapsid 
which is core protein encapsulating the RNA genome is surrounded by a host-derived 
double-layer envelope containing the glycoproteins E1 and E2 (Bartosch et al., 2003, 
Nielsen et al., 2004). The association of HCV virions and various serum lipoproteins 
[low- and very-low-density lipoproteins (LDLs and VLDLs)] in circulation forms a 
complex of lipoviralparticles (LVP) and facilitates viral entry into hepatocytes 
(Thomssen et al., 1992, Andre et al., 2002). 
 
1.1.8 HCV life cycle 
The HCV life cycle consists of multiple steps such as HCV entry, translational 
polyprotein processing, viral replication and viral assembly and egress (Figure 1.4). A 
short summary of the each step of HCV life cycle is provided below. 
 
HCV entry: HCV entry requires a set of essential host receptors on the hepatocyte 
surface. These include the low-density lipoprotein receptor (LDL-R) (Agnello et al., 







Figure 1.4: Schematic representation of HCV life cycle. 
The multiple steps of HCV life cycle comprise of (a) virus-cell attachment and 
internalisation, (b) viral uncoating, (c) translation and polyprotein processing, (d) RNA 
replication and membranous web formation, (e) viral packaging and assembly, and (f) 





tetraspanin (CD81) (Pileri et al., 1998), scavenger receptor class B type I (SR-BI) 
(Scarselli et al., 2002), the tight junction component claudin-1 (CLDN1) (Evans et al., 
2007) and occludin (OCLN) (Ploss et al., 2009) (Figure 1.5). The initial step of viral 
entry is an attachment of HCV particles to the hepatocyte cell surface via low-affinity 
interactions with LDL receptors and glycosaminoglycans (GAGs) (Agnello et al., 1999, 
Germi et al., 2002), subsequently leading to the high-affinity interaction of hypervariable 
region 1 (HVR1) of HCV glycoprotein E2 to the scavenger receptor class B type I (SR-
BI) (Dao Thi et al., 2012, Scarselli et al., 2002). This binding induces the conformational 
change in E2 epitope and allows the high-affinity binding of the viral particle with CD81 
(Bankwitz et al., 2010, Petracca et al., 2000). This CD81 and HCV E2 interaction results 
in the activation of the signal transduction which induces the lateral movement of CD81 
and the HCV E2 complex towards the tight junction areas of the hepatocyte (Brazzoli et 
al., 2008), and subsequently results in an interaction with claudin-1 (CLDN1) (Evans et 
al., 2007, Harris et al., 2010). The interaction between CLDN1 and the CD81-bound 
HCV triggers clathrin-mediated endocytosis (Blanchard et al., 2006, Farquhar et al., 
2012) which results in viral particle internalisation. Although OCLN is necessary for 
viral entry, its precise role remains unknown (Ploss et al., 2009, Sourisseau et al., 2013). 
Moreover, the cholesterol receptor Niemann-Pick C1-like 1 (NPC1L1) and transferrin 1 
receptor have been reported to be essential co-factors for HCV entry, however the 
mechanism of these proteins are not yet understood (Sainz et al., 2012, Martin and 








Figure 1.5: Schematic representation of HCV entry. 
A set of essential host receptors including low-density lipoprotein receptor (LDL-R), 
glycosaminoglycans (GAGs), tetraspanin (CD81), scavenger receptor class B type I (SR-






containing early endosomes where the acidic pH inside induce the virus to uncoat (Coller 
et al., 2009, Farquhar et al., 2012) which results in the release of the viral genome into the 
cytosol to further undergo viral translation and replication processes (Niepmann, 2013). 
 
HCV replication: Following entry, viral replication is initiated by translation of the 
single open reading frame from the positive sense RNA by host machinery using the 
HCV IRES. The single polyprotein is subsequently modified via post-translational 
process by host and viral proteases to produce the structural proteins (core, E1 and E2), a 
transmembrane protein p7 and non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A 
and NS5B) (Sharma, 2010, Sklan et al., 2009, Moradpour et al., 2007). The membranous 
web which is the major site of viral RNA synthesis is then formed by the alteration of the 
cellular membrane, predominantly the endoplasmic reticulum (ER), which is driven 
primarily by the HCV non-structural protein NS4B, although other HCV non-structural 
proteins do play a role (Romero-Brey et al., 2012). The membranous web contains the 
HCV RC and is the site of HCV replication (Egger et al., 2002). The HCV RC comprises 
non-structural proteins, viral RNA and a number of cellular host factors (Gosert et al., 
2003, Moradpour et al., 2003). Along with viral proteins, several host factors such as 
phosphatidylinositol 4-kinase III alpha (PI4III), vesicle-associated membrane protein-
associated protein A (VAP-A) and oxysterol-binding protein (OSBP) have been shown to 
contribute to the membranous web formation [reviewed in (Chukkapalli and Randall, 
2014)]. The RNA dependent RNA polymerase, NS5B is responsible for the de novo 
synthesis of negative-strand RNA, which serves as the template for synthesising multiple 




replication, and also utilised to form new virions through the association with core 
protein. 
 
HCV assembly and egress: Following viral replication, the newly synthesised RNA is 
subsequently packaged into nucleocapsids to form the new virions. Although the precise 
mechanisms of HCV assembly and egress remain unclear, it is thought that the early steps 
of assembly of new virions occur on the cytosolic side of the ER membrane in close 
association with lipid droplets (LDs). The core protein is synthesised and matures at the 
ER membrane (Boulant et al., 2005) and subsequently migrates to the surface of LDs 
(Counihan et al., 2011) where RCs are recruited to this site via the interaction of core and 
NS5A associated with RCs (Miyanari et al., 2007, Masaki et al., 2008). The viral 
glycoproteins E1 and E2 are synthesised and translocated into the ER membrane (Duvet 
et al., 1998, Dubuisson et al., 1994), where the acquisition of a lipid envelope is required 
for the late stages of viral assembly. The immature virions subsequently undergo 
maturation through the cellular secretory pathway before releasing from the cell by 
exocytosis in a noncytolytic manner to complete the life cycle (Jones and McLauchlan, 
2010, Bartenschlager et al., 2011, Popescu et al., 2011b, Lindenbach and Rice, 2013). 
 
1.1.9 HCV model systems  
Historically, studies of the molecular virology and viral pathogenesis of HCV were 
limited, due to the lack of a robust cell culture system that provided the complete viral 
life cycle. Furthermore, there was no small animal model system, with the chimpanzee 




achieved in 1999 when the HCV subgenomic replicon system was developed (Lohmann 
et al., 1999), allowing autonomous replication of HCV RNA and expression of the non-
structural proteins, although no progeny virions were produced due to the lack of 
structural proteins (Figure 1.6A). Variation to this replicon system subsequently emerged, 
including a full-length replicon and HCV replicons containing reporter constructs (Ikeda 
et al., 2002, Ikeda et al., 2005, Robinson et al., 2010, Beard et al., 1999). The HCV 
pseudo-particles (HCVpp) model (Figure 1.6B) which is a lentiviral or retroviral-based 
system was later generated and used for HCV entry studies (Bartosch et al., 2003, Hsu et 
al., 2003). In 2005, the infectious cell culture system (HCVcc) (Figure 1.6C) which 
enabled viral replication and the production of infectious virions, offered a complete viral 
life cycle in cell culture, and revolutionised in vitro HCV research (Lindenbach et al., 
2005, Wakita et al., 2005, Zhong et al., 2005). In this study, we have utilised the HCV 
replicon and the infectious cell culture (HCVcc) systems, which will be described below. 
 
1.1.9.1 HCV replicon systems 
The HCV replicon system has been utilised extensively for the study of HCV replication, 
host-viral protein interactions, and for antiviral drug testing [reviewed in (Bartenschlager, 
2002, Horscroft et al., 2005)]. The genomic (HCV structural and non-structural proteins) 
(Ikeda et al., 2002) and subgenomic (non-structural proteins) (Lohmann et al., 1999, 
Blight et al., 2000) replicons utilise the human hepatocellular cell line (Huh-7) for 





Figure 1.6: Schematic representation of cell culture-based HCV model. 
Different systems for the study of HCV life cycle; (A) HCV replicon, (B) HCV pseudoparticles (HCVpp) and (C) HCV infectious cell 




Both the subgenomic and genomic replicons do not produce infectious HCV virions. The 
replicon systems are bicistronic and consist of two internal ribosomal entry sites (IRES). 
The HCV IRES in the first cistron controls the expression of a neomycin resistance gene, 
while the structural and non-structural proteins are under the control of an 
encephalomyocarditis virus (EMCV) IRES. Initially, HCV RNA is in vitro transcribed 
under the control of the T7 promoter and electroporated into Huh-7 cells and neomycin 
resistant clones are isolated and subsequently characterised to achieve efficient and 
autonomous HCV replication cell lines. The replicon systems do not allow for the 
complete study of HCV life cycle as they fail to produce infectious virus. These systems 
have been improved by the insertion of reporter genes such as fluorescent proteins and 
firefly luciferase which allow for high-throughput quantification of HCV replication, 
HCV live imaging (Schaller et al., 2007, Krieger et al., 2001, Ikeda et al., 2005).  
 
1.1.9.2 Infectious cell culture model 
A major development in understanding the HCV life cycle was generated in 2005 when a 
genotype 2a HCV cDNA isolated from a Japanese patient with fulminant hepatitis (JFH-
1) was found to replicate efficiently and produce infectious viral particles in Huh-7 
hepatocellular cell lines (Figure 1.6C). Infectious HCV particles in supernatants produced 
from cell culture-derived HCV JFH-1 (HCVcc) can be passaged in vitro on Huh-7 cells, 
as well as in animal models (chimpanzees and human liver chimeric mice) (Wakita et al., 
2005, Zhong et al., 2005, Lindenbach et al., 2005, Lindenbach et al., 2006). HCV viral 
titres of this cell culture-derived HCV genotype 2a clone were initially low, however the 




Jc1 (genotype 2a) (Pietschmann et al., 2006). This system provides the greatest advance 
in HCV research and has opened up the study of the full HCV life cycle. In addition, the 
HCVcc system has been improved by creation of luciferase and fluorescent protein-
tagged viruses (Koutsoudakis et al., 2006, Schaller et al., 2007). 
 
1.2. Innate immune response to viral infection 
1.2.1 Overview  
The innate immune response to pathogen infection is the first line of host defence to 
combat and eliminate pathogens including parasites, bacteria, fungus and viruses. This 
type of response is not specific to particular microorganisms and unlike the adaptive 
response, it does not provide a long-term host response, however it is rapid and required 
for the activation of the adaptive immune response. A series of conserved proteins or 
molecules of pathogens called “pathogen-associated molecular patterns, or PAMPs” are 
recognised by cellular receptors called “pattern recognition receptors or PRRs”. PAMPs 
are conserved and shared by different pathogens such as proteoglycan, glycoproteins, 
lipopolysaccharide, and nucleic acids. PRRs are proteins expressed in a vast variety of 
different cell types and can be classified by their ligand specificity, function, and cellular 
localisation. The recognition of PAMPs and PRRs activates downstream signalling 
cascades which result in the production of immune products such as cytokines, 
chemokines and interferon. Induction of an antiviral immune response upon viral 
infection triggers the recognition of viral components by host PRRs and results in the 
activation of viral recognition pathways that ultimately induces the production of 




replication (Sen, 2001), and also induces type III IFN which is important in HCV 
infection [reviewed in (Bruening et al., 2017, Boisvert and Shoukry, 2016, Shin et al., 
2016)]. 
 
1.2.2 Innate immune response to RNA virus infection 
1.2.2.1 Cellular recognition of RNA viruses 
The host innate immune response to RNA viral infection is initiated by the recognition of 
PAMPs by specific PRRs that can be broadly classified as cytoplasmic or membrane-
bound PRRs. Toll-like receptors (TLRs) and RIG-I like receptors (RLRs) are the 
predominant PRRs in the detection of RNA virus infection. TLRs are membrane-bound 
receptors present on either the plasma membrane or in endosomes to sense the invading 
microorganism. The human TLRs consist of 10 members and among these receptors, the 
endosomal TLRs; TLR3, TLR7 and TLR8 have been shown to recognise nucleic acids of 
different types of RNA viruses (Table 1.1), whereas the endosomal TLR9 recognises 
unmethylated 2’-deoxyribo cytidine-phosphate-guanosine (CpG) DNA motif of bacterial 
and viral DNA (Hemmi et al., 2000). Additionally, TLR2 and TLR4 that are present on 
the cellular membrane have been reported to sense viral proteins such as HCV core and 
mouse mammary tumour virus (MMTV) or murine leukaemia virus envelope proteins 
(Dolganiuc et al., 2004, Rassa et al., 2002).  
 
The TLR-independent mechanism of viral recognition, the RLR system, is an alternative 
pathway of virus sensing and plays a central role in the antiviral immune response 




Table 1.1: Recognition of endosomal TLRs and RNA viruses 
TLRs Virus family RNA virus References  
TLR3 Flaviviridae Hepatitis C virus (Li et al., 2005a) 
West Nile virus (Daffis et al., 2008, Kawai 
and Akira, 2008, Wang et 
al., 2004) 
Picornaviridae Coxsackievirus B3 (Negishi et al., 2008) 
Poliovirus (Oshiumi et al., 2011) 
Rhinovirus (Hewson et al., 2005) 
Reoviridae Reovirus (Kawai and Akira, 2008, 
Wang et al., 2004, 
Alexopoulou et al., 2001) 
Pneumoviridae* Respiratory syncytial 
virus 
(Rudd et al., 2005) 
Orthomyxoviridae Influenza A virus (Guillot et al., 2005) 




(Alexopoulou et al., 2001) 
TLR7 Orthomyxoviridae Influenza A virus (Diebold et al., 2004, 
Lund et al., 2004) 
Flaviviridae Hepatitis C virus (Dolganiuc et al., 2006, 
Sato et al., 2007) 
Pneumoviridae* Respiratory syncytial 
virus 
(Phipps et al., 2007) 
Rhabdoviridae Vesicular stomatitis virus (Lund et al., 2004) 
Retroviridae Human 
immunodeficiency virus 
(Beignon et al., 2005, 
Alter et al., 2007) 
Flaviviridae Dengue virus (Wang et al., 2006) 
Paramyxoviridae Sendai virus (Melchjorsen et al., 2005, 
Lee et al., 2007) 
TLR7/8 Retroviridae Human 
immunodeficiency virus 
(Heil et al., 2004, Beignon 
et al., 2005, Alter et al., 
2007) 
Flaviviridae Hepatitis C virus (Zhang et al., 2016) 
 





mammalian cell types. RLRs belong to the family of aspartate-glutamate-any amino acid-
aspartate/histidine (DExD/H)-box helicases and comprise of three classes: the retinoic 
acid-inducible gene I product (RIG-I), melanoma differentiation-associated antigen 5 
(MDA5) and laboratory of genetics and physiology 2 (LGP2) (Kang et al., 2002, 
Yoneyama et al., 2004, Yoneyama et al., 2005, Yoneyama and Fujita, 2007). These three 
members of RLRs share a common structure including a central DExD/H box RNA 
helicase domain with an ATP-binding motif to hydrolyse ATP, and a C-terminal domain 
(CTD). RIG-I and MDA5, but not LGP2 also contain an N-terminal domain consisting of 
tandem caspase activation and recruitment domains (CARD) that is responsible for 
signalling (Figure 1.7) (Yoneyama et al., 2004, Yoneyama et al., 2005, Saito et al., 2007). 
RLRs are typically expressed at low levels in resting cells but are significantly increased 
upon viral infection and IFN stimulation (Kang et al., 2004, Yoneyama et al., 2004, 
Yoneyama et al., 2005, Imaizumi et al., 2005). In this chapter, we will focus on RLR 
signalling pathways upon viral infection. 
 
1.2.2.1.1 Retinoic acid-inducible gene I (RIG-I) 
RIG-I is a large protein (925 residues, 106 kDa) and highly conserved between 
vertebrates. Overexpression of RIG-I has been shown to limit replication of VSV and 
EMCV, and knockdown of RIG-I by siRNA reduces the production of type I IFN upon a 
variety of viral infections including Newcastle disease virus (NDV), Sendai virus (SeV) 
and EMCV (Yoneyama et al., 2004). Additionally, studies in RIG-I-deficient mice 








Figure 1.7: Schematic representation of the RLRs structural domains. 
The three members of RLRs including RIG-I, MDA5 and LGP2 comprise the similar 
motifs of CARD domains (caspase activation and recruitment domain) which present on 
RIG-I and MDA5, but not in LGP2, a central DEAD box helicase and a C-terminal 






range of cell types, excepting plasmacytoid dendritic cells (pDCs) where TLRs 
preferentially sense RNA virus to stimulate an antiviral response (Kato et al., 2005). RIG-
I is auto-repressed in the resting state to maintain low activity in the absence of RNA 
ligands. RIG-I senses short double-stranded RNA (dsRNA) or 5’ triphosphate (5′ppp) 
uncapped ssRNA (Kato et al., 2006). Following binding to viral RNA components, RIG-I 
hydrolyses ATP to induce conformational change and subsequent releasing of CARD 
domains, allowing the interaction with the adaptor protein MAVS (Mitochondrial 
antiviral-signalling protein), to activate downstream signalling events that will be 
discussed in detail in subsequent sections (Kawai et al., 2005, Meylan et al., 2005, Jiang 
et al., 2011, Kowalinski et al., 2011). 
 
1.2.2.1.2 Melanoma differentiation-associated antigen 5 (MDA5)  
MDA5 displays the same overall domains as RIG-I and triggers signalling through 
CARD domains. MDA5 is essential to trigger the production of cytokine responses and 
crucial in the antiviral response. Overexpression of MDA5 increases type I IFN 
production and promotes antiviral activity against VSV and EMCV and knockdown of 
MDA5 gene has been shown to inhibit the type I IFN promoter (Yoneyama et al., 2005). 
Additionally, MDA5-deficient mice reduced type I IFN secretion in response to poly 
(I:C) stimulation and failed to develop an antiviral response against EMCV, which 
effectively escapes RIG-I sensing (Gitlin et al., 2006, Kato et al., 2006). A significant 
increase in morbidity and mortality and a reduction of an antiviral cytokine response 
were shown in MDA5
-/- 
mice upon SeV infection (Gitlin et al., 2010). MDA5 has been 
shown to display an antiviral action itself or in cooperation with RIG-I against a number 




(Faul et al., 2010), rotavirus (Sen et al., 2011), murine hepatitis virus (Roth-Cross et al., 
2008) and  murine norovirus 1 (McCartney et al., 2008). MDA5 typically recognises long 
dsRNA (at least 2 kb) (Kato et al., 2008), and initiates type I IFN production via CARD 
domains similar to RIG-I (Kang et al., 2002).  
 
RIG-I and MDA5 do not respond to extracellular nucleic acid and have been shown to be 
essential in the activation of innate immune signalling against a board range of viruses. A 
list of RNA virus recognised by RIG-I and MDA5 are shown in Table 1.2. 
 
1.2.2.1.3 Laboratory of genetics and physiology 2 (LGP2) 
The third member of the RLRs, LGP2 is not well studied. LGP2 shares homology to 
RIG-I and MDA5, but lacks CARD domains and is thought to act as a negative regulator 
of RIG-I/MDA5 signalling. A study in LGP2-deficient cells has shown resistance to VSV 
infection and overexpression of LGP2 has been shown to inhibit SeV and NDV-induced 
ISRE activation (Venkataraman et al., 2007, Rothenfusser et al., 2005). In contrast, 
LGP2
-/-
 mice exhibit impaired production of type I IFN in response to EMCV infection 
(Venkataraman et al., 2007). EMCV is specially sensed by MDA5, and this suggests a 
positive regulatory effect of LGP2 on MDA5. 
 
1.2.2.2 RIG-I-like receptors (RLRs) downstream signalling cascade 
The activation of RLR signalling is coordinated by several processes and requires the 
relevant adaptor molecules including Riplet, TRIM25, and MAVS to initiate signal 




Table 1.2: Recognition of RLRs and RNA viruses. 
RLR Virus family RNA virus References  
RIG-I Flaviviridae Hepatitis C virus (Sumpter et al., 2005, 
Saito et al., 2007) 
West Nile virus (Fredericksen et al., 
2008b) 
Japanese encephalitis virus (Kato et al., 2006) 




(Zhou et al., 2010) 
Paramyxoviridae Sendai virus (Yoneyama et al., 
2005, Kato et al., 2005) 
Newcastle disease virus (Kato et al., 2005) 
Measles virus (Plumet et al., 2007) 
Pneumoviridae* Respiratory syncytial virus (Loo et al., 2008) 
Rhabdoviridae Vesicular stomatitis virus (Yoneyama et al., 
2005, Kato et al., 2005) 
Rabies virus (Faul et al., 2010) 
Orthomyxoviridae Influenza A virus (Kato et al., 2006) 
Reoviridae Rotavirus (Sen et al., 2011) 
Filoviridae Ebola (Cardenas et al., 2006) 
Bunyaviridae Rift Valley fever virus 
(RVFV)  
(Habjan et al., 2008) 
La Crosse virus (LACV) (Habjan et al., 2008, 
Weber et al., 2013) 
MDA5 Flaviviridae Dengue virus (Loo et al., 2008) 
West Nile virus (Fredericksen et al., 
2008b) 
Rhabdoviridae Rabies virus (Faul et al., 2010) 
Reoviridae Rotavirus (Sen et al., 2011) 
Paramyxoviridae Sendai virus (Gitlin et al., 2010) 
 





well-characterised, while the mechanisms underlying MDA5 and LGP2 are not as well 
described. However, it is thought that sensing by both RIG-I and MDA5 activate the 
same signalling cascade which in turn induces the production of type I IFN and 
proinflammatory cytokine production (Yoneyama et al., 2005). In this chapter, we will 
focus on RIG-I downstream signalling that is depicted in Figure 1.8. RIG-I is present in 
the cytoplasm and is auto-inhibited and kept in a closed conformation in the resting state 
or in the absence of viral ligands. RIG-I is activated upon recognition with RNA ligands 
such as 5’ di- or triphosphate dsRNA and undergoes the process of dephosphorylation 
and Lys (K) 63-polyubiquitination by the regulation of E3 ubiquitin ligase, Riplet and 
TRIM25. This results in conformational changes to open up the CARD domains and 
facilitates the association of RIG-I and the adaptor protein MAVS through a CARD-
CARD domain interaction. This interaction induces the formation of the MAVS 
signalosome or innate immune synapse (Horner et al., 2011), which in turn activates the 
essential transcription factors in RLR signalling including interferon regulatory factor 3 
(IRF3), IRF7 and NF-B. IRF3/7 are phosphorylated through non-canonical IB kinases 
IKK or TBK1, while the activation of NF-B requires the IKK complex (IKK/β/). 
Phosphorylated IRF3 and IRF7 form homodimers and heterodimers which translocate to 
nucleus to activate the transcription of a specific set of genes involved in the innate 
antiviral response (Xu et al., 2005, Seth et al., 2005, Kawai et al., 2005, Meylan et al., 
2005, Saha et al., 2006, Kumar et al., 2006). Activated IRF3/7 and NF-B promote the 









act in an autocrine and paracrine manner ultimately to induce the production of 
interferon-stimulated genes (ISGs). IRF3 is constitutively expressed in most cell types, 
whilst the expression of IRF7 is maintained at low level and is enhanced upon the 
production of IFN (Marie et al., 1998, Sato et al., 1998). Therefore, IRF3-dependent gene 
transcription is in many cases induced rapidly following RIG-I activation while IRF7 
drives a delayed response.  
 
Mitochondrial Antiviral-Signalling Protein (MAVS): MAVS is an adaptor protein that 
plays an essential role in the innate antiviral response. It is also called VISA (virus-
induced signalling adapter), IPS-1 (IFN- Promoter Stimulator 1) and Cardif (CARD 
Adaptor Inducing IFN-). MAVS, a 540-amino-acid protein comprises a CARD domain 
at the N terminus, a proline-rich region, and a membrane-targeting transmembrane 
domain at the C-terminus for its localisation to various cellular compartments (Figure 
1.9). Overexpression of MAVS increases the induction of type I IFN and ISGs, and 
knockdown of MAVS by siRNA inhibits this response upon VSV and NDV infection and 
in response to dsRNA stimulation (Kawai et al., 2005). Additionally, mouse embryonic 
fibroblasts (MEFs) from MAVS-deficient mice are susceptible to EMCV and VSV 
infection and have been shown to be severely impaired in the production of 
proinflammatory cytokines and type I IFN upon infection with a diverse RIG-I/MDA5-
recognised RNA viruses. In contrast, MAVS was dispensable for type I IFN production 
following DNA virus infection (Kumar et al., 2006). This indicates a central role of 
MAVS in both RIG-I/MDA5-dependent signalling mechanism in response to infection 






Figure 1.9: Schematic representation of MAVS structure. 
MAVS (540 amino acids, 57 kDa) is composed of three distinct domains which are N-
terminus CARD for interacting with CARD of RIG-I/MDA5, a proline-rich region 
containing TRAF-interacting motifs, and a transmembrane domain at C-terminus for 





1.2.2.3 The interferon response to viral infection 
Viral infection of mammalian cells results in the activation of viral recognition pathways 
triggered by replication intermediates and/or viral proteins (as described above) that 
ultimately induces an innate immune response to limit viral replication (Sen, 2001). 
Interferon (IFN), particularly type I interferon (IFN-α and β) is one of the essential 
components of innate immunity against the infection of the majority of viruses (DNA and 
RNA) including HCV infection. Interferons are glycoproteins and divided into three 
classes (I, II and III). Type I IFN was the first discovered family and composes of 
multiple members: IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-δ, IFN-τ, and IFN-ω (Pestka et al., 
2004, Perry et al., 2005, Sen, 2001, Sang et al., 2014). Type II IFN is composed of solely 
IFN-γ, while type III IFN family comprises IFN-λ1 (IL-29), IFN-λ2 (IL-28A), and IFN-
λ3 (IL-28B) (Schneider et al., 2014, Pestka et al., 1987, Kotenko et al., 2003, Dornhoff et 
al., 2011). All IFNs share a common feature as antiviral agents, however type I IFNs are 
the most common type that are induced following viral infection; however type III IFN 
has also been shown to be critical in the innate antiviral response to HCV infection (Shin 
et al., 2016). 
 
Type I IFN binds to its heterodimer receptor which is composed of IFN- receptor 1 
(IFNAR1) and IFNAR2 subunits, while type II IFN binds to an IFN- receptor complex 
(IFNGR) which consists of IFNGR1 and IFNGR2 subunits. Type III IFN signals through 
interleukin-10 receptor 2 (IL-10R2) and IFN- receptor 1 (IFNLR1). Binding of IFNs to 
their specific receptor triggers the expression of hundreds of interferon-stimulating genes 




response to viral infection is highlighted by the fact that most viruses have evolved 
strategies to combat either IFN production or IFN action (Katze et al., 2002). It was 
considered that a handful of ISGs was responsible for the direct antiviral process (i.e., 
MxA, PKR and 2,5-OAS) (Sen, 2001). However, it is now becoming apparent that many 
ISGs possess antiviral activity either directly or indirectly. The full repertoire of ISGs 
responsible for antiviral activity has not been revealed and the function of many ISGs 
remains to be clarified. 
 
1.2.2.4 Interferon Transduction Pathway 
Upon binding of IFNs to their specific receptors, there is activation of both the Janus 
kinase (JAK) and subsequently, signal transducer and activator of transcription (STAT) 
complexes (see Figure 1.8). Binding of both type I and III IFNs to their specific cell-
surface receptors (IFNAR1/2 or IL-10R2/IFNLR1), initiates the activation of JAK 
family, specifically JAK1 and TYK2 (Silvennoinen et al., 1993). JAK1 and TYK2 
undergo tyrosine phosphorylation on the intracellular domains of IFNAR and enable 
recruitment of the signal transducer and activator of transcription (STAT) 1 and STAT2. 
STAT1 and STAT2 are then phosphorylated at tyrosine residue 701 and 690 respectively. 
Phosphorylated STA1 and STAT2 dimerise and associate with interferon regulatory 
factor 9 (IRF9) to form the transcription factor complex, interferon-stimulated gene factor 
3 (ISGF3). This ISGF3 multimeric molecule undergoes nuclear translocation and binds to 
the IFN-stimulated response element (ISRE) in the promoter to activate the transcription 
of hundreds of ISGs that display numerous biological functions, one of which is to 




1.2.2.5 Interferon-stimulated genes (ISGs) 
ISG expression, the product of stimulation of cells with IFNs, was first discovered more 
than 30 years ago (Knight and Korant, 1979) and since that initial report, more than 300 
ISGs have been identified (de Veer et al., 2001). Originally it was thought that only a 
handful of ISGs existed, with classical ISG’s such as PKR, OAS and Mx1, all displaying 
antiviral activity. However, mice and cells defective in one or more classical ISGs (PKR, 
OAS and Mx1) still retain antiviral function, suggesting the redundancy or the existence 
of several effectors that contribute to protection against viral infection (Zhou et al., 1999). 
It is increasingly clear that IFNs induce a diverse range of ISG expression upon viral 
infection and/or IFN stimulation. The ISG expression profile depends on cell type, type 
of viral infection, and dose/time point of IFN treatment. ISGs exert their antiviral 
functions at multiple stages of virus life cycle, however most ISGs remain to be 
characterised. Several ISG screening studies have aimed to identify antiviral ISGs and 
some of them have been well-characterised including the potent classical ISGs, PKR, 
Mx1, OAS and more recent discoveries such as ISG15, ISG20, ZAP, IFITM1-3, and 
viperin. A summary of antiviral ISGs has been reviewed in (Schoggins and Rice, 2011).  
 
1.2.3 Innate immune recognition of HCV 
1.2.3.1 Cellular recognition and downstream signalling events upon HCV infection 
Like many +ve stranded RNA viruses, HCV infection of hepatocytes is recognised by 
RIG-I and endosomal TLRs, in particular TLR3. (Horner and Gale, 2013). RIG-I is the 
best-described PRR and is a key sensor for recognition of HCV RNA specifically 5’ 




al., 2008, Kato et al., 2008, Cui et al., 2008, Uzri and Gehrke, 2009). The RIG-I pathway 
is activated within hours after HCV infection and activation of RIG-I is sufficient to limit 
HCV replication (Loo et al., 2006, Sumpter et al., 2005).  
 
Along with RLRs, HCV infection can be detected by TLRs. The endosomal TLR3 and 
TLR7 have been shown to induce a host anti-HCV response, although the precise 
mechanisms are not yet understood (Wang et al., 2009a, Li et al., 2012, Zhou et al., 2016, 
Zhang et al., 2009, Lee et al., 2006). TLR3 is highly expressed in primary hepatocytes 
derived from CHC patients, while there is no difference in the expression level of TLR2 
and TLR7 between HCV-infected patients and controls (Tarantino et al., 2013). TLR3 
activation has also been shown to block HCV replication (Wang et al., 2009a, Li et al., 
2012), and this highlights the essential role of TLR3 in the host antiviral response against 
HCV infection. In addition to TLR3, TLR7 can recognise HCV RNA and induce the 
production of type I IFN in plasmacytoid dendritic cells (pDCs) (Takahashi et al., 2010). 
Recognition of HCV RNA by RIG-I and TLRs leads to the phosphorylation, 
dimerisation, and nuclear translocation of transcription factors IRF3/7 and NF-κB that 
culminate in the production of type I IFN and proinflammatory chemokines and 
cytokines. 
 
1.2.3.2 ISGs targeting HCV 
Prior to development of microarray technology, it was thought that only a handful of 
ISGs were expressed, however microarray studies of cells stimulated with IFN- 




al., 2001). Many of these ISGs have been shown to relate to antiviral activity and 
modulation of the immune responses, but others possess functions involved in lipid 
metabolism, apoptosis and protein degradation. A significant number of ISGs have been 
demonstrated to be upregulated in liver biopsies derived from acute or chronic HCV 
infection of chimpanzee or humans (Bigger et al., 2004, Sarasin-Filipowicz et al., 2008). 
Additionally, expression of 36 unique ISGs including IRF7, Mx1, OASL, OAS2, viperin 
and many ISGs with unknown function have been shown to increase in combination with 
a reduction in HCV viral titer (Brodsky et al., 2007). Collectively, this suggests that HCV 
infection can induce an innate antiviral response, however in many cases HCV can persist 
for reasons that are not completely understood. 
 
Several discovery-based screens have been conducted in hepatoma cells to identify ISGs 
responsible for controlling HCV. A fluorescence-activated cell sorting (FACS)-based 
phenotypic screen was performed to determine the anti-HCV activity of 389 ISGs 
(Schoggins et al., 2011). In this approach, each ISG was inserted into the bicistronic 
lentiviral vector that also expressed the red fluorescent protein, TagRFP. Lentiviral 
transduction was used to express individual ISG and TagRFP following by challenging 
with HCV expressing a green fluorescent protein (GFP). A reduction of HCV reporter 
signal indicating the inhibition of viral replication within the ISG/TagRFP-positive cells 
was quantified using FACS. The strongest anti-HCV activity was observed in known key 
sensor and signalling molecules including RIG-I, MDA5, IRF1 and IRF7. Additionally, 
other ISGs (DDIT4, NT5C3, IFI44L, MAP3K14, IRF2, and OAS) were shown to impact 




inhibit HCV replication to a similar level as IFN- stimulation, suggests that a single ISG 
is not responsible for control of HCV, but rather the combination of a number of ISGs. 
 
In contrast to the ectopic study above, several groups have utilised RNA interference-
based screens to identify ISGs. Using a whole-genome RNA interference-based screen, 
93 genes were identified that mediate the suppression of HCV replication, and 23 of these 
genes were involved in mRNA processing and 9 genes involved in translation initiation 
(Zhao et al., 2012). The other group conducted an RNA interference (RNAi)-mediated 
gain-of-function screen and they identified several new genes including IFIT3, TRIM14, 
PLSCR1 and NOS2 that mediate anti-HCV activity. All of these ISGs identified in this 
study were induced by both IFN- and IFN-, suggesting a substantial overlap of the 
effectors specific to HCV (Metz et al., 2012).  
 
Several of these ISGs have been shown to play a role in the inhibition of HCV 
replication, i.e., the ISG 2’-5’-OAS has been shown to inhibit HCV replication through 
the RNase L pathway (Han and Barton, 2002). ISG6-16 can increase the anti-HCV 
activity of IFN-α (Zhu et al., 2003), while IFIT1 (also known as ISG56) has direct 
antiviral activity against HCV by suppressing of HCV IRES translation (Wang et al., 
2003). Interestingly, enhanced expression of both ISG6-16 and ISG56 were observed in 
the liver biopsies from acute and chronic HCV-infected chimpanzees, suggesting that 
these ISGs may contribute to control HCV replication or spread (Su et al., 2002, Bigger 
et al., 2004). Additionally, PKR and the 3’ to 5’ exonuclease, ISG20, have been 




Moreover, viperin which belongs to the group of ISGs has been shown to be significantly 
expressed in HCV liver biopsies and has been reported to inhibit HCV replication via its 
interaction with non-structural protein 5A (NS5A) (Helbig et al., 2005, Helbig et al., 
2011). The interferon-induced transmembrane (IFITM) family, in particular IFITM1-3 
have been identified as important anti-HCV factors (Wilkins et al., 2013, Narayana et al., 
2015). IFITM1 has been shown to impair HCV entry into hepatocytes by disturbing the 
binding of virus and host co-receptor, specifically CD81 and occludin (Wilkins et al., 
2013), whilst IFITM2 and IFITM3 have recently been demonstrated to exert anti-HCV 
activity by interfering with the late stages of HCV entry, possible by directing the 
endocytosed HCV virion for degradation to the lysosome (Narayana et al., 2015). 
Although large-scale screens identified numerous ISGs that suppress HCV replication, 
the molecular mechanisms underlying the antiviral function remain to be characterised to 
expand our knowledge on the association of the host with HCV, and ultimately to 
improve antiviral therapy against HCV. 
 
1.3. Viperin 
Viperin, also known as RSAD2 (radical SAM domain-containing 2) and cig5 
(cytomegalovirus inducible gene 5) was first identified in human cytomegalovirus 
(HCMV) infection of primary human fibroblasts, where two cDNA fragments termed 
cig5 and cig33 (cytomegalovirus inducible gene 5 and 33) were later found to form one 
transcript which was renamed as viperin (virus inhibitory protein, endoplasmic reticulum 





1.3.1 Viperin protein structure and subcellular localisation 
Human viperin is composed of 361 amino acids with a predicted molecular mass of 
approximately 42 kDa and belongs to the MoaA superfamily of radical S-
adenosylmethionine (SAM) enzymes (Shaveta et al., 2010, Duschene and Broderick, 
2010). It contains three distinct domains (Figure 1.10); 1) an N-terminal domain which 
varies between species and contains an amphipathic α-helix and a leucine zipper, 2) a 
highly conserved central domain that composes of three cysteine residues organized in a 
CxxxCxxC motif, and 3) a C-terminal domain that is highly conserved between species 
and has recently been shown to be an essential part of antiviral activity against a broad 
range of viruses. The N-terminal α-helix domain (residues 9-42) of viperin is responsible 
for anchoring within the endoplasmic reticulum (ER) membrane and is also associated 
with its ability to localise to lipid droplets (Hinson and Cresswell, 2009). The central 
domain (residues 71–182) contains motifs that are members of the ‘Radical SAM’ 
enzyme family, in which the CxxxCxxC motif is responsible for binding iron-sulfur 
clusters. The highly conserved C-terminal domain (residues 218-361) is important for the 
dimerisation of viperin and its role might be involved in protein-protein interactions 
and/or mediating an enzyme activity through substrate recognition. In addition, it has 
been reported that an aromatic amino acid residue at the C-terminus of viperin is required 
for its antiviral activity against HCV and DENV (Jiang et al., 2008, Helbig et al., 2011, 








Figure 1.10: The structure of viperin. 
Viperin composes of an N-terminal amphipathic -helix for subcellular localisation, a 
number of conserved domains including the radical S-adenosyl methionine (SAM), a 
leucine zipper domain and a C-terminal region which has been reported as an antiviral 






1.3.2 Regulation of viperin expression 
Viperin is induced in most cell types by type I IFN, type II IFN, type III IFN, double-
stranded DNA, double-stranded RNA (dsRNA) analogues poly I:C, lipopolysaccharide 
(LPS) and infection with a number of viruses. Type I IFN (IFN/) is able to upregulate 
viperin expression in most cell types, whilst type II IFN (IFN) has shown to induce 
viperin expression in primary macrophages (Hinson et al., 2010). Expression of viperin is 
induced by the stimulants (mentioned above) through the classical IFN signalling 
pathways that activate the Jak/STAT pathway and culminates in the formation of the 
transcription factor complex ISGF3 (see section 2.4), which is able to bind the viperin 
promoter and induce its expression. Viperin expression has been shown to be regulated 
by ISGF3 complex, and counter-regulated by positive regulatory domain I-binding factor 
1 (PRDI-BF1, also called BLIMP1) (Severa et al., 2006a). Promyelocytic leukaemia zinc 
finger (PLZF) has shown to be essential for the induction of a subset of antiviral ISGs 
including viperin. Additionally, PLZF-deficient mice defective in upregulation of the key 
antiviral ISGs and also viperin that are consequently more susceptible to viral infection 
(Xu et al., 2009). 
 
A range of viruses including human cytomegalovirus (HCMV), vesicular stomatitis virus, 
Japanese encephalitis virus (JEV) and Chikungunya virus (CHIKV) can induce viperin 
independent of IFN production. (Chin and Cresswell, 2001, Boudinot et al., 2000, Chan 
et al., 2008, White et al., 2011). IFN-independent viperin expression is directly regulated 
by IRF1 or IRF3 (Grandvaux et al., 2002, DeFilippis et al., 2006, Stirnweiss et al., 2010). 




production type I IFN and results in the transcription of ISGs. MAVS resides on 
mitochondria, MAM and recently has shown to localise on peroxisomes (Dixit et al., 
2010). The peroxisomal MAVS activates IRF1 and IRF3 that results in the immediate 
and transient expression of a subset of ISGs including viperin, whilst the mitochondrial 
MAVS activates the induction of viperin and other IFNs that results in a stable antiviral 
effect (Dixit et al., 2010). Hence, IFN-mediated viperin expression is regulated by ISGF3 
and PLZF, while IRF1 and IRF3 control IFN-independent viperin expression. 
 
1.3.3 Antiviral functions of viperin 
Viperin is expressed in a wide variety of species such as mammals and fish, and more 
recently has been found in reptiles (Milic et al., 2015). In addition, the expression of 
viperin is induced by a broad range of viruses, such as the Flaviviridae family; HCV 
(Helbig et al., 2005, Wang et al., 2012), Dengue virus (DENV) (Fink et al., 2007, Helbig 
et al., 2013), Japanese encephalitis virus (JEV) (Chan et al., 2008), West Nile virus 
(WNV) (Szretter et al., 2011), Tick-borne encephalitis virus (TBEV) (Upadhyay et al., 
2014) and yellow fever virus (Khaiboullina et al., 2005); the Togaviridae family, Sindbis 
virus (SINV) (Chan et al., 2008, Zhang et al., 2007) and Chikungunya virus (CHIKV) 
(White et al., 2011); and others including Sendai virus (SeV) (Severa et al., 2006b), 
vesicular stomatitis virus (VSV) (Boudinot et al., 2000), pseudorabies virus (Boudinot et 
al., 2000), rhinovirus (Proud et al., 2008), lymphocytic choriomeningitis virus (LCMV) 
(Hinson et al., 2010), reovirus (Dixit et al., 2010), HIV (Nasr et al., 2012) and rabies 





1.3.3.1 In vitro antiviral function  
The antiviral effect of viperin was first demonstrated in HCMV infection. Constitutive 
expression of viperin in human fibroblasts significantly reduced the expression of 
proteins indispensable for HCMV maturation and assembly including gB, pp28 and pp65 
(Chin and Cresswell, 2001). Subsequently, viperin has been shown to exert antiviral 
action against both DNA and RNA viruses (Chin and Cresswell, 2001, Helbig et al., 
2005, Jiang et al., 2010, Wang et al., 2007, Upadhyay et al., 2014), however its 
mechanism is not fully understood. HeLa cells overexpressing viperin using a 
tetracycline-inducible system have been shown to block budding and release of influenza 
A virus by disrupting lipid rafts on the plasma membrane and increasing membrane 
fluidity (Wang et al., 2007, Tan et al., 2012). In this circumstance, viperin was found to 
bind and inhibit farnesyl diphosphate synthase (FPPS), a key enzyme involved in 
isoprenoid biosynthesis including cholesterol and sterol. Overexpression of FPPS 
reversed the effect of viperin on viral budding and restored normal membrane fluidity, 
however the precise mechanism by which viperin affects membrane fluidity and perturbs 
lipid rafts remains to be elucidated (Wang et al., 2007). Viperin was significantly 
upregulated by HIV-1 infection in monocyte-derived macrophages (MDMs) but is not 
induced in CD4+ T cells and monocyte-derived dendritic cells (MDDCs). Moreover, 
viperin overexpression in HEK293 cells directly inhibited HIV-1 production, and the 
radical SAM domain of viperin is responsible for this capability. Infection of HIV-1 in 
MDMs was also found to redistribute viperin to CD81 compartments, a marker for the 




significantly enhanced HIV-1 cDNA levels, indicating that viperin may interact with 
FPPS to inhibit HIV-1 viral egress (Nasr et al., 2012). 
 
Viperin has been shown to inhibit a range of viruses in Flaviviridae family including 
HCV, DENV, WNV, and TBEV (Helbig et al., 2005, Jiang et al., 2008, Helbig et al., 
2011, Jiang et al., 2010, Helbig et al., 2013, Szretter et al., 2011, Upadhyay et al., 2014). 
Expression of viperin in an inducible manner was shown to impede HCV replication in a 
HEK293 HCV replicon-based system. In this system, both of the radical SAM and the C-
terminal domain were found to be important for anti-HCV activity (Jiang et al., 2008). 
Further work by our laboratory and other groups has demonstrated that the C-terminal 
domain of viperin is critical for limiting HCV replication in both an HCV replicon and 
infectious HCV culture system in hepatocyte cell lines, while the radical SAM domain 
was not required in this case. Additionally, viperin has been shown to interact with HCV 
NS5A and the proviral host factor, vesicle-associated membrane protein-associated 
protein A (VAP-A). It is postulated that viperin may impact the NS5A and VAP-A 
interaction within HCV RC to target a critical step for HCV replication (Helbig et al., 
2011, Wang et al., 2012). Viperin has recently shown to inhibit DENV-2 in several cell 
types including Huh-7, A549 and primary human MDMs. In this instance, a C-terminal 
domain of viperin has shown once again to be crucial for anti-DENV-2 through the 
interaction with DENV2 NS3 protein, while the N-terminal amphipathic helix and the 
radical SAM domain is dispensable for this antiviral activity (Helbig et al., 2013). More 
recently, viperin was shown to exhibit a strong activity towards TBEV via its radical 
SAM domain. In addition, the C-terminal region of viperin has been shown to interact 




machinery and this interaction is important for viperin stability and Fe-S cluster 
formation (Upadhyay et al., 2014). Thus, the radical SAM domain is indispensable for 
antiviral activity against TBEV, while the C-terminal domain is an indirect requirement 
for this response. Most recently, we have shown that ectopic expression of viperin 
significantly impaired Zika virus (ZIKV) replication and once again the C-terminal 
domain of viperin is required for this anti-ZIKV activity (Van der Hoek et al., 2017). In 
addition, ZIKV replication increased in mouse embryonic fibroblast cells (MEFs) 




mice, reinforcing its antiviral role 
against ZIKV infection. Viperin is able to inhibit the replication of multiple viruses from 
the Flaviviridae family. The evidence to date suggesting that its antiviral function is 
achieved through different domains of the protein, however the C-terminal domain is 
crucial in mediating this action.  
 
1.3.3.2 In vivo antiviral function  
In vivo experiments have shown that viperin is able to restrict both WNV and CHIKV 
infection in a mouse model. WNV infected viperin knockout (KO) mice show increased 
lethality and enhanced viral replication in the CNS (Szretter et al., 2011), while CHIKV 
infected viperin KO mice show increased viral replication and joint pathology (Teng et 
al., 2012). In the case of influenza virus (IFV), there was no difference in the 
susceptibility of IFV infection, pulmonary damage and IFV titres between wild type 
(WT) and viperin KO mice (Tan et al., 2012). This result is in contrast to the study using 




redundancy of ISGs in innate immune response, and the production of other ISGs that 
can compensate for the effect of lacking viperin. 
 
1.3.4 Evade and co-opt of viperin by viruses 
It is increasingly clear that viperin is able to combat diverse viral infections, however this 
effect drives the evolution of the virus to evade or counteract the host immune response. 
JEV has been shown to circumvent the antiviral function of viperin (Chan et al., 2008), 
while HCMV utilises viperin to enhance infectivity (Seo et al., 2011). Overexpression of 
viperin or depletion of viperin by RNAi did not influence JEV replication. This is in 
direct contrast to the effect on other flaviviruses such as HCV, DENV and WNV. In 
addition, viperin has been shown to be degraded in JEV-infected cells through a 
proteasome-dependent mechanism suggesting that JEV evades the antiviral effect of 
viperin by negative regulation of viperin expression, however the mechanism of this 
degradation is unknown (Chan et al., 2008). To date, only one virus, HCMV has been 
shown to co-opt viperin to enhance viral infectivity. Previous studies have shown that 
viperin is induced in human fibroblasts following HCMV infection, in addition, 3 days 
post-infection, viperin redistributed from its normal localisation on the ER to Golgi 
apparatus and then to cytoplasmic vesicles containing the viral proteins, gB and pp28. 
(Chin and Cresswell, 2001). Further studies have shown that HCMV replication is 
impaired in shRNA mediated viperin knockdown cells. In this work, they found that 
HCMV infection transferred viperin to the mitochondria before transporting it to the 
Golgi and the HCMV assembly compartments. The interaction of viperin and HCMV 




binds to the β subunit of the mitochondrial trifunctional protein (TFP), a protein that 
facilitates β-oxidation of fatty acids to generate adenosine triphosphate (ATP). This 
interaction inhibits TFP and subsequently results in a decrease of ATP levels which leads 
to a major disruption of the actin cytoskeleton that required for viral infection. 
Interestingly, replacing of the N-terminal amphipathic helix of viperin with a 
mitochondrial localisation sequence, either from vMIA or a host cellular mitochondrial 
protein, Tom70 had a similar effect, indicating the direct role of viperin in mediating 
actin cytoskeleton disruption independently of vMIA. Moreover, Fe-S binding cluster of 
the radical SAM domain has shown to be necessary for this effect but it is not required 
for binding to TFP (Seo et al., 2011). 
 
Additionally, we have recently shown that overexpression of viperin is able to inhibit 
ZIKV replication, however ZIKV infection was found to attenuate the expression of a 
panel of ISGs, including viperin, IFIT1, IFITM1, ISG15, OAS1 and Mx1 in Huh-7 cells, 
placental (HTR8/SVNeo and JEG3) and neural progenitor derived cells (NPCs). This 
suggests that ZIKV perhaps evade the host innate immune response by impairing the ISG 
expression profile (Van der Hoek et al., 2017), and most likely through binding of ZIKV 
NS5 protein to STAT2 and prevention of downstream signalling (Kumar et al., 2016, 
Grant et al., 2016). The diversity of viperin activity as both anti- and pro-viral protein has 
been shown in Figure 1.11 (Helbig and Beard, 2014).  
 
1.3.5 Roles of viperin in immune signalling 





Figure 1.11: Viperin exerts a role in both antiviral and proviral host protein. 






however there is emerging evidence that viperin acts as a mediator in the immune 
signalling pathways. This role has been observed in viperin knockout mice (viperin
−/−
) 
that were healthy and exhibited no obvious phenotypic change. Challenging of these 
knockout mice with ovalbumin (OVA) that induces a mixed of Th1 and Th2 response 
resulted in a significant decrease in OVA-specific IgG1, suggesting that viperin may 
possibly regulate the Th2 response (Qiu et al., 2009). This study has also shown that 
stimulation of CD4+ T cells derived from viperin
−/− 
mice with anti-CD3 resulted in a 
significant reduction of Th2 cytokine expression (IL-4, IL-5 and IL-13), in association 
with a defect in the GATA-3 induction and a decrease of DNA binding activities of NF-
B and AP-1. This data suggests that viperin is involved in the adaptive immune 
response by promoting T-cell activation and differentiation.   
 
Further work has demonstrated that pDCs derived from viperin-deficient mice show a 
defect in the production of type I IFN in response to TLR7/9 stimulation, suggesting the 
ability of viperin to modulate TLR7 and TLR9 signalling in pDCs to promote the 
production of type I IFN (Saitoh et al., 2011). The N-terminal amphipathic helix domain 
of viperin that targets to lipid droplet appeared to be responsible for this effect. In 
addition, viperin was found to interact and recruit the signalling adaptor proteins IRAK1 
and TRAF6 to lipid droplets to facilitate ubiquitination of IRAK1, which in turn induces 
the nuclear translocation of IRF7 to stimulate the expression of type I IFN. Furthermore, 
it has recently been shown that siRNA-mediated knockdown of viperin in carcinoma cell 
lines (EJ) partially attenuated the CD40L-mediated upregulation of IFN- and abrogated 




(Moschonas et al., 2012). Taken together, it is becoming clear that viperin is able to 
orchestrate various aspects of innate immune signalling that may ultimately contribute to 
the antiviral response. 
 
In contrast to the previous reports, recent work has shown that viperin and MAVS co-
localised to the MAM that resulted in inhibition of the MAVS-dependent signalling 
pathway. It was revealed that bone marrow macrophages (BMM) derived from viperin 
KO mice could significantly increase their production of IFN- in response to poly I:C 
stimulation. In addition, co-expression of viperin and MAVS reduced the expression of 
IFN- in 293 cells when compared to MAVS expression alone, indicating that viperin 
negatively regulate MAVS-dependent signalling mechanism (Hee and Cresswell, 2017). 
The author explained that this conflicting result may be a result of the cell types used in 
this experiment. 
 
The fact that viperin displays multiple biological functions including antiviral activity 
against both RNA and DNA viruses and has a role in innate immune signalling, along 
with the diversity of its capabilities as both an anti- and pro-viral protein, suggests that 
viperin is a critical protein in the host response to viral infection. These functions are 
most likely regulated by viperin ability to bind host and viral proteins. To date, viperin 
has been shown to interact with 6 host proteins (FPPS, TFP, IRAK1, VAP-A, TRAF6, 
MAVS and CIAO1) (Wang et al., 2007, Seo et al., 2011, Saitoh et al., 2011, Helbig et al., 
2011, Wang et al., 2012, Hee and Cresswell, 2017, Upadhyay et al., 2014) and 3 viral 
proteins (HCV NS5A, DENV NS3, HCMV vMIA) (Helbig et al., 2011, Wang et al., 




explain its diverse function and is likely that novel interacting partners remain to be 
discovered and characterised. This represents a major gap in our understanding of the 
biology and molecular mechanism of this important ISG viperin that mediates pro-/anti-
viral responses or facilitates innate immune signalling, and will be a major topic of this 
thesis.   
 
1.4 Peroxisomes and the antiviral response 
1.4.1 Peroxisomes and their functions 
Peroxisomes are essential dynamic and multifunctional organelles found in eukaryotic 
cells including yeast, plants, and mammals. They are a single membrane organelle with 
size ranging from 0.1-1.0 m diameter. They are normally spherical but can change in 
their size, number, and shape depending on cell types and environment (Grabenbauer et 
al., 2000, Schrader et al., 2013). They contain catalase and oxidase enzymes that are 
indispensable for cell metabolism and also comprise at least 50 other enzymes depending 
on the cell type and organism (Wanders and Waterham, 2006). The metabolic function of 
peroxisomes is generally involved in lipid metabolisms such as biosynthesis of either 
phospholipids (plasmalogens), cholesterol,  bile acids, and catabolism or decomposition 
of amino acid, fatty acids, hydrogen peroxide (H2O2) (Table 1.3) (Smith and Aitchison, 
2013, Titorenko and Rachubinski, 2001). In addition, peroxisomes morphologically 
interact and communicate with other subcellular compartments such as ER, mitochondria 
and lipid droplets, although the precise role of how these organelles communicate and 





Table 1.3: Metabolic functions of peroxisomes*. 
Biosynthesis 
Bile acids and cholesterol 
Hormonal signalling molecules 
Polyunsaturated fatty acids 








Decomposition of H2O2 by catalase 
- and -Oxidation of fatty acids 
Superoxide radical destruction by superoxide dismutase 
Other 
Being as a platform in innate antiviral response 
 





Peroxisomes require a set of proteins, called the peroxins that are encoded by the PEX 
gene in their formation and maintenance (Hettema et al., 1999, Smith and Aitchison, 
2013). Peroxisomes can be formed through two mechanisms which are i) de novo 
generation in which pre-peroxisomal vesicles are derived from the ER and ii) growth and 
division (fission) (Figure 1.12). In de novo biogenesis, the ER contributes to the 
formation of pre-peroxisomes whereby peroxisomal membrane proteins (PMPs) are 
inserted into the ER membrane to form a new peroxisome, while the growth and division 
mechanism is responsible for the expansion of a number of peroxisomes. In this pathway, 
pre-existing peroxisomes undergo elongation, constriction, fission to produce daughter 
peroxisomes and subsequently growth and maturation to generate new peroxisomes. 
 
1.4.2 Peroxisomes and RLR signalling 
For many years the peroxisome was thought to only have a role in metabolic functions of 
the cell. However, most recently it is now emerging that peroxisomes are a platform for 
innate immune signalling. Several mitochondrial proteins such as Fis1 and Mff have been 
found to exist on peroxisomes, and more interestingly MAVS is similar in structure to 
these proteins. This led to a seminal study in which MAVS has been shown to reside on 
peroxisomes in addition to the mitochondria, and promote innate antiviral response from 
this organelle (Dixit et al., 2010). In this study, specific engineered localisation of MAVS 
to peroxisomes, mitochondria or the cytoplasm revealed that peroxisomal MAVS 
activated the immediate and transient IFN-independent signalling pathway to induce the 
expression of ISGs, while mitochondrial MAVS triggered a delayed IFN-dependent 






Figure 1.12: Two pathways of peroxisome biogenesis in mammals. 
(Agrawal and Subramani, 2016) 
  












primary site for induction of type III IFN (Odendall et al., 2014). This work has 
demonstrated that RLR signalling is able to induce the expression of type III IFNs (IFN-
) upon sensing of RLR by a diverse range of pathogens including reovirus, Sendai virus 
(SeV), and Dengue virus (DENV), as well as the pathogenic bacteria, Listeria 
monocytogenes (Odendall et al., 2014). In addition, peroxisomal MAVS is required for 
the expression of IFN-1, but not IFN-, whilst wild type and mitochondrial MAVS 
induced both types of IFNs upon SeV and DENV infection. Moreover, neutralisation of 
IFNR following reovirus infection in T84 intestinal epithelial cells resulted in a strong 
reduction of the ISGs viperin and IFIT1, suggesting the role of type III IFNs in 
controlling the antiviral ISGs expression even in the presence of type I IFNs. 
Furthermore, disruption of mitochondrial function in primary human keratinocytes by 
treatment with protonophore carbonyl cyanide m-chlorophenylhyddrazone (CCCP) that 
does not impact peroxisome function resulted in the inhibition the production of IFN-, 
while the expression of IFN-1 and viperin was enhanced, indicating that the RLR 
signalling pathway remain activate even in cells lacking mitochondrial function, and 
likely selectively induces from peroxisomes (Odendall et al., 2014). However, more 
recent work has shown that peroxisomal MAVS is able to activate the expression of both 
type I and III IFNs with the comparable level to mitochondrial MAVS following 
infection with various RNA viruses (Bender et al., 2015). Taken together, these 
observations indicate that peroxisomes act as a platform for the innate antiviral response. 
However, There is some controversy regarding the temporal and IFN-type induced via 
peroxisomal MAVS, with one report suggesting peroxisomal MAVS is activated early 




IFN- and equally expressed from peroxisomal MAVS. This discrepancy is most likely 
due to the different MAVS constructs and the sensitivity of assays that were used to 
measure type I IFN (Dixit et al., 2010, Odendall et al., 2014, Bender et al., 2015).   
 
1.4.3 Peroxisome evasion by viruses 
A number of viruses including HCMV, DENV, and WNV attempt to evade peroxisome-
mediated antiviral responses, by inducing the degradation and fragmentation of the 
peroxisome (You et al., 2015, Magalhaes et al., 2016). This is further confirmation that 
the peroxisome plays a role in innate signalling. Flavivirus infection with DENV and 
WNV has been shown to mediate the degradation of peroxisomes in A549 cells that 
results in a decrease in peroxisome number and in catalase enzyme activity (You et al., 
2015). In addition, the viral capsid protein of DENV and WNV was found to interact 
with peroxisomal membrane protein, PEX19, indicating that sequestration or degradation 
of peroxisomes may arise from the direct interaction of viral capsid and PEX19 (You et 
al., 2015). More recently, the HCMV vMIA protein (mitochondria-localized inhibitor of 
apoptosis) was found to reside on peroxisomes and induce their fragmentation. In 
addition, a reduction of IRF1 and viperin was found in the presence of vMIA, suggesting 
that vMIA disrupts the peroxisomal MAVS antiviral signalling. vMIA has also been 
shown to interact with PEX19 and specifically bind to peroxisomal MAVS, suggesting 
that the strategy of HCMV is to evade innate antiviral response by highjacking the 
peroxisomal membrane proteins (Magalhaes et al., 2016). Collectively, this confirms that 
the peroxisome is a significant organelle in innate immune signalling, however our 




1.5. Hypothesis and Aims  
The overall aim of this thesis is to determine the anti-HCV mechanism of viperin at the 
cellular level. The first objective was to define how viperin displays anti-HCV activity 
and investigate how viperin interacts with or alters the HCV membranous web at the 
ultrastructural level. Viperin interacts with a number of cellular and viral proteins, 
however this interaction does not explain the diverse nature of viperin function. 
Subsequent aims were therefore focused on the identification and characterisation of 
novel viperin cellular interacting partners in the hope of defining the antiviral or innate 
immune modulatory function of viperin. 
 
Hypothesis – Viperin localises to the HCV RC to impact HCV replication and 
furthermore novel viperin interacting partners remain to be discovered that will define the 
function of this multifunctional protein. 
 
We specifically aim to: 
1. Determine the anti-HCV mechanism of viperin at the level of the HCV RC. 
2. Identify novel cellular interacting partners of viperin using a yeast two-hybrid system. 







Materials and methods 
 
2.1 General Molecular Methods 
2.1.1 Synthetic oligonucleotides (primers) 
Synthetic oligonucleotides/primers in lyophilised form were ordered from GeneWorks at 
PCR/sequencing purity grade (see primer sequences in Appendix I). Stock of 
oligonucleotides was prepared by resuspending in MilliQ water to make up to a 
concentration of 20 μM. All oligonucleotides were stored at -20C. The volume of MilliQ 
water to make up a 20 μM of stock oligonucleotides was determined using the following 
formula: 
Volume of MilliQ water (ml) = number of nmoles of oligonucleotides/20 
 
2.1.2 Bacterial transformation 
The frozen α-Select Chemically Competent E. coli cells were purchased from Bioline
TM
 
for bacterial transformation. Competent cells were thawed on ice and 50 μl aliquots were 
placed in a pre-chilled microcentrifuge tube. Approximately 5-10 ng of plasmid DNA or 
5 μl of ligation product was added to the cell suspension and the tube was gently mixed 
by tapping and incubated on ice for 30 min. The mixture was then heat shocked at 42°C 
for 45 sec and immediately placed on ice for 2 min. Then, 950 μl of SOC medium (see 
Appendix II) was added to the transformation reaction and incubated at 37°C with 
shaking at 200 rpm for 1 hr. To transform the ligation reaction, cells were centrifuged 




were resuspended in the remaining SOC medium. The suspension was spread on LB-agar 
containing an appropriate antibiotic and incubated at 37°C overnight. For transformation 
of the plasmid DNA, 50-100 μl of the transformation reaction were plated on LB-agar 
containing an appropriate antibiotic and the plate was incubated at 37°C overnight. 
 
2.1.3 Small scale plasmid DNA extraction (Mini-preparation)   
A single transformed bacterial colony was inoculated into 5 ml of LB broth containing 
appropriate antibiotic and incubated with shaking at 200-250 rpm at 37°C overnight. The 
bacterial culture was pelleted by centrifugation at 5,000  g for 5 min and supernatant 
was discarded. Plasmid DNA extraction was performed using a QIAprep Spin Miniprep 
Kit (Qiagen) as per manufacturer’s instructions. In brief, cell pellets were resuspended in 
250 l of buffer P1 containing ribonuclease A (RNaseA). 250 l of buffer P2 was added 
and the preparation was gently mixed by inverting the tube. Then, 350 l of buffer N3 
was added and the mixture was centrifuged at 12,000  g for 5 min. The supernatant was 
collected and put in the mini spin column and subsequently centrifuged at 12,000  g for 
5 min. The column was washed with 750 l of PE buffer and then placed into the new 
collection tube. EB buffer (30-50 l) was added the column and the column/tube was 
centrifuged for 1 min to elute the plasmid DNA. 
 
2.1.4 Large scale plasmid DNA extraction (Maxi-preparation)  
A single transformed bacterial colony was inoculated into 200 ml of LB broth containing 
appropriate antibiotic. The culture was incubated with shaking at 37°C overnight. The 




AvantiTM J-25I Beckman Coulter centrifuge (JA10 rotor). Plasmid DNA extraction was 
performed using a NucleoBond
®
 Xtra Maxi kit (Macherey-Nagel) as per manufacturer’s 
instructions. In brief, cell pellets were resuspended in 12 ml of RES buffer containing 
ribonuclease A (RNaseA). 12 ml of LYS buffer was added and the preparation was gently 
mixed by inverting the tube and incubated at room temperature (RT) for 5 min. Then, 12 
ml of NEU buffer was added to the mixture and mixed by inverting 10-15 times before 
transferring to a pre-equilibrated NucleoBond Xtra column with filter. 15 ml of EQU 
buffer was added to the column with filter. The filter was then discarded and the column 
was washed with 25 ml of WASH buffer. Plasmid DNA was eluted with 15 ml of ELU 
buffer and subsequently precipitated with 10.5 ml of isopropanol. The precipitated 
plasmid DNA was pelleted by centrifugation at 15,000  g, 4C for 30 min using an 
AvantiTM J-25I Beckman Coulter centrifuge (JA25.50 rotor). The pellet was washed 
with 70% ethanol and resuspended with an appropriate volume of EB buffer. 
 
2.1.5 Restriction endonuclease digestion 
Restriction enzymes were obtained from New England Biolabs® Inc (NEB). Restriction 
enzyme digestions were performed in a 20 l total volume, which contained 1 g of 
plasmid DNA or 5 l of ligation reaction (see section 2.1.7), 10 Units of restriction 
enzyme(s) and 1 appropriate NEBuffer. The digestion reactions were incubated at 37C 
for 1-2 hr. The units of enzyme and appropriate buffer were provided on the NEB 





2.1.6 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed using 1-2% w/v agarose gel. The gels were 
prepared by dissolving molecular grade agarose (AppliChem) in 1 TAE buffer (see 
Appendix II). Gels were cast in a BioRad® Sub-Cell GT Minitank. DNA samples were 
mixed with 6 Loading dye (New England Biolabs) and loaded into wells on the agarose 
gel. Electrophoresis was performed at 100 Volts. To estimate the product size, 0.5 g of 1 
kb or 100 bp DNA markers (New England Biolabs) were run simultaneously. Following 
electrophoresis, gels were stained in 3 GelRed
TM
 Nucleic Acid Gel Stain in DMSO 
(Biotium Inc) for 10-15 min. DNA bands were visualised under UV Transilluminator 
(BioDoc-ItTM Imaging System, UVP) using Quantity One
®
 Version 4.6 Basic software 
(BioRad). 
 
2.1.7 DNA ligation 
Ligation reactions were performed using the Quick Ligation
TM
 Kit (NEB). Ligation 
mixtures contained 50 ng of digested plasmid, a 3-fold molar excess of the similarly 
digested insert DNA, 10 μl of Quick Ligation Reaction Buffer (2) and 1 μl of Quick T4 
DNA Ligase (2,000 Units/μl) and dH2O to a final volume 20 l. The reaction was then 
mixed thoroughly and incubated at RT for 5 min and chilled on ice before being used in a 
transformation process or being stored at -20°C until use.   
 
2.1.8 DNA purification from agarose gel 
DNA bands were purified from agarose gels using a MinElute® Gel Extraction Kit 




excised from the gel with a clean, sharp scalpel and the gel slices were mixed with 3 
volumes of QG buffer (100  mg of the gel slice was equal to 100 l) and the agar was 
melted at 50C for 5-10 min until the gel slice was completely dissolved. One gel volume 
of isopropanol was added to the mixture and then applied to the QIAquick column 
following by centrifugation at 12,000  g for 1 min. The flow-through was discarded and 
the column was washed with 750 l of PE buffer (centrifugation at 12,000  g for 1 min). 
To elute the DNA from the column, the column was placed into a new 1.5 ml 
microcentrifuge tube and 30-50 μl of EB buffer (10 mM Tris-HCl, pH 8.5) was added to 
the column. After 1 min incubation at RT, the column/tube was centrifuged at 12,000  g 
for 1 min. 
 
2.1.9 DNA sequencing 
DNA sequencing (Sanger sequencing) was performed by the Australian Genome 
Research Facility (AGRF, Australia). Samples were prepared according to the sample 
submission guidelines. The DNA sample consisted of 1μg of plasmid DNA, 9.6 pmol of 
an appropriate forward or reverse primer and adjusted to 12 l with dH2O. DNA 
sequencing results were analysed using FinchTV software (version 1.4.0) (Geospiza, 
Perkin Elmer®) and compared to known sequences in the Genbank database using the 
Basic Local Alignment Search Tool (BLAST) from the National Centre for 





2.1.10 Total RNA extraction 
Total cellular RNA was extracted using TRIzol® Reagent (Life technologies
TM
). Cells 
grown in a monolayer in 6-well or 12-well culture trays (Corning Life Sciences) were 
washed with PBS once and directly lysed by adding 1 ml of TRIzol® Reagent per well of 
the 6-well tray. Cell lysates were transferred to RNase-Free 1.5 ml microcentrifuge tubes 
(Ambion). One-fifth volume of chloroform (0.2 ml for 1 ml of TRIzol) was added to the 
preparation, mixed thoroughly, incubated at 25C for 2-3 min, and subsequently 
centrifuged at 12,000  g at 4C for 15 min. The top aqueous layer was transferred to a 
new tube. Total RNA was precipitated by adding 0.5 volume of cold isopropanol, mixed 
well and incubated at RT for 10 min. The RNA pellet was precipitated by centrifugation 
at 12,000  g at 4C for 10 min and washed with 1 volume of 75% (v/v) ethanol in 
RNase-free dH2O. After centrifugation at 7,500  g at 4C for 5 min, the total RNA pellet 
was air-dried at RT. The RNA pellet was dissolved in 10-20 l of RNase-free dH2O. 
RNA samples were kept at -80C until use.  
 
2.1.11 Nucleic acid quantification 
DNA or RNA samples were quantified using the Nanophotometer (Implen GmbH). The 
absorbance at 260 nm was read and concentrations of samples of were calculated using 
the following formula: 
Nucleic Acid (g/ml) = A260nm x dilution factor x 50 (DNA) or 40 (RNA)  
The purity of nucleic acids was determined by measuring the ratio of the absorbance at 
260 nm and 280 nm (A260nm/A280nm). The DNA and RNA preparations used in this study 




2.1.12 First-strand cDNA synthesis 
First-strand cDNA was produced from the total RNA using M-MLV Reverse 
Transcriptase RNase H minus, point mutant (Promega). The reaction was performed in a 
pre-chilled RNase-free microcentrifuge tube containing 1 g of total RNA, 1 g of 
random hexamer primer (Geneworks) and RNase-free dH2O to a final volume of 14 l. 
The preparation was mixed gently and incubated at 70C for 5 min. The tube was then 
cooled down at 4C for a further 5 min and the following mixture of 5 μl of 5 M-MLV 
RT Reaction Buffer (Promega), 1.25 μl of 10 mM each dNTP mix (Promega), 0.5 μl of 
40 Units/μl RNAsin
®
 RNase Inhibitor (Promega), 1 μl of 200 Units M-MLV RT, RNase 
H (-) Point Mutant (Promega) and 3.25 l dH2O was added to the tube. Samples were 
mixed gently and incubated at RT for 10 min, then 42°C for 50 min. Finally, samples 
were diluted to a final volume of 100 l with dH2O and stored at -20°C. 
 
2.1.13 Polymerase Chain Reaction (PCR) 
PCR reactions were performed using a Thermal Cycler (S1000TM, BioRad®). Q5® 
High-Fidelity DNA polymerase enzymes were mainly used for cloning purposes. The 
reactions were prepared in a 0.2 ml PCR tube containing 25 l of Q5 High-Fidelity 2 
Master Mix, 1.25 l each of 20 M forward and reverse primers, 10 ng of DNA template 
and dH2O to a final volume of 50 l. PCR conditions consisted of initial denaturation at 
98C for 30 sec, followed by 30 cycles of 98C for 10 sec, an appropriate annealing 
temperature for 30 sec, 72C for 20-30 sec/kb and ended up with a final extension at 
72C for 2 min. The PCR reactions were visualised by agarose gel electrophoresis (see 




2.1.14 Real-Time Quantitative PCR (qPCR) 
Quantitative PCR was used to determine relative levels of target RNA using the 
comparative CT method. qPCR reactions were performed using SYBR® Green PCR 
Master Mix (Applied Biosystems). The reactions consisted of 5 l of cDNA, 10 l of 
SYBR® Green PCR Master Mix and 300 nM each forward and reverse primer (see 
Appendix I). All samples were analysed in duplicate and also processed to quantify the 
RPLPO housekeeping gene in parallel to normalise input cDNA levels. An ABI StepOne 
Plus Real-Time PCR System (Applied Biosystems) coupled with the ABI PRISM 7000 
SDS Software was used to control the reaction and comprised denaturation at 95°C for 10 
min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. A final step of 95°C 
for 15 sec, 60°C for 1 min, followed by increasing the temperature by 0.5°C increment up 
to 95°C was performed to facilitate the melting curve. Data were analysed using the 
StepOne
TM
 v2.2 software and the threshold was set at 0.2 for all experiments. 
 
2.1.15 Extraction of cellular proteins 
Total cellular proteins were extracted from 80-90% confluent cell monolayers in 6-well 
trays. Culture media was removed and cells were washed with PBS. Pre-chilled RIPA 
buffer or NP-40 buffer (200 l) (see Appendix II) containing protease inhibitor cocktail 
(Sigma Aldrich) was added to the well. Cell lysate was then transferred to a 1.5 ml 
microcentrifuge tube and placed on ice for 20 min. The lysates were centrifuged at 
12,000  g at 4C for 10 min. The supernatant protein fraction was collected and then 





2.1.16 SDS-PAGE and protein transfer 
SDS-PAGE was performed as described by Laemmli (1970). Protein samples were 
prepared by boiling for 5 min with 1 SDS PAGE sample buffer (see Appendix II) before 
loading onto the gel (Mini Protean 4-15% Precast Gels, Biorad) alongside 7.5 μg 
Precision Plus Protein® Standards-Kaleidoscope (BioRad). Gels were run in SDS-PAGE 
running buffer at 100 Volts for 1-2 hr depending on protein size. Gels were then 
equilibrated in cold Transfer Buffer (see Appendix II) for 5-10 min. Nitrocellulose 
Blotting Membrane (Amersham ™ Hybond ECL) and filter papers were soaked in cold 
Transfer Buffer before assembling the Western Blot Transfer Apparatus (Mini Trans Blot 
Electrophoretic Transfer Cell, BioRad) as per manufacturer’s instruction. Proteins were 
transferred onto the Nitrocellulose Blotting Membrane at 100 Volts for 90 min in a cold 
room. 
 
2.1.17 Western blotting 
Following protein transfer, membranes were blocked with 5% skim milk in 0.1% TBS-T 
for 1 hr with gentle agitation. Membranes were rinsed twice with 0.1% TBS-T (see 
Appendix II) and then incubated in the appropriate dilution of primary antibody in 1% 
skim milk (see Appendix III) overnight at 4°C. Thereafter, membranes were washed three 
times in 0.1% TBS-T for 5 min per wash with gentle agitation to remove unbound 
primary antibody. Membranes were then incubated with gentle agitation in the 
appropriate horseradish peroxidase-conjugated secondary antibody for 1 hr and washed 
as described before. Secondary antibody detection was carried out using the ECL Plus 






 West Femto Maximum Sensitivity Substrate detection kit 
(ThermoScientific) with chemiluminescent detection as per manufacturer’s instructions. 
Protein bands were visualised by a Chemi DocTM MP Imaging System (BioRad) or by 




Whole Cell lysate preparation using NP-40 buffer as described in 2.1.15 were subjected 
to co-immunoprecipitation. All steps were performed at 4°C. Lysates were pre-cleared by 
incubation with 20 µl of protein A/G PLUS agarose (Santa Cruz Biotechnology) for 30 
min. Samples were then centrifuged at 3,000 × g for 30 sec at 4°C, and supernatants were 
collected and incubated with 1 µg of the appropriate antibody for overnight. Protein A/G 
PLUS agarose beads (20 µl) were equilibrated with NP-40 lysis buffer and then added to 
each sample prior to incubation for 1 hr. Beads were then pelleted by centrifugation at 
3,000 × g for 30 sec at 4°C and washed 5 times with 500 μl of NP-40 lysis buffer. 
Washed beads were resuspended in 30 µl of 2 SDS-PAGE sample buffer and boiled for 
10 min followed by Western blot analysis. 
 
2.1.19 Dual Renilla luciferase assay 
Luciferase activity was measured using the Dual Luciferase Assay System (Promega). 
Cells were seeded at 5  10
4
 cells/well in 12-well trays, cultured overnight and co-
transfected with the plasmid of interest (500 ng), ISRE-luc or IFN-β-Luc (500 ng) and 




poly I:C (for IFN-β-Luc) for 8 hr and then washed once with PBS. 5× Passive Lysis 
Buffer (Promega) was diluted to 1× lysis buffer with MilliQ water, and 80 l of working 
lysis buffer was added to each well followed by a single freeze-thaw to harvest the cell 
lysate. 20 l of cell lysate was then added to an Opti-plate 96 (Perkin Elmer) and 
luciferase out-put was measured on a GloMax
TM
 96 Microplate Luminometer (Promega). 




 In situ Proximity Ligation Assay  
Cells were seeded at 7  10
4
 cells/well in 12-well trays and cultured overnight prior to 
transient transfection. Cells were washed with 1x PBS and then trypsinised by adding 200 
l of trypsin and incubated for 2-5 min before adding 800 l of complete media. 200 l 
of cell suspension was then plated per well into 96-well trays. After cell attachment (24 
hr), cells were fixed with cold Acetone:Methanol (1:1) for 5 min, then washed 3 times 
with PBS. Proximity ligation assays (PLA) were conducted using the Duolink
®
 In situ kit 
(Olink
®
 Biosciences) as per manufacturer’s instructions. In more detail, fixed cells were 
blocked with 5% BSA in PBS for 1 hr at RT and then washed 3 times with PBS. A 
mixture of appropriate primary antibodies (different species such as mouse and rabbit) 
was added and the plate was incubated for 1 hr at RT, and then washed 5 times with PBS. 
An isotype control for each primary antibody species was used as a negative control. 
PLA probe mixture (anti-mouse minus and anti-rabbit plus) in 1% BSA was added to the 
wells and the plate was incubated at 37°C in a humidity chamber for 1 hr. Cells were then 
washed with wash buffer A (Olink
®
 Biosciences) 2 times for 5 min each. The ligation 




ligase. 40 l of ligation solution was added to wells and incubated at 37°C in humidity 
chamber for 30 min. The plate was washed 2 times with wash buffer A for 2 min each. 
An amplification step was performed by adding the mixture of 8 l of 5 amplification 
stock, 31.5 l of dH2O and 0.5 l of polymerase to the wells and incubating at 37°C in a 
humidity chamber for 1 hr. The reaction was washed 2 times with wash buffer B (Olink
®
 
Biosciences) for 10 min each, before a final wash with 0.01 wash buffer B for 1 min. 
Nuclear DAPI staining (described in section 2.6.5) was generally performed after 
proximity ligation assay. The cells were visualised by wide-field fluorescence 
microscopy and a red dot indicated a protein-protein interaction.  
 
2.2 Yeast Two-Hybrid system 
Yeast two-hybrid experiments were performed using the Matchmaker Gold Yeast Two-
Hybrid system (Clontech) according to manufacturer’s instructions. Briefly, yeast two-
hybrid systems are tools for identifying and characterising novel protein-protein 
interactions. In a Matchmaker GAL4-based two-hybrid assay, a known protein of interest 
or bait protein (viperin in this study) is expressed as a fusion to the Gal4 DNA-binding 
domain (DNA-BD), while libraries of prey proteins derived from a cDNA library are 
expressed as fusions to the Gal4 activation domain (AD) (Fields and Song, 1989, Chien 
et al., 1991). When a bait protein interacts with a prey protein, the DNA-BD and AD are 
brought into close proximity to restore GAL4 function and subsequently activate 





2.2.1 Competent yeast cell preparation 
Competent yeast cells were prepared using a Yeastmaker Yeast Transformation System 2 
(Clontech). Yeast cells from a frozen stock were streaked on YPDA agar plate (see 
Appendix IV). The plate was incubated at 30C for 3-5 days until colonies appeared. One 
yeast colony (diameter 2–3 mm) was then inoculated into 3 ml YPDA medium in a sterile 
15 ml culture tube and incubated at 30°C with shaking at 250 rpm for 8–12 hr. 5 l of the 
culture were transferred to 50 ml of YPDA in a 250 ml flask and incubated with shaking 
until the OD600 reached 0.15–0.3 (16–20 hr). Yeast cells were pelleted by centrifugation 
at 700 g for 5 min at RT. The supernatant was discarded and the pellet was resuspended 
in 50 ml of fresh YPDA. Cells were incubated at 30°C with shaking until the OD600 
reaches 0.4-0.5 (3-5 hr). Cells were pelleted at 700 g for 5 min at RT and washed in 30 
ml sterile, dH2O. The cell pellet was resuspended in 1.5 ml of 1.1xTE/LiAc, then 
transferred to a 1.5 ml microcentrifuge tube and centrifuged at 14,000  g for 15 sec. The 
supernatant was discarded and the cell pellet was resuspended in 600 μl of 1.1xTE/LiAc. 




2.2.2.1 Small scale transformation 
The transformation was performed in a pre-chilled 1.5 microcentrifuge tube. Plasmid 
DNA (100 ng) was combined with 5 μl of denatured-carrier DNA (10 μg/μl). Competent 
yeast cells (50 μl) were added to the mixture. PEG/LiAc (500 μl) was then added, gently 




was added and the transformation mixture was incubated at 42°C for 15 min. Yeast cells 
were then pelleted by centrifugation for 15 sec at 14,000  g. The supernatant was 
removed and cells were resuspended in 1 ml of YPD plus medium. Yeast cells were 
pelleted by 14,000  g centrifugation and resuspended in 0.9% (w/v) NaCl solution. The 
cell suspension was diluted to 1/10 and 1/100 and 100 μl of each dilution was spread onto 
an appropriate SD selective medium. 
 
2.2.2.2 Library scale co-transformation  
The library scale co-transformation was performed in a pre-chilled 15 ml tube. Bait 
pDNA was combined with linearised prey plasmid and purified ds cDNA (see section 
2.2.5.2.3) and then 20 μl of denatured-carrier DNA (10 μg/μl) was added. Competent 
yeast cells (600 μl) were added to the mixture.  PEG/LiAc (2.5 ml) was then added, 
gently mixed and incubated at 30°C for 45 min with gentle mixing every 15 min. DMSO 
(160 μl) was added and the mixture was incubated at 42°C for 20 min. Yeast cells were 
then pelleted by centrifugation at 700  g for 5 min. The supernatant was removed and 
cells were resuspended in 3 ml of YPD plus medium and incubated at 30°C with shaking 
for 90 min. Yeast cells were pelleted by centrifugation at 700  g for 5 min and 
resuspended in 0.9% (w/v) NaCl solution. The cell suspension was diluted to 1/10 and 
1/100 and 100 μl of each dilution was spread onto an appropriate SD selective medium. 
 
2.2.3 Plasmid DNA extraction from yeast cells  
A single colony was inoculated into an appropriate medium and incubated at 30°C with 




Isolation Kit (Clontech) as per manufacturer’s instructions. An overnight culture was 
pelleted by centrifugation and washed with 500 μl of 10 mM EDTA. The washed yeast 
cell pellet was then resuspended in 200 μl of ZYM buffer. Yeast cell walls were disrupted 
by adding 20 μl of Zymolase suspension and incubated with gentle shaking at 30°C for 1 
hr. The spheroplasts (disruption of yeast cell walls) were pelleted by centrifugation at 
2,000  g for 10 min and then subjected to plasmid DNA extraction by SDS/alkaline lysis 
method. Briefly, the spheroplasts were resuspended in 250 µl of Y1 Buffer/RNase A 
solution and lysed by adding 250 µl of Y2 Lysis Buffer. Y3 Neutralization Buffer (300 
µl) was then added and mixed gently by inverting the tube 6-8 times. The lysate was 
clarified by centrifuging at 11,000  g for 5 min at RT. The supernatant was transferred 
to a Yeast Plasmid Spin Column inside a 2 ml collection tube and centrifuged at 11,000  
g for 1 min. The column flow-through was discarded and the spin column was washed 
with 450 µl of Y4 Wash Buffer. Plasmid DNA was eluted by adding 50 µl of YE Elution 
Buffer and incubated at RT for 1 min before centrifugation at 11, 000  g for 1 min. 
 
2.2.4 Construction and testing of the bait (viperin) protein expression plasmid  
2.2.4.1 Cloning of pGBKT7-viperin 
pLenti6-Viperin-Flag plasmid (Helbig et al., 2013) was diluted to 1 ng/l and used as a 
template for viperin-coding DNA sequence amplification. Viperin was amplified using a 
Thermo Cycler (BioRad). The PCR reaction mixture (50 l) consisted of 2 l of 
template, 1.25 l forward and reverse primers (Appendix I) (at 20 M), 25 l of Q5 
High-Fidelity 2 Master Mix (New England Biolabs, USA), and made up to 50 l with 




(each cycle was 10 sec at 98°C, 30 sec at 50°C, and 1.15 min at 72°C) were performed 
and this was followed by 2 min at 72°C for the final extension. The PCR product was 
visualised on 1% agarose gel using electrophoresis, GelRed staining and a UV 
transilluminator. The PCR product was then purified using a PCR clean-up kit (Qiagen).  
 
The bait plasmid (pGBKT7) (Clontech, see Appendix V) and purified-viperin amplicon 
were double digested with EcoRI-HF and BamHI-HF at 37C overnight. The double 
digested-products were subjected to 1% agarose gel electrophoresis and then purified 
from the agarose gel using MinElute® Gel Extraction Kit (Qiagen). The viperin amplicon 
was ligated with the linearised pGBKT7 plasmid. The ligation reaction was then 
transformed into -Select Chemically Competent Cells (Bioline), plated on a LB-Kan 
plate and incubated at 37C overnight. Five clones were randomly picked to screen the 
positive clones. They were individually inoculated into 5 ml of LB-Kan broth and 
incubated at 37°C with shaking at 200 rpm overnight. The cells were harvested by 
centrifugation at 4,000  g for 5 min. The plasmids from each clone were extracted from 
E. coli cell pellets using a miniprep kit (Qiagen).  
 
The recombinant plasmids were double digested with the EcoRI-HF and BamHI-HF 
restriction endonucleases. The mixture was incubated at 37°C for 3 hr. The digested 
product was subjected to 1% agarose gel electrophoresis and GelRed staining in order to 
ensure that the plasmid contained the correct DNA insert. The recombinant plasmids that 




undesired mutations was selected for large-scale plasmid DNA preparation (see section 
2.1.4). 
 
The recombinant pGBKT7-viperin plasmid was then transformed into competent 
Saccharomyces cerevisiae strain Y2H gold and plated on the SD/-Trp selective medium 
agar (see Appendix IV) and incubated at 30C for 3-5 days. After incubation, five clones 
were randomly picked to check viperin insertion in pGBKT7 plasmid by colony PCR 
before being subjected to viperin expression analysis. Yeast colonies were resuspended in 
20 l of 20 mM NaOH, then boiled at 95°C for 10 min and 1 l of the boiled yeast cells 
was used as a template for colony PCR. 
 
2.2.4.2 Viperin expression 
A colony of selected transformed yeast clones was inoculated into 2 ml of SD/-Trp broth 
(see Appendix IV) and the culture was grown at 30°C with shaking at 200-250 rpm 
overnight. 100 l of the overnight culture was added into 10 ml of SD/-Trp broth. The 
preparation was incubated at 30°C with shaking at 200-250 rpm until the OD600 reached 
0.4-0.6. Yeast cells were pelleted and resuspended in pre-warmed complete cracking 
buffer (see Appendix IV) containing a cocktail protease inhibitor. 100 l of cracking 
buffer was used per 7.5 OD600 units of cells. The cell suspension was then transferred to a 
1.5 ml microcentrifuge tube containing 80 l of glass beads per 7.5 OD600 units of cells. 
Samples were heated at 70°C for 10 min and then vigorously vortexed for 1 min. Cell 
debris was pelleted by centrifugation at 14,000  g, 4°C for 10 min and the supernatant 




debris was pelleted by centrifugation at 14,000  g, 4°C for 5 min and the supernatant 
was subjected to Western blot analysis to confirm the presence of viperin in the yeast 
cells using anti-cMyc clone 4A6 (Millipore) and specific anti-viperin antibody (Enzo life 
sciences). 
 
2.2.4.3 Toxicity and auto-activation testing 
One clone of yeast cells expressing viperin was selected for toxicity and auto-activation 
analysis. Yeast cells carrying pGBKT7-viperin or pGBKT7-empty (negative control) 
were plated onto the SD/-Trp, SD/-Trp/X and SD/-Trp/X/A agar plates (see Appendix 
IV) and grown at 30C for 3-5 days. Saccharomyces cerevisiae strain Y2H gold carrying 
pGBKT7-53 was mated with Saccharomyces cerevisiae strain Y187 carrying pGADT7-T 
and plated on DDO/X/A (see Appendix IV) for use as a positive control for auto-
activation testing. If the bait protein is not toxic to the yeast cell, the size of colonies 
containing bait plasmid are similar to colonies containing the empty plasmid on SD/-Trp. 
White colonies on SD/-Trp/XA plate represent non auto-activation of the bait protein. 






Table 2.1: Expected results of toxicity and auto-activation testing 
Sample  Selective agar plate 2 mm colonies Color  
Viperin autoactivation test SD/-Trp Yes  White  
Viperin autoactivation test SD/-Trp/X Yes  White  
Viperin autoactivation test SD/-Trp/X/A No No growth 
Negative control SD/-Trp Yes  White  






2.2.5 Construction of the IFN--stimulated Huh-7 cDNA library  
2.2.5.1 Optimisation of the concentration and time point of IFN- for Huh-7 
stimulation 
Huh-7 were seeded at 7  10
4 
cells/well in 12-well culture tray and subsequently treated 
with IFN--2A at 100, 250 and 1,000 Units/ml. Huh-7 cells were stimulated with IFN--
2A at a concentration of 1,000 Units/well for 8, 16 and 24 hr (time course analysis). Each 
IFN--2A concentration and time point was assessed in triplicate. Cells were then 
collected for RNA extraction and cDNA synthesis with following analysis by real time 
RT-PCR. 
 
2.2.5.2 IFN--stimulated Huh-7 cDNA library construction 
The library was generated using Make Your Own “Mate & Plate” Library System 
(Clontech). The process to generate the library was described below. 
2.2.5.2.1 Generating IFN--stimulated Huh-7 cell cDNA library 
Huh-7 cells at 7  10
4 
cells were stimulated with IFN--2A at the optimal concentration 
and time point (1000 Units/ml, 8 hr). Cells were harvested for RNA extraction using 
RNeasy Mini Kit (Qiagen). Total RNA was used as a template for generating the first 
strand cDNA using an oligo-dT primer. In brief, 1.5 g (3l) of total RNA was combined 
with CDS III (oligo-dT primer) and the mixture was incubated at 72°C for 2 min and 
immediately cooled on ice for 2 min. A master mix (9 l) containing the following 
components; 2 l of 5 First-Strand buffer, 1 l of 100 mM DTT, 1 l of 10 mM dNTP 
mix and 1 l of SMART MMLV Reverse Transcriptase was prepared and added to the 




modified oligo was added to reaction mixture and incubated at 42°C for 10 min followed 
by 75°C for 10 min. After cooling down at RT, 1l of RNase H (2 Units) was added and 
the reaction was incubated at 37°C for 20 min. The cDNA was used for long-distance 
PCR (LD-PCR) amplification. 
 
2.2.5.2.2 Double-stranded cDNA (ds cDNA) synthesis by long-distance PCR 
Double-stranded cDNA (ds cDNA) was amplified by long-distance PCR (LD-PCR) using 
Advantage
 
2 Polymerase Mix (Clontech). The LD-PCR reaction mixture was set up in 2 
reactions. Each reaction (100 l) consisted of 2 l of first-strand cDNA (from 2.2.5.2.1), 
70 l of dH2O, 10 l of 10 Advantage 2 PCR buffer, 2 l of 50 dNTP mix, 2 l of 
5’PCR primer, 2 l of 3’PCR primer, 10 l of 10 Melting solution and 2 l of 50 
Advantage 2 Polymerase Mix. The LD-PCR mixture was placed in a Thermo cycler 
(BioRad) and the cycler program was started at 95°C for 30 sec. Following incubation, 
20 cycles (each cycle was 10 sec at 95°C, 6 min with increasing by 5 sec every cycle at 
95°C) were performed, with a final step of 68°C for 5 min. The PCR products (7 l) from 
two reactions were separately visualised by 1% agarose gel electrophoresis and GelRed 
staining using UV transilluminator. The LD-PCR product was subsequently purified as 
described in Section 2.2.5.2.3. 
 
2.2.5.2.3 Double-stranded cDNA (ds cDNA) purification  
The LD-PCR product was purified using CHROMA SPIN + TE 400 column (Clontech). 
Briefly, both samples (93 l of each reaction) from 2.2.5.2.2 was applied separately to the 




700  g for 5 min. Two purified-samples were combined and cDNA precipitation was 
performed. One in ten volume of 3M sodium acetate was added and followed by 2.5 
volumes of ice-cold 95-100% ethanol. The sample was placed at -20°C for 1 hr and then 
centrifuged at 14,000 rpm for 20 min at RT. The supernatant was discarded and the pellet 
was air-dried for 10 min. The cDNA pellet was resuspended in 20 l dH2O. This ds 
cDNA library was ready for the following screening process. 
 
2.2.6 Screening viperin interacting partners by co-transformation method 
pGBKT7-viperin plasmid (5 g), purified-ds cDNA library (5 g, from section 
2.2.5.2.3) and linearised pGADT7-Rec plasmid (3 g) were combined in a pre-chilled 
microcentrifuge tube and transformed into competent Saccharomyces cerevisiae strain 
Y2H gold. The co-transformation reaction was performed according to section 2.2.2.2 
and subsequently resuspended in 15 ml of 0.9% (W/V) NaCl in the last step before 
plating. The resuspended-cells were diluted to 1:10, 1:100, 1:1,000 and 1:10,000 and 100 
l of each dilution was plated on SD/-Trp, SD/-Leu and DDO plates (25mm dish) (see 
Appendix IV) to quantify the transformation efficiency. Two hundred microliters of the 
remainder were spread on DDO/X/A plate (100 mm dish) (see Appendix IV) for 50 
plates and incubated at 30°C for 3-5 days.  
 
2.2.7 Rescue plasmid from yeast cells 
After incubation, all of the blue colonies that grew on DDO/X/A were streaked on a 
higher stringency QDO/X/A agar plate (see Appendix IV). All of the colonies that grew 




The mixture of bait and prey plasmids were rescued from yeast cells using Easy Yeast 
Plasmid Isolation Kit (Clontech) as described in section 2.2.3. All of the mixture 
plasmids were transformed into bacterial cells and plated on LB-Amp to select prey 
plasmids. The positive prey plasmids were identified by sequencing analysis using a T7 
sequencing primer (see Appendix I). The positive interactions were confirmed by the co-
transformation method. Candidate prey plasmid and pGBKT7-viperin or pGBKT7-empty 
plasmid were co-transformed into competent Saccharomyces cerevisiae strain Y2H gold 
and then plated onto DDO/X and DDO/X/A. The genuine and false positive interactions 





Table 2.2: Genuine and false positive interactions 




DDO/X Yes Blue 
DDO/X/A Yes Blue 
pGBKT7 empty + 
candidate prey 
DDO/X Yes White 




DDO/X Yes Blue 
DDO/X/A Yes Blue 
pGBKT7 empty + 
candidate prey 
DDO/X Yes Blue 






2.3 Tissue Culture Techniques 
2.3.1 Tissue culture medium 
Mammalian cell lines were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 4.5 g/L D-Glucose, 25 mM HEPES and 2 mM L-glutamine (Gibco BRL, 
Invitrogen). Standard DMEM was supplemented with 10% (w/v) foetal calf serum (FCS; 
Trace Biosciences), Penicillin (Invitrogen; 100 U/ml) and Streptomycin (Invitrogen; 
100μg/ml).  Blasticidin HCL 5 μg/ml (Invitrogen), Puromycin 3 μg/ml (Sigma-Aldrich) 
or Geneticin (G418) 800 μg/ml (Invitrogen) were added for selection and maintenance of 
stable cell lines in this study.  
 
2.3.2 Cell maintenance 





, or 175 cm
2




 or 10 cm
2
) or tissue culture 
trays (6, 12, 24, 48 or 96-well) (Corning Life Sciences). Near-confluent cells were 
passaged by removing culture medium, washing once with 1 PBS (see Appendix II), 
trypsinising with a small volume of Trypsin-EDTA (see Appendix II). Cells were then 
placed in the CO2 incubator at 37°C for 3-5 min. Fresh culture medium was added to 
resuspend the cells. Cells were counted using a Neubauer Haemocytometer (Brand) with 
Trypan Blue (see section 2.3.3). Cells were grown at 37°C, 5% CO2 in a humidified 
Panasonic CO2 incubator (Panasonic Healthcare CO., Ltd). Cells were passaged every 2-





2.3.3 Trypan blue exclusion 
Cells were counted using a Neubauer Haemocytometer (Brand) and Trypan Blue Stain 
solution (prepared by the Tissue Culture Service Unit). Typsinised cells were mixed with 
an equal volume of Trypan Blue and loaded into a haemocytometer. Cell concentration 
was then calculated using the following equation: 




2.3.4 Cryopreservation of cells 
Cells were cryopreserved in liquid nitrogen. 80% confluent of cells were trypsinised, 
resuspended in fresh culture media and centrifuged at 1,000  g for 5 min. Culture media 
were removed and cell pellets were resuspended in fresh culture media. An equal volume 
of 2 freezing media [50% media, 30% FCS, 20% DMSO (Sigma)] was added to cell 
suspension and mixed gently. Cells were aliquoted (1 ml/vial) in sterile cryopreservation 
tubes (CryoTubeTM vials, NUNCTM). Cryotubes were transferred to a freezing chamber 
(Nalgene®) containing fresh isopropanol and placed in a -80°C freezer to achieve a 
cooling rate of -1°C/min. For long-term storage vials were stored in a liquid nitrogen 
based cryopreservation system, while stocks for short-term use (within 3 months) were 
kept in the -80°C freezer. 
 
2.3.5 Resuscitation of frozen cells 
Cryopreserved vials containing frozen cell lines were thawed quickly in a 37°C water 
bath and gently transferred to a T25 cm
2
 or T75 cm
2
 tissue culture flask containing pre-




overnight. Fresh tissue culture medium containing an appropriate antibiotic (if necessary) 
was replaced the next day. 
 
2.3.6 Transient transfection of plasmid DNA 
Mammalian cells were transiently transfected with expression plasmid DNA using 
Viafect (Promega) to achieve protein overexpression. Cells were seeded at 3 × 10
4
 cells 




(12-well tray) and 2 × 10
5
 cells (6-well tray) 24 hr prior to 
transfection such that the cells were 50-70% confluent at the time of transfection. 
ViaFect™ Transfection Reagent was used as per manufacturer’s instruction. Briefly, 
ViaFect reagent was warmed up at RT for 10 min before use. Transfection complexes 
were prepared by mixing 100 μl of Opti-MEM
® 
media (Life Technologies) with 3 μl of 
ViaFect reagent and 2 μg of DNA (for each transfection per well of a 6-well tray). 
Following 15-20 min incubation at RT, the mixture was added drop-wise to the cell 
monolayer. The plates were then gently swirled and returned to normal tissue culture 
condition (37ºC, 5% CO2). Assays were performed 24-72 hr post transfection.  
 
2.3.7 Generation of stable cell lines 
Stable over-expressing cell lines were generated using a direct transfection method or an 
intermediate lentiviral or retroviral particle production method. 
2.3.7.1 Direct transfection 
Cells were transfected with plasmid DNA using the protocol as previously described in 
section 2.3.6. A specific antibiotic at an appropriate concentration (see section 2.3.1) for 




days post-transfection. Untransfected cells treated with the same antibiotic were used a 
negative control. The cell line was considered as stable cells after the negative control 
culture was non-viable.  
 
2.3.7.2 Lentiviral particle production 
The lentiviral particles were produced in 293FT cell line. 293FT cells were seeded in a 6 
well tray at a concentration of 2 × 10
5
 cells/well to be transfected the following day. The 
total plasmid DNA was prepared by mixing an equal amount of target plasmid DNA with 
the lentiviral packaging plasmids psPAX2 (a packaging plasmid, Addgene plasmid # 
12260), pMD2.G (VSV-G envelope expressing plasmid, Addgene plasmid # 12259) and 
pRSV-Rev (3rd generation lentiviral packaging plasmid, Addgene plasmid # 12260). The 
transfection mixture was prepared by mixing 100 μl of Opti-MEM® media (Life 
Technologies) with 3 μl of ViaFect reagent and 2 μg of total plasmid DNA and 
incubating for 15-20 min. The mixture was added to the cells before returning them to a 
standard CO2 incubator. Culture media were changed the following day. The supernatants 
from 293FT cells were harvested at 48 and 72 hr post-transfection, then pooled, filtered 
through a 0.45 μm filter membrane, aliquoted into vials and stored at -80°C.   
 
To generate the stable cells, the naïve cell lines or Huh-7 cells in this study were seeded 
at 2×10
5
 cells/well in 6-well tray prior to lentiviral transduction. The lentiviral aliquot 
was rapidly thawed and then diluted 1:3 in complete media containing a final 
concentration of 8 μg/ml of polybrene (Millipore). The diluted lentiviral particles were 




cells were returned to the incubator. The antibiotic selection was started 3 days post-
transduction (Blasticidin at 5 μg/ml for pLenti6/V5 derivatives, puromycin at 3 μg/ml for 
pTRIPz and GIPz shRNA derivatives). Treatment of non-transduced cells was used as a 
negative control. The polyclonal cell line was considered as stable cells when the 
negative control culture was non-viable. 
 
2.3.7.3 Stable transduction of GIPz shRNA OSBP to generate OSBP knockdown cell 
lines 
Six clones of plasmid DNA carrying shRNA targeting to OSBP were obtained from Open 
Biosystems (Thermo Scientific) in a pGIPz lentiviral construct encoding a green 
fluorescent protein. Lentiviral particles expressing OSBP shRNA were generated as 
described in section 2.3.7.2, and transduced Huh-7 cells were selected using 3 μg/ml 
puromycin (Invitrogen). Huh-7 cells were used as a negative control for puromycin 
selection. Non-targeting control (NTC) shRNA were also generated and used as a control 
for further experiments. The cells were considered as stable cell lines when the negative 
control culture was non-viable. Knockdown cells were tested by Western blot analysis 
using anti-OSBP (Proteintech). 
 
2.3.7.4 Retroviral particles production 
The process to generate the retroviral particles and make the stable cell lines by retroviral 
transduction was similar to the lentiviral particle production process as described in 
section 2.3.7.2. pCL-Ampho retroviral packaging plasmid (Novus Biologicals #NBP2-




2.3.7.5 Generation of MAVS knockout (MAVS-KO) cell lines by CRISPR/Cas9 
technology 
20 nucleotides guide sequences (sgRNA) targeting to the gene of interest (MAVS) were 
designed on Benchling and generated with BsmBI overhangs as complementary DNA 
primers (see Appendix I). These primers were annealed and ligated into BsmBI digested 
LentiCRISPR v2 plasmid (Addgene). Following transformation into competent cells (see 
section 2.1.2) and mini-preparation (see section 2.1.3), a diagnostic BsmBI digestion was 
performed to deduce which clones have the correct guide sequence. Lentivirus was 
generated as described previously in section 2.3.7.2. Huh-7 cells were transduced for 5 hr 
with lentivirus containing LentiCRISPR v2 encoding the MAVS sgRNA, and 
subsequently replaced with fresh complete media. Monoclonal populations of each 
potential knockout colony were obtained by dilution (1:100-1:200) onto 150 mm dishes 
to separate a single cell and once at a suitable size (approximately 4 weeks), colonies 
were isolated using a colony ring. Knockout cells were confirmed for MAVS-KO by 
immunofluorescence staining and Western blot analysis.  
 
2.3.7.6 Generation of MAVS-KO Huh-7 expressing MAVS-WT, MAVS-pex or 
MAVS-mito stable cells  
MAVS-WT (Addgene plasmid # 52135), MAVS-mito (Addgene plasmid # 44556) and 
MAVS-pex (Addgene plasmid # 44557) plasmids were gifts from Jonathan Kagan (Dixit 
et al., 2010). Retroviral particles containing each construct were produced and introduced 




expressing cells were then enriched by cell sorting (BD FACSAria
TM
 II) for higher GFP 
fluorescence signal compared to the background control. 
 
2.4 Cell lines 
2.4.1 HeLa  
The HeLa cell line is derived from cervical cancer cells taken from Henrietta Lacks 
(Scherer et al., 1953). 
 
2.4.2 293FT 
The 293FT cell line (Thermo Scientific) is derived from human embryonal kidney (HEK) 
cells transformed with the SV40 large T antigen. It is fast-growing, highly transfectable 
and produces high viral titers. 
 
2.4.3 Huh-7 
The Huh-7 cell line is a human hepatocyte-derived carcinoma cell line, originally isolated 
from a 57-year-old Japanese male (Nakabayashi et al., 1982). 
 
2.4.4 Huh-7.5 
The Huh-7.5 cell line is derived from the Huh-7 cells which used to harbour replication 
of an HCV subgenomic replicon but were cured after IFN-α treatment. This cell line is 
highly permissive for HCV infection (Blight et al., 2002) as it has shown to be defective 
in RIG-I signalling (Sumpter et al., 2005). These cells were kindly provided by Charles 





Huh-7 cells were stably transduced with lentiviral particles containing a pGIPz transgene 
cassette encoding a non-targeting control (NTC) shRNA and maintained under 
puromycin selection.  
 
2.4.6 Huh-7+shOSBP 
Huh-7+shOSBP cells are Huh-7 cells stably transduced with lentiviral particles 
expressing shRNA targeting to the OSBP gene and maintained under puromycin 
selection. This polyclonal stable cell line displayed knocked down OSBP expression.  
 
2.4.7 Huh-7+T7 
Huh-7+T7 cells are Huh-7 cells stably expressing T7 RNA polymerase and maintained 
under puromycin selection.  
 
2.4.8 MAVS-KO Huh-7 cells 
MAVS KO Huh-7 cells are Huh-7 cells that display a complete loss of MAVS function 
generated by CRISPR/Cas9 editing technology. 
 
2.4.9 MAVS-KO Huh-7 stably expressing MAVS-WT, MAVS-mito or MAVS-pex 
cells 
MAVS-KO Huh-7 stably expressing MAVS-WT, MAVS-mito or MAVS-pex cells were 





2.4.10 Subgenomic replicon 
Huh-7.5 cells were transfected by electroporation with in vitro transcribed RNA 
generated from SGRm-JFH1 plasmid. The SGRmJFH1 plasmid was modified by 
removal of the RLuc-encoding sequence from SGRm-JFH1BlaRL plasmid, kindly 
provided by Kui Li (University of Tennessee Health Science Center) (Zhou et al., 2011). 
Individual blasticidin-resistant colonies harbouring replication of the SGRmJFH1 
replicon were then expanded and screened. One clone (clone # 16) displaying 
homogenous NS5A staining was named “subgenomic replicon cells” and chosen for 
further experiments. This cell line was kindly provided by Nick Eyre (Eyre et al., 2016).  
 
2.4.11 Mouse embryonic fibroblast cells (MEFs) 
Viperin KO MEFs were derived from viperin deficient mice generated by CRISPR/Cas9 
technology (Van der Hoek et al., 2017). Genomic analysis confirmed disruption of the 
viperin locus. Wild type MEFs from the original inbred C57BL/6 mouse strain were used 
as a control.  
 
2.5 HCVcc Infectious System 
2.5.1 Generation of HCVcc viral stocks 
2.5.1.1 Preparation of HCV RNA  
To generate the HCV Jc1 stock, 5 g of plasmid containing HCV clone (pJc1) was 
digested with the MluI at 37C overnight. HCV RNA was synthesised using a T7 High 
Yield RNA Synthesis Kit (New England Biolabs® Inc) as per manufacturer’s instruction. 




μl of each ATP, CTP, GTP, UTP, 2 μl of 10 Reaction Buffer, 2 μl of T7 RNA 
polymerase enzyme and 1 μg of digested plasmid DNA in a total volume of 20 μl. The 
preparation was thoroughly mixed and incubated at 37°C for 3 hr. After incubation, 
samples were subsequently treated with 1 μl (2 Units) of TURBO DNAseTM (Ambion®) 
for 15 min at 37°C. Reactions were then transferred to a new pre-chilled RNAse free 
microcentrifuge tubes to perform RNA extraction using a standard protocol as previously 
described in section 2.1.10). The concentration of RNA was measured using a UV 
spectrophotometer Nanophotometer® (IMPLEN) and RNA integrity was checked by 1% 
agarose gel electrophoresis.  
 
2.5.1.2 HCV RNA transfection 
Huh-7.5 cells were cultured in two 175 cm
2 
flasks until they were 80-90% confluent. 
Cells were harvested by trypsinisation and washed twice with 10 ml of Opti-MEM. Cells 
were then counted and resuspended in Opti-MEM at a concentration of 1  10
7
 cells/ml. 
0.4 ml of cell suspension was aliquoted per electroporation cuvette (Gene Pulser
®
 
cuvette), 10 μg of RNA was then added and the suspension was gently mixed. 
Electroporation was performed with a single pulse at 0.27 kV, 100 Ohms and 960 μF 
using a Gene Pulser XcellTM (BioRad). Electroporated-cells were then immediately 
plated into 175 cm
2 
flasks containing 20 ml of fresh complete culture media. Cells were 
cultured for 2-10 days post-transfection and subcultured into new culture flasks when 
cells approached confluence. Virus-containing supernatants were collected at 





2.5.1.3 Concentration of HCV viral stocks using PEG precipitation 
Virus-containing supernatants were transferred into 50 ml disposable centrifuge tube and 
adjusted to 40 ml with complete culture media. 10 ml of 40% (w/v) polyethylene glycol 
(PEG) in PBS (MW: 8000, Sigma) was added to give a final concentration of 8% (w/v). 
Tubes were then mixed well by inversion and incubated at 4C overnight. Tubes were 
centrifuged at 3,900  g for 30 min at 4C and the supernatant was then discarded. The 
virus-containing pellets were resuspended in 1-2 ml complete media. Concentrated viral 
stocks were aliquoted into screw cap microcentrifuge tubes and stored at -80C. Viral 
titres were calculated as described in 2.5.1.4.  
 
2.5.1.4 Titration of infectious virus – Focus Forming Assay (FFA) 
Infectious HCV stocks were titrated using focus forming assays. Huh-7 cells were seeded 
at 2  10
4
 cells/well into 96-well trays. The next day, the PEG precipitated viral stock 
was serially diluted ten-fold in fresh culture media, to a final dilution of 1 in 10,000. 
Culture media were removed from near confluent Huh-7 cells and replaced with 40 l of 
inoculum (in duplicate for each dilution). The cells were then cultured for 3 hr, washed 
once with PBS and replaced with fresh complete culture media. The cells were cultured 
for a further 3 days. At 3 days post-infection, cell monolayers were fixed with 100 l of 
ice-cold Acetone:Methanol (1:1), incubated at 4C for 15 min and subsequently labelled 
by immunostaining (see section 2.6.4) using anti-HCV antisera or purified antibody 
(prepared as previously described in (Eyre et al., 2009). HCV-positive cells were 




microscope). The foci of HCV-positive cells were counted in each well (average 
duplicates). The viral titre was calculated using the following formula: 
Titre [focus forming units (ffu/ml)] = Number of foci x dilution factor x 25 
 
2.5.2 General protocol for HCVcc infection 
Huh-7 cells were seeded at 7 × 10
4
 cells in 12-well culture tray and subsequently infected 
with HCV Jc1 virus at MOI 0.1-1 in a 300 l volume of complete media for 3 hr. 
Infected-cells were then washed twice with PBS and returned to the incubator for 24 hr 
before cells were harvested for mRNA quantification (real time RT-PCR) experiments or 
immunofluorescence analysis. 
 
2.6 Fluorescence Microscopy 
2.6.1 Coverslip preparation 
Coverslips were used for high-resolution imaging. Coverslips were sterilised and then 
placed in 24-well tissue culture trays. Coverslips were then coated with 0.2% gelatin in 
PBS and incubated for 20 min, followed by washing once with PBS before seeding cells.  
 
2.6.2 Acetone/Methanol fixation 
To prepare Acetone:Methanol (1:1, v/v) fixative solution, an equal volume of Acetone 
(Ajax Finechem Pty Ltd) and analysis grade Methanol (Merck) were mixed well and 
stored at -20°C. Cell monolayers were washed with 1× PBS and then fixed with ice-cold 




cells were washed 3 times with PBS. Fixed cells were kept in PBS at 4°C before 
immunofluorescence labelling (see section 2.6.4). 
 
2.6.3 4% Paraformaldehyde fixation 
Cell monolayers in tissue culture trays were washed with 1× PBS and then fixed with ice-
cold 4% paraformaldehyde (w/v) (see Appendix II) for 20 min at RT. The fixative 
solution was discarded and cells were then washed 3 times with 1× PBS.  Cells were 
subsequently permeabilised by adding 0.1% Triton-X 100 (Sigma-Aldrich) in PBS 
followed by incubation at RT for 10 min.  
 
2.6.4 Immunofluorescence labelling 
Immunofluorescence labelling was performed after fixation (see section 2.6.2 and 2.6.3). 
Fixed cells were first blocked with 5% BSA in PBS (see Appendix II) for 1 hr at RT and 
then washed 3 times with PBS. Cells were labelled with primary antibody (see Appendix 
III) diluted in 1% BSA in PBS (see Appendix II) for 1 hr at RT. After washing 3 times 
with PBS, an appropriate dilution of fluorescence-conjugated secondary antibody (see 
Appendix III) was added to the wells and samples were incubated for 1 hr in the dark at 
RT. Following labelling, samples were washed 3 times with PBS. Where necessary, cells 
were also stained with the nuclear stain DAPI (see section 2.6.5) for 1 min in the dark. 
Cells were finally washed 3 times with PBS and samples were stored in PBS at 4°C or 
mounted on microscope glass slides (see section 2.6.6). Samples were visualised using a 
Nikon Eclipse TiE fluorescence inverted microscope and images were captured using 




2.6.5 DAPI nuclear staining 
DAPI nuclear staining was normally performed after immunofluorescence staining. The 
4’, 6-Diamidino-2-phenylindole (Sigma-Aldrich) stock solution (1 mg/ml) was diluted 
1:1,000 in dH2O to a final concentration of 1 μg/ml and added to the cells for 1 min. Cells 
were then washed 3 times with PBS. Samples were stored at 4°C prior to fluorescence 
microscopy visualisation. 
 
2.6.6 Slide mounting 
After staining, coverslips were mounted on glass slides using ProLong® Gold antifade 
reagent (Invitrogen) or the SlowFade® Antifade Kit (Invitrogen
TM
, Life Technologies). A 
half-drop of antifade reagent was placed on a glass slide. Coverslips, coated in a cell 
monolayer, were placed cells down towards the mounting reagent on the glass slide. 
After leaving the mounting reagent to dry for approximately 15-20 min, coverslips were 
sealed using clear nail polish before visualising using a fluorescent microscope or storage 
at 4°C, in the dark. 
 
2.6.7 Microscope specification 
Immunofluorescent stained samples were visualised using a Nikon TiE inverted 
fluorescence microscope and images were captured using NIS Elements software. 
 
2.6.8 Deconvolution 
Deconvolution is a computationally intensive image processing technique for improving 




microscope. Immunofluorescence images were initially acquired over a z-stack 
comprising 50 to 70 images (0.1-0.25 m Z-steps), taking into consideration a medium 
background and a limited number of iterations (10). Deconvolution was performed after 
z-stacks using the NIS-A Blind Deconvolution WF module of NIS-Element Advanced 
Research v 3.22.14 software (Nikon).  
 
2.7 Three Dimensional-Structured Illumination Microscopy (3D-SIM) 
3D-SIM images were acquired at the Microbial Imaging Facility (The University of 
Technology Sydney). 3D-SIM was implemented using a V3 DeltaVision OMX 3D-SIM 
system fitted with a Blaze module (Applied Precision, GE Healthcare, Issaquah, USA). 
Solid-state multimode lasers provided wide-field illumination and multi-channel images 
were captured simultaneously using a × 60 1.4 numerical aperture UPlanSApo objective 
(Olympus, Toyko Japan), standard filter sets and a scientific CMOS 512 × 512 pixels 15-
bit camera (pco.edge, PCO AG, Kelheim, Germany). Interference patterns were made by 
interfering light beams
 
(Strauss et al., 2012). Specimens were sectioned using a 125-nm 
z-step and images were deconvolved using SoftWorX software (Applied Precision, GE 
Healthcare). 
 
Image Analysis: Wide-field, deconvolved or f3D-SIM images were rendered and 
analysed using IMARIS software (v7.7 or above, Bitplane Scientific). Final images were 
processed using linear adjustments to signal contrast and brightness without alteration of 





2.8 DAB staining of APEX2-tagged proteins for electron microscopy 
Huh-7 cells were seeded at 5 × 10
6
 cells in 150 mm cell culture dishes prior to 
transfection with 36 g of APEX2-tagged expression plasmid. Cells were washed twice 
with cold 1 PBS before fixing with EM fixative (see Appendix II) for 30 min at 4°C 
with gentle agitation. The fixative reagent was discarded and cells were washed 5 times 
with cold PBS for 2 min each. Cells were incubated in cold PBS containing 20 mM 
glycine for 5 min to quench unreacted glutaraldehyde and then washed 5 times with cold 
PBS for 2 min per wash. SIGMAFAST DAB with Metal Enhance (Sigma-Aldrich) was 
prepared immediately prior to use by dissolving 1 DAB/Cobalt tablet and 1 Buffer/Urea 
Hydrogen Peroxide tablet in 5 ml of MilliQ water (scale up as required, ~5 ml/150 mm 
dish). PBS was removed from cells and replaced with DAB/H2O2 solution. Cells were 
incubated in DAB/H2O2 solution for 1-15 min depending on APEX2 expression levels 
and localisation. Dark colour development was monitored by eye or light microscopy. 
Following sufficient colour development, DAB/H2O2 solution was immediately removed 
from cells and cell monolayers were washed 5 times with cold PBS for 2 min each. Cells 
were carefully scraped from dishes and resuspended in cold PBS before transferring to 
1.5 ml microcentrifuge tube. Cells were pelleted by centrifugation at 3,000  g for 10 min 
at 4°C. At Adelaide Microscopy, cells were pelleted by centrifugation at 3,000  g for 5 
min, resuspended in 2% osmium tetroxide (Electron Microscopy Sciences) and incubated 
for 30 min on rotation. Cells were washed 5 times with ice-cold MilliQ water for 2 min 
each, then resuspended in ice-cold 2% aqueous uranyl acetate and incubated for 30 min 
with rotation. Samples were dehydrated in a series of cold graded ethanol (70%, 90%, 




with anhydrous ethanol for 10 min at RT to avoid condensation, then infiltrated in 
anhydrous ethanol:resin (1:1) and incubated for 30 min with rotation. Supernatants were 
removed and pellets were incubated in 100% resin. 100% resin was changed 3 times for 
at least 1 hr each with one resin incubation step occurring overnight. The resin-embedded 
sample was polymerised in an oven at 70°C for at least 24 hr. Ultrathin (80 m thick) 
sections were cut (Leica Ultracut UTC6) and mounted by a specialist at Adelaide 
Microscopy. Electron micrographs were acquired using a Tecnai G2 Spirit transmission 
electron microscope (Adelaide Microscopy, The University of Adelaide). 
 
2.9 Data analysis                                 






Understanding the antiviral role of viperin against Hepatitis C virus 
 
3.1 Introduction 
The ISG, viperin (RSAD2) is a unique and highly conserved protein that is significantly 
expressed following viral infection. It is able to restrict replication of a broad range of 
RNA viruses including hepatitis C virus (HCV) (Helbig et al., 2005, Wang et al., 2012), 
dengue virus (DENV) (Fink et al., 2007, Helbig et al., 2013), Tick-borne encephalitis 
virus (TBEV) (Upadhyay et al., 2014), respiratory syncytial virus (RSV) (McGillivary et 
al., 2013), influenza virus (Tan et al., 2012, Wang et al., 2007) and HIV (Nasr et al., 
2012). We previously reported that viperin interacts with the vesicle-associated 
membrane protein-associated protein subtype A (VAP-A), a host pro-viral cellular 
protein, and the HCV non-structural protein NS5A, a protein essential for HCV 
replication and virion assembly (Helbig et al., 2011). These interactions occur at sites of 
HCV replication within the HCV RC and at the lipid droplet (LD) interface, a site known 
to be important for the assembly of HCV virions. However, the ability of viperin to 
restrict HCV replication in the context of an HCV replicon strongly suggests that viperin 
exerts its antiviral effect at the level of RNA replication. Thus, while we have identified 
that HCV NS5A and the cellular protein VAP-A interact with viperin, our understanding 
of the precise molecular mechanism(s) of how viperin exerts its antiviral effect remains 
unknown. VAP-A is a known pro-viral host factor and also binds to the cholesterol 
recruiting protein oxysterol-binding protein (OSBP) (Wyles et al., 2002). OSBP also 




HCV replication organelles. This raises the question of whether viperin interacts with 
VAP-A to perturb the function of OSBP in RC formation and ultimately HCV 
replication. Moreover, high-resolution analysis of viperin localisation at the 
ultrastructural level is required to better understand its influence on HCV replication 
organelle morphology and function. Therefore, the aim of this chapter was to determine if 
viperin’s interaction with VAP-A can alter the interaction of VAP-A and OSBP and to 
investigate the localisation of viperin at the ultrastructural level by electron microscopy 
(EM) in the context of HCV RC formation. 
 
3.2 Viperin does not require OSBP for its anti-HCV activity 
3.2.1 Does viperin expression impact the interaction between VAP-A and OSBP? 
Viperin has been shown by our laboratory to colocalise and interact with HCV NS5A and 
the host HCV pro-viral factor vesicle-membrane-protein-associated protein A (VAP-A) 
using immunofluorescence and fluorescence energy resonance transfer (FRET) analysis 
respectively (Helbig et al., 2011). VAP-A is a host protein that is involved in regulation 
of cholesterol exchange and trafficking (Weir et al., 2001) and has been shown to be 
important for HCV replication, likely via trafficking of cholesterol to the HCV RC (Tu et 
al., 1999, Evans et al., 2004, Gao et al., 2004). Moreover, another cholesterol recruiting 
protein, OSBP, also plays a role in HCV RC formation and integrity, and is recruited to 
the RC by association with phosphatidylinositol-4-phosphate (PI4P), a product of the 
activation of phosphatidylinositol 4-kinase III alpha (PI4KA) by HCV NS5A (Wang et 
al., 2014, Amako et al., 2009). It is thought that OSBP and VAP-A are recruited to 




NS5B, that are not only involved in HCV replication, but also in the process of 
membrane remodelling. A summary of the viral and cellular proteins involved in this 
process are outlined in Figure 3.1 (Chukkapalli and Randall, 2014). Interestingly it was 
recently demonstrated that the antiviral effector protein, interferon-inducible 
transmembrane protein 3 (IFITM3), interacts with VAP-A that can, in turn, inhibit the 
interaction between VAP-A and OSBP leading to disruption of cholesterol homeostasis 
and inhibition of viral entry (Amini-Bavil-Olyaee et al., 2013). Furthermore, VAP-A and 
OSBP play an important role in controlling intracellular lipid and cholesterol homeostasis 
(Wyles et al., 2002, Raychaudhuri and Prinz, 2010), which is required for many viral 
infections such as influenza A virus (IAV), vesicular stomatitis virus (VSV) and herpes 
simplex virus (HSV) (Manes et al., 2003, Schroeder, 2010, Veit and Thaa, 2011, Wang et 
al., 2009b, Gianni and Campadelli-Fiume, 2012). Based on the above observations of an 
interaction of viperin with HCV NS5A and VAP-A, and the association of VAP-A and 
OSBP, it is possible that the interaction of viperin and VAP-A may block the association 
of VAP-A and OSBP to alter RC formation, and therefore impact HCV replication. We 
therefore investigated the impact of viperin expression on the association of VAP-A and 
OSBP.  
 
To determine if the association between VAP-A and OSBP is retained in the presence of 






Figure 3.1: HCV membranous web formation. 
HCV infection modifies the membrane of the endoplasmic reticulum to generate its 
replication compartment. HCV nonstructural proteins (NS3-NS5B) and several cellular 
host factors such as PI4KA, VAP-A and OSBP contribute to HCV RC and membranous 





fused with a FLAG epitope tag at the N-terminus. The OSBP ORF including the FLAG 
tag was amplified from the plasmid OSBP-pOTB7 (Thermo Scientific) using specific 
primers (see Appendix I) and subsequently cloned into pLenti6/V5-D-TOPO. 
Recombinant plasmids were digested with BamHI and MluI that revealed release of a 
2.4 kb band confirming generation of successful recombinant plasmids (Figure 3.2). The 
recombinant plasmids were sequenced and the results demonstrated 100% sequence 
identity to Homo sapiens OSBP (GenBank accession no. BC011581). Exogenous OSBP 
expression was confirmed following transfection of pLenti6-OSBP-FLAG into Huh-7 
cells and immunostaining using an anti-FLAG antibody (Figure 3.3). As expected, 
FLAG-positive (and hence OSBP-positive) Huh-7 cells were clearly visible with a 
perinuclear staining pattern consistent with Golgi localisation, as has been previously 
described (Amako et al., 2009). 
 
As discussed above, previous studies have shown that viperin associates with VAP-A and 
NS5A and moreover that VAP-A and NS5A associate with OSBP. Thus, to investigate 
the hypothesis that viperin may modify the association of VAP-A and OSBP, we 
transfected Huh-7 cells with various combinations of viperin, VAP-A and OSBP 
expression constructs to assess localisation/interaction of these proteins. Initially, we 
transfected Huh-7 cells with plasmids expressing VAP-A-mCherry and OSBP-FLAG, 
and visualised protein expression accordingly. As expected IF analysis of OSBP and 
VAP-A revealed significant overlap of fluorescent signals, suggesting co-localisation 
likely at the ER-Golgi contact sites (Mesmin et al., 2013). In contrast, viperin and OSBP 







Figure 3.2: The OSBP gene was successfully cloned into pLenti6/V5-D-TOPO. 
To confirm the positive clones, plasmid DNA was extracted from transformant clones 
and digested with BamHI and MluI. Lane M, 1 kb DNA marker; lanes 1-4, a recombinant 







Figure 3.3: Exogenous OSBP expression in Huh-7 cells. 
To investigate expression of OSBP-FLAG, Huh-7 cells were transiently transfected with 
a plasmid expressing OSBP-FLAG for 24 hr prior to immunostaining using mouse anti-
FLAG (green) and Alexa Fluor 488-conjugated goat anti-mouse IgG secondary antibody 
(Ab). Nuclei were counterstained with DAPI (blue) and immunofluorescence images 
were visualised by immunofluorescence analysis using a Nikon TiE inverted fluorescent 





shown previously (Hinson and Cresswell, 2009a, Helbig et al., 2011). Interestingly, 
expression of viperin and VAP-A results in co-localisation of the two proteins, that is 
marked by a significant redistribution of VAP-A from the ER to a perinuclear LD 
localisation (Figure 3.4). This suggests that while viperin does not interact with OSBP 
directly it is possible that the interaction of viperin with VAP-A may sequester VAP-A 
from OSBP to impact HCV replication. 
 
To address this possibility, we transfected Huh-7 cells with plasmids expressing viperin, 
VAP-A and OSBP and assessed protein expression/co-localisation 24 hr post-
transfection. Based on the strong co-localisation of viperin and VAP-A as seen above we 
hypothesised that viperin would sequester VAP-A from OSBP, however, this was not the 
case as while an interaction between viperin and VAP-A was evident there was also 
significant co-localisation of both VAP-A and OSBP. This data indicates that in the 
context of viperin, VAP-A and OSBP expression, viperin does not alter the interaction 
between VAP-A and OSBP (Figure 3.5). 
 
3.2.2 Generation of stable OSBP knockdown cells 
To further determine the role of OSBP in viperin’s antiviral action, OSBP knockdown 
cell lines were created using a lentiviral vector encoding shRNAs targeting OSBP. 293FT 
cells were co-transfected with one of each of the 6 clones of pGIPZ OSBP-shRNA or 
pGIPZ non-targeting shRNA control (NTC) and the essential plasmids for lentiviral 
packaging. Huh-7 cells were then transduced with the resulting lentiviruses. The stable 






Figure 3.4: Co-localisation of VAP-A, OSBP and viperin. 
To investigate the co-localisation of these proteins, Huh-7 cells were co-transfected with 
a pair of VAP-A-mCherry/viperin-GFP/OSBP-FLAG expression plasmids and returned 
to culture for 24 hr prior to staining with mouse anti-FLAG and (A) Alexa Fluor 488-
conjugated goat anti-mouse IgG or (B) Alexa Fluor 555-conjugated goat anti-mouse IgG. 
Nuclei were counterstained with DAPI. Strong co-localisation of (A) VAP-A/OSBP and 
(C) VAP-A/viperin, but not (B) viperin/OSBP was observed by immunofluorescence 
analysis using a Nikon TiE inverted fluorescent microscope (60x magnification). Scale 








Figure 3.5: VAP-A colocalises with OSBP in the context of viperin expression. 
To investigate whether viperin impedes the co-localisation of VAP-A and OSBP, Huh-7 cells were triple transfected with VAP-A-
mCherry (red), viperin-GFP (green) and OSBP-FLAG (blue) for 24 hr prior to staining with mouse anti-FLAG and Cy5-conjugated 
goat anti-mouse IgG secondary Ab. Nuclei were counterstained with DAPI (white). Co-localisation of VAP-A/OSBP and VAP-
A/viperin was observed by immunofluorescence analysis using a Nikon TiE inverted fluorescent microscope (60x magnification). 
Scale bars are 10 μm and 1 μm for main images and inset, respectively. Red and white arrows indicated the co-localisation of VAP-




subjected to Western blot analysis to confirm the endogenous OSBP knockdown. Five 
clones of stable cell lines were obtained after puromycin selection. Clone no. 2 and 5 
showed 82 and 74% knockdown of OSBP compared to the control (NTC) cell line 
(Figure 3.6). 
 
To further confirm the involvement of OSBP in viral replication, the OSBP knockdown 
and control cell lines were infected with HCV and DENV, and the effects on viral 
replication were determined by real time RT-PCR. OSBP knockdown was found to limit 
HCV replication as shown in Figure 3.7, implying that OSBP is co-opted by HCV but not 
DENV. This result is consistent with previous reports which showed that OSBP has an 
impact on HCV replication but is not required for replication of DENV (Amako et al., 
2009, Wang et al., 2014). 
 
3.2.3 OSBP does not impact on viperin’s antiviral activity. 
The OSBP knockdown cell lines (both clones) were utilised to assess the effectiveness of 
viperin’s ability to limit HCV replication in the absence of OSBP through viperin 
overexpression prior to HCV infection. OSBP knockdown and control cell lines were 
transfected with a plasmid expressing viperin-FLAG and an empty plasmid control, 
followed by real time RT-PCR quantification to assess HCV replication. Although, only a 
slight decrease in HCV replication was observed in the context of viperin overexpression, 
likely due to the lower transfection efficiency of about 25-30%, there was no difference 
in the levels of HCV replication in the context of viperin overexpression in OSBP 






Figure 3.6: Stable OSBP knockdown cell lines. 
To confirm knockdown of endogenous OSBP, whole cell lysates of 5 clones of OSBP 
knockdown cell lines and the non-targeting shRNA control (NTC) cell line were 
subjected to Western blot analysis using anti-OSBP and anti--actin (loading control) 
antibodies. Clone no. 2 and 5 displayed the strongest OSBP knockdown, with 82 and 
74% knockdown efficiencies, respectively, compared to NTC control, following 







Figure 3.7: The involvement of OSBP in HCV and DENV replication. 
To determine whether OSBP is required for HCV and DENV replication, OSBP 
knockdown (clones # 2 and 5) and control (NTC) cell lines were infected with HCV 
(1,000 ffu) and DENV (MOI 1) for 24 hr prior to real time RT-PCR analysis. OSBP 
knockdown resulted in a significant decrease of HCV replication (left bar graph), while 




the empty plasmid control (Figure 3.8). This suggests that OSBP is not required for the 
effectiveness of viperin in its anti-HCV activity, although further studies are required to 
definitely resolve whether viperin and OSBP impact on one another’s function and the 
molecular mechanisms involved. 
 
3.3 Visualisation of viperin by EM 
3.3.1 Investigation of the cellular localisation of viperin and its impact on HCV 
membranous web formation. 
Our results above suggest that viperin may not exert its antiviral effect through 
modulating the interaction of VAP-A and OSBP. However, it should be noted that the 
above interaction studies were performed in the absence of HCV replication. It is possible 
that in the context of HCV protein expression and the resulting alteration of cellular 
membranes, viperin, VAP-A and/or OSBP protein localisation may be altered. Given 
previous work from our laboratory showing an interaction between viperin and NS5A 
and VAP-A (also this thesis), we next investigated viperin protein localisation in the 
context of HCV-induced membranous web formation by transmission electron 
microscopy (TEM). While traditional methods to visualise protein localisation at the 
ultrastructural level such as immuno-EM have been used successfully to localise proteins 
to specific cellular compartments, these approaches are hampered by harsh tissue 
processing, which in many cases destroys fine cellular structures (Sosinsky et al., 2007, 
Schnell et al., 2012). As such, these approaches are time-consuming, technically 
challenging and often prone to false positive/negative results. However, this problem has 






Figure 3.8: Viperin does not require OSBP for its anti-HCV activity. 
To determine whether OSBP is required for viperin’s ability to limit HCV replication, 
OSBP knockdown and control (NTC) cell lines were transiently transfected with pLenti6-
viperin-FLAG or control plasmids for 24 hr followed by HCV infection (MOI0.005) for 
24 hr prior to real time RT-PCR analysis. The relative fold change of HCV replication in 
each cell line transfected with a plasmid expressing viperin-FLAG were expressed 
relative to that of each cell line transfected with the empty plasmid control. There was no 
significant difference in the relative fold change of HCV replication in the context of 
viperin expression compared to empty plasmid controls, suggesting that OSBP is not 
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interest (Martell et al., 2012). The APEX2 tag consists of a genetically engineered 
APEX2 peroxidase that can catalyse the conversion of DAB into an osmophilic polymer 
that can be visualised by TEM following staining with OSO4, allowing the location of the 
target protein with respect to cellular membranes. The insertion of an APEX2 tag allows 
for TEM studies to be performed using standard EM fixation protocols without the use of 
cryo-EM, hence resulting in significantly improved ultrastructural cellular morphology. 
Therefore, we generated a viperin expression construct with an APEX2 tag at the N-
terminus that was used to explore the localisation of viperin at the ultrastructural level.  
 
3.3.2 Generation of viperin-APEX2 tag 
The APEX2-coding sequence was amplified using specific primers and pcDNA3 
APEX2-NES plasmid (addgene # 49386) as a template and subsequently cloned into the 
pLenti6/V5-D-TOPO plasmid using BamHI and XhoI restriction sites. An N-terminal 
FLAG tag was included to facilitate detection. Candidate clones were digested with 
BamHI and XhoI to confirm the correct size of the inserted gene (813 bp) (Figure 3.9). 
This pLenti6-APEX2-FLAG plasmid was used as a control for further experiments. We 
next excised human viperin from pLenti6-viperin-mCherry using XhoI and SacII (our 
laboratory construct) and ligated it into a linearised pLenti6-APEX2 plasmid. Positive 
transformants were confirmed by digestion with BamHI and SacII (Figure 3.10). The 
recombinant plasmids were confirmed by Sanger sequencing and showed 100% identities 
to Homo sapiens radical S-adenosyl methionine domain containing 2 or viperin 
(Accession no. NM_080657.4) and fused in frame with the APEX2 tag. For the 






Figure 3.9: Patterns of BamHI and XhoI digestion of APEX2 control plasmids. 
To confirm the positive clones, plasmid DNA was extracted from transformant clones 
and digested with BamHI and XhoI. Lane M, 1 kb DNA marker; lanes 1-3, a recombinant 







Figure 3.10: Patterns of BamHI and SacII digestion of viperin-APEX2 plasmids. 
To confirm the positive clones, plasmid DNA was extracted from transformant clones 
and digested with BamHI and SacII. Lane M, 1 kb DNA marker; lanes 1-4, a recombinant 





3.3.3 Expression of viperin-APEX2 tag in Huh-7 cells 
To confirm expression of the viperin-APEX2 fusion protein, a plasmid expressing 
viperin-APEX2 was transfected into Huh-7 cells and 24 hr post-transfection cells were 
fixed, permeabilised and immunostained for the FLAG epitope. Huh-7 cells were also 
transfected with an expression plasmid expressing the APEX2 tag alone to control for 
APEX2 expression. As expected, both viperin fused with the APEX2 tag and APEX2 
proteins were expressed and located in the cytoplasm as shown by immunofluorescence 
analysis (Figure 3.11). However, the expression patterns of the two proteins were very 
different with APEX2 alone revealing an amorphous cytoplasmic distribution, while 
viperin-APEX2 showed a staining pattern indistinguishable to that of FLAG-tagged 
viperin, in which viperin associated with the ER and LDs. This suggests that the insertion 
of an APEX2 tag does not impact the cellular localisation of viperin. 
 
3.3.4 Viperin cellular localisation visualised by transmission electron microscopy 
(TEM) 
APEX2 is a monomeric engineered plant peroxidase that enables simple and specific 
labelling of tagged proteins via its catalysis of H2O2-mediated polymerisation of 3’3’-
diaminobenzidine (DAB) into a tightly localised precipitate that gives clear contrast 
following staining with OSO4. However, excessive polymerisation of DAB, and hence 
increased precipitate, can result in suboptimal resolution of protein localisation. It was 
therefore necessary to determine the optimal polymerisation time prior to TEM studies. 
This was achieved by transiently transfecting Huh-7 cells with a plasmid expressing 






Figure 3.11: Viperin-APEX2 expression in Huh-7 cells. 
To investigate the expression of viperin-APEX2 and APEX2 control, Huh-7 cells were 
transiently transfected with pLenti6-APEX2 control, pLenti6-viperin-APEX2 or pLenti6-
viperin-FLAG for 24 hr and protein expression was analysed by immunostaining using 
mouse anti-FLAG and Alexa Fluor 555-conjugated goat anti-mouse IgG secondary Ab. 
Nuclei were counterstained with DAPI (blue). Viperin-APEX2 and APEX2 alone were 
expressed and localised in the cytoplasm. The expression and localisation pattern of 
viperin-APEX2 was similar to that of the viperin-FLAG (non-APEX2 tag) visualised by 
immunofluorescence analysis using a Nikon TiE inverted fluorescent microscope (60x 




incubating with DAB for 2, 5, 7, 8, 10 and 12 min. Following this DAB precipitate was 
visualised by light microscopy. The objective here was to select a time post DAB 
treatment that allows for optimal EM resolution of DAB precipitates. As revealed in 
Figure 3.12, there was an appreciable increase in DAB precipitate over the given time 
course in viperin-APEX2 transfected cells, with 10 minutes determined to be the optimal 
exposure time for DAB staining. 
 
To visualise the localisation of viperin in Huh-7 cells by TEM, a large scale transfection 
with pLenti6-viperin-APEX2 was performed in a 150 mm cell culture dish followed by 
sample preparation for TEM (see Chapter 2, section 2.7). The Huh-7 cell pellet was 
sectioned and processed by an EM specialist at Adelaide Microscopy. Electron 
micrographs of both transfected and untransfected cells were acquired using a Tecnai G2 
Spirit transmission electron microscope (Adelaide Microscopy). Analysis of multiple 
fields of view revealed that there were cells positive for the DAB precipitate and thus 
positive for viperin expression (transfected with pLenti6-viperin-APEX2) and cells 
negative for DAB precipitate representing untransfected cells. In comparison to viperin 
negative cells, it was immediately apparent that there was an increase in the number of 
lipid droplets present within the cell. Furthermore, consistent with immunofluorescence 
data (Figure 3.13) where Huh-7 cells were transfected with plasmids expressing viperin-
GFP and ADRP-mCherry (ADRP, lipid droplet marker), there was a significant 
localisation of viperin to the outer membrane of the lipid droplet and in some instances 
there was a strong association of viperin with the LD and the mitochondria (Figure 3.14, 






Figure 3.12: Optimisation of DAB staining for EM. 
Huh-7 cells were transiently transfected with pLenti6-viperin-APEX2 and returned to 
culture for 24 hr followed by fixing with EM fixative reagent. Fixed cells were stained 
with DAB for various time points. Images were visualised by bright field fluorescence 
microscopy, using a Nikon TiE inverted fluorescent microscope (10x magnification). 







Figure 3.13: Localisation of viperin on LDs. 
To investigate whether viperin localises to LDs, ADRP was used as an LD marker. Huh-7 
cells were transiently transfected with pLenti6-viperin-mCherry (red) and ADRP-GFP 
(green), cultured for 24 hr and fixed prior to counterstaining of nuclei with DAPI (blue). 
Serial (0.25-m) z-sections of immunofluorescence images were acquired using a Nikon 
TiE inverted fluorescent microscope and deconvoluted using the 3D AutoQuant Blind 
Deconvolution plug-in of NIS Elements Advanced Research v 3.22.14 software. Images 
are single representative z-sections. Strong co-localisation of viperin and the LD marker 
ADRP was observed using deconvolution fluorescence microscopy (60x magnification). 






Figure 3.14: An ultrastructural view of viperin localisation. 
Huh-7 cells were transiently transfected with viperin-APEX2 and APEX2 control, 
returned to culture for 24 hr and stained with DAB for 10 min followed by EM sample 
preparation. (A) Viperin-APEX2 and (B) APEX2 control were visualised using a Tecnai 
G2 Spirit transmission electron microscope. Tx, transfected cells; UT, untransfected 





APEX2 expression, as APEX2 expression alone was distributed evenly throughout the 
cell and did not specifically localise to a specific compartment.  
 
3.4 Viperin enhances lipid droplet accumulation 
It was clearly evident in EM and IF images (see Figure 3.13 and 3.14) that in cells 
expressing viperin, there was a significant increase in the number of LDs. Indeed if the 
number of LDs increased in viperin expressing cells, we then assumed that neutral lipid 
would also be increased in the cell. With this assumption in mind, and to indirectly 
quantify the number of LDs in cells expressing viperin, Huh-7 cells were transfected with 
pLenti6-viperin-mCherry or pLenti6-mCherry control, and LDs were stained with 
BODIPY 493/503 prior to cell imaging using an Operetta high-content microscope in 
non-confocal mode (Perkin Elmer: CeSSA, Cell Screen SA). Image analysis was 
performed using Harmony software and DAPI staining to detect nuclei was used for cell 
counts. Approximately 4,000-5,000 cells were counted from each transfection 
experiment, and the mean of BODIPY 493/503 intensity was analysed per cell. 
Transfection efficiency derived from the transfection with pLenti6-viperin-mCherry and 
pLenti6-mCherry control was 25% and 48%, respectively (see raw data in Appendix X). 
The intensity of BODIPY 493/503 fluorescence per cell in viperin expressing cells was 
significantly higher compared to cells not expressing viperin. Furthermore, in cells 
expressing mCherry alone there was no increase in BODIPY 493/503 fluorescence, 
indicating that the effect was not an artefact of mCherry expression, or the transfection 
protocol (Figure 3.15). This result suggested that viperin promotes LD formation or 






Figure 3.15: Viperin enhances LD accumulation. 
To investigate whether viperin increased cellular LD content, Huh-7 cells were 
transfected with pLenti6-viperin-mCherry or pLenti6-mCherry control. LD staining was 
quantified following staining with BODIPY 493/503 via imaging using an Operetta high-
content microscope in non-confocal mode. 25-fields were taken per well covering about 
50% of the well in the central area. This equates to approximately 4,300 cells per 
analysis. 12 replicates were performed per condition and image analysis was performed 
using Harmony software. Cell counts were determined by enumeration of DAPI stained 
nuclei. The BODIPY 493/503 intensities of viperin-transfected cells were approximately 
two-fold higher than those of mCherry control-transfected cells. Data are means  SD 





mitochondria. This may be of significance in viperin-mediated enhancement of innate 
immune signalling to combat viral infection. 
 
3.5 Viperin restricts membranous web formation in a non-replicative model 
Although several groups, including our laboratory, have reported that viperin displays its 
anti-HCV activity by limiting HCV RNA replication (Helbig et al., 2005, Wang et al., 
2012), the molecular mechanism(s) that underpins this is poorly defined. As outlined 
above, the interaction of viperin with NS5A and VAP-A, both HCV RC components, 
suggests that viperin may alter RC formation and hence impact HCV replication. 
Therefore, viperin-APEX2 was utilised as a tool to determine the impact of viperin on 
HCV RC formation. The HCV replicon system provides efficient autonomous replication 
of HCV in cell culture, and has been used as a model for the molecular study of HCV 
RNA replication, viral-host interactions and membranous web formation (Blight and 
Norgard, 2006) and for all purposes would be a good model to study the interaction of 
viperin with host factors and the impact on viral replication and/or membranous web 
formation. However, HCV replicon cells are difficult to transfect and furthermore viperin 
is extremely potent in shutting down HCV replication, making these types of studies 
difficult in HCV replicon cell lines. Therefore, we adopted a non-replicative model of 
membranous web formation that is mediated by T7 RNA polymerase-driven NS3-5B 





3.5.1 A non-replicative model of HCV membranous web formation 
The alteration of host membranes to establish the HCV RC can largely be attributed to 
expression of the HCV NS4B protein; however, most of the HCV non-structural proteins 
play some role in this process [reviewed in (Wang and Tai, 2016)]. Therefore it is 
possible to generate HCV membranous web formation by expressing the HCV non-
structural proteins in the absence of HCV RNA replication. This can be achieved using 
T7 RNA polymerase (T7)-driven expression of the HCV NS3 to NS5B coding region that 
has been previously described by Tai, AW and Salloum, S (Tai and Salloum, 2011). In 
this model, a stable Huh-7 cell line expressing T7 RNA polymerase is transfected with a 
plasmid containing a T7 promoter driving expression of the HCV non-structural proteins. 
We were gifted two T7 based expression plasmids, one expressing NS3 to NS5B from an 
HCV genotype 2a [pTM1(NS3-5B)] construct and another that was essentially the same 
with the exception that the NS5A protein was fused with GFP to allow simple detection 
of the HCV non-structural proteins. A schematic of these plasmids is presented in Figure 
3.16. 
 
Initially, we generated a stable Huh-7 cell line expressing T7 RNA polymerase by 
retroviral transduction. Cells were selected with puromycin and expanded. To test 
expression of T7 polymerase, a T7 stable cell line was transiently transfected with 
pTM1(NS3-5B)/NS5A-GFP, and 24 hr post-transfection cells were visualised for GFP 
expression using fluorescence microscopy. Huh-7/T7 cell lines revealed GFP expression, 
indicating expression of T7 RNA polymerase and HCV non-structural protein expression 







Figure 3.16: Schematic diagram of T7 driving the expression of HCV NS3-5B. 
The pTM1(NS3-5B) and pTM1(NS3-5B)/NS5A-GFP constructs were kindly gifted by 
Tai, AW and Salloum, S (Tai and Salloum, 2011). Expression of subgenomic NS3-NS5B 








Figure 3.17: Expression of pTM1(NS3-5B)/NS5A-GFP in the T7 stable cell line. 
To test if the T7 stable cell line carries T7 RNA polymerase enzyme integration, Huh-7 
cells and the T7 stable cell line were transiently transfected with pTM1(NS3-5B)/NS5A-
GFP. Strong GFP expression which indicates the presence of T7 RNA polymerase was 
observed in (B) the T7 stable cell line but not in (A) Huh-7 cells by fluorescence analysis 






pTM1(NS3-5B)/NS5A-GFP. Following transfection, NS3 was visualised by 
immunofluorescence microscopy using an antibody directed to NS3 (mouse monoclonal 
clone 2E3, BioFront Technologies). Clearly, NS3 was expressed and furthermore, there 
was co-localisation with NS5A (GFP tag) in large and small puncta that represent HCV 
RC (Figure 3.18) (Tai and Salloum, 2011). This system was to be employed in analysis of 
the impact of viperin expression on HCV-induced membrane rearrangements in the 
absence of potentially confounding effects of viperin on HCV RNA replication. 
 
3.5.2 Viperin blocks formation of the altered cellular membranous web. 
Previously published studies from our laboratory have shown that HCV NS5A interacts 
with viperin as determined by IF and FRET analysis. In a productive HCV replication 
system, this interaction occurred at the LD interface as well as the RC (Helbig et al., 
2011). Therefore, prior to investigation of viperin localisation by EM in the context of 
membranous web formation, we evaluated the interaction of viperin with NS5A in the 
absence of RNA replication using the pTM1(NS3-5B)/NS5A-GFP system by 
immunofluorescence microscopy. Co-transfection of pLenti6-viperin-APEX2 and 
pTM1(NS3-5B)/NS5A-GFP into stable T7 expressing cell line and subsequent IF 
analysis revealed significant overlap of viperin and NS5A fluorescent signal indicating 
co-localisation of both viperin and NS5A (Figure 3.19). 
 
To further investigate if viperin alters membranous web formation at the ultrastructural 






Figure 3.18: pTM1(NS3-5B)/NS5A-GFP expression results in NS3 and NS5A 
production. 
To test that the non-replicative model is able to produce an essential polyprotein (NS3-
NS5B) for membranous web formation, T7 stable cells were transiently transfected with 
pTM1(NS3-5B)/NS5A-GFP prior to staining with mouse anti-NS3 and Alexa Fluor 555-
conjugated goat anti-mouse IgG secondary Ab. A strong co-localisation of NS5A and 
NS3 was observed by immunofluorescence analysis using a Nikon TiE inverted 
fluorescent microscope (60x magnification). Scale bars are 10 μm and 1 μm for main 







Figure 3.19: Co-localisation of viperin and NS5A. 
To test that viperin colocalises with NS5A in the non-replicative model, T7 stable cells 
were co-transfected with pTM1(NS3-5B)/NS5A-GFP and viperin-APEX2 prior to 
staining with mouse anti-FLAG and Alexa Fluor 555-conjugated goat anti-mouse IgG 
secondary Ab. Co-localisation of viperin and NS5A was observed by 
immunofluorescence analysis using a Nikon TiE inverted fluorescent microscope. (A) 
20x magnification and scale bars are 50 μm. (B) 60x magnification and scale bars are 10 




viperin-APEX2 and pTM1(NS3-5B)/NS5A-GFP was performed in 150 mm dish prior to 
EM sample preparation as previously described in section 3.3.4. Co-transfection of a 
plasmid expressing APEX2 control and pTM1(NS3-5B)/NS5A-GFP was used as a 
control. As shown in Figure 3.20, no membranous web formation was observed in 
ectopic viperin-expressing cells, while single-, double- and multi-membrane vesicles 
(SMV, DMV, MMV) were observed in APEX2 control expressing cells. To confirm that 
no membranous web formation was present in viperin-transfected cells, all cells (30 
cells) in a grid EM sample were explored and there was no discernable membranous web 
formation in any cells. This indicates that viperin disrupts the formation of membranous 
webs, the sites of viral replication. 
 
3.6 Discussion 
HCV infection is a major health problem worldwide and there is currently no vaccine to 
protect from HCV infection. Although highly effective direct-acting antiviral drugs 
(DAAs) have been developed and approved, these therapies are costly and not available 
for all patients, particularly in developing countries. Therefore, many studies have 
attempted to understand the complete mechanisms of the viral life cycle and to 
investigate at the molecular level how host antiviral responses function to combat HCV 
infection. A more detailed understanding of host-virus interactions will facilitate 
development of improved anti-HCV agents that can be available for all patients and 
eventually reduce the burden of the disease. Since the ISG viperin was identified and 
shown to be a potent antiviral factor against a broad range of viruses (see section 3.1), we 






Figure 3.20: Viperin blocks membranous web formation. 
To investigate whether viperin restricts the HCV RC, the presence of viperin in a non-
replicative model was set up by co-transfecting T7 stable cells with viperin-APEX2 and 
pTM1(NS3-5B)/NS5A-GFP. Co-transfection of APEX2 control and pTM1(NS3-
5B)/NS5A-GFP in T7 stable cells was used as a control. All samples were stained with 
DAB for 10 min followed by EM sample preparation. EM images of (A) HCV replicon 
cells, (B) non-replicative model +APEX2 control and (C) non-replicative model + 
viperin-APEX2 control were visualised using a Tecnai G2 Spirit transmission electron 
microscope at Adelaide Microscopy, The University of Adelaide. Tx, transfected cells; 
UT, untransfected cells; LD, lipid droplet. White, blue and red arrows indicate single, 




Our laboratory has previously reported that viperin co-localises and interacts with the 
HCV NS5A protein, and a host pro-viral cellular protein (VAP-A) at HCV RC; the sites 
of HCV replication (Helbig et al., 2011). VAP-A is a well-characterised pro-HCV host 
factor that plays a role in lipid metabolism and traffic and has been shown to bind to the 
cholesterol recruiting protein, oxysterol-binding protein (OSBP) (Wyles et al., 2002). 
Several viral non-structural and host cellular proteins including VAP-A and OSBP have 
been shown to be important for HCV replication, which is summarised in Figure 3.1 
(Chukkapalli and Randall, 2014). Moreover, it is interesting that binding of the antiviral 
effector protein, interferon-inducible transmembrane protein 3 (IFITM3) to VAP-A 
results in the inhibition of an interaction between VAP-A and OSBP, that ultimately 
culminates in the disruption of cholesterol homeostasis and blockade of viral entry 
(Amini-Bavil-Olyaee et al., 2013). Therefore, it is plausible that viperin may also block 
the interaction of VAP-A and OSBP to alter the formation of HCV RCs and hence inhibit 
HCV replication.  
 
Initially, co-localisation of each protein was investigated, and we found that viperin did 
co-localise with VAP-A, but not OSBP, while as expected VAP-A co-localised with 
OSBP. It is well-documented that VAP-A is primarily localised to the ER (Skehel et al., 
2000, Prosser et al., 2008), while OSBP localises to the Golgi (Amako et al., 2009). We 
also noted that the localisation pattern of VAP-A changed from ER localisation to 
viperin-positive LDs upon viperin expression. However, in the context of overexpression 
of viperin, VAP-A and OSBP in the same cells, we found that VAP-A retains its strong 




at different cellular compartments. Specifically, the co-localisation of viperin and VAP-A 
was strongest at the surface of LDs, while the association of VAP-A and OSBP seemed 
to be at ER and Golgi contact sites (Figure 3.5), which is consistent with the study of 
Wyles and colleagues (Wyles et al., 2002). Although VAP-A still co-localises with OSBP 
in the presence of viperin, this analysis was performed in the absence of HCV infection. 
Therefore, the interaction of VAP-A and OSBP may be altered in the context of HCV-
induced cellular membrane rearrangements (Romero-Brey and Bartenschlager, 2014). 
Furthermore, VAP-A, along with OSBP has been shown to play roles in lipid metabolism 
and exchange from the ER to other organelles such as mitochondria, lipid droplets, and 
the plasma membrane (Raychaudhuri and Prinz, 2010). In addition, host lipids are 
important for many steps of HCV life cycle including replication, assembly and secretion 
(Ye, 2007). Consistent with its localisation to the ER and LDs, the antiviral activity of 
viperin against a diverse set of viruses may be reflective of viperin-mediated alteration of 
cholesterol/lipid homeostasis through an interaction with the host proviral protein, VAP-
A. Viperin induced alteration in lipid raft fluidity has been shown in the case of influenza 
and HIV infection, in which viperin binding to the host farnesyl diphosphate synthase 
(FPPs) resulted in disruption of the plasma membrane through perturbing lipid rafts and 
hence inhibition of viral release from the plasma membrane (Wang et al., 2007, Nasr et 
al., 2012). Further studies are required to determine whether viperin-mediated alterations 
of HCV RC lipid content contributes to its antiviral activity against HCV. 
 
To further investigate the potential involvement of OSBP in viperin’s antiviral function, 




knockdown cell lines (82 and 74% in clone no.2 and 5, respectively) were successfully 
generated (Figure 3.6). Infection of these two knockdown cell lines with HCV and 
DENV resulted in a reduction of HCV replication, while there was no effect on DENV 
replication. This suggests that OSBP plays a central role in the HCV, but not the DENV 
life cycle, and this result is consistent with studies by Wang and colleagues (Wang et al., 
2014). To further investigate whether OSBP is required for the antiviral activity of 
viperin, HCV replication was determined in the context of viperin overexpression in 
OSBP knockdown cell lines. We found that ectopic expression of viperin in the context 
of depletion of OSBP did not impact HCV replication (Figure 3.8). These results 
supported the IF analysis in which viperin did not perturb the direct interaction of VAP-A 
and OSBP. An alternative explanation is that the small amount of remaining OSBP in the 
shRNA knockdown cells may be sufficient for viperin to exhibit its antiviral activity. 
Therefore, the association of these three cellular proteins (viperin, VAP-A and OSBP) 
will be of interest to further investigate in the context of HCV infection. Collectively, our 
results suggest that the molecular mechanism of viperin to restrict HCV replication is not 
through direct disruption of the interaction of VAP-A and OSBP. However, the fact that 
viperin binds to VAP-A and HCV NS5A, and viperin could interfere with the interaction 
of VAP-A and NS5A (Helbig et al., 2011, Wang et al., 2012), raises the possibility that 
viperin may instead disrupt the interaction of VAP-A and NS5A, which then, in turn, 
inhibits membranous web formation to ultimately impair HCV replication. 
 
As previously discussed above, viperin could interrupt the binding of VAP-A and NS5A, 
leading us to determine the localisation of viperin in the context of HCV-induced 




at the ultrastructural level by electron microscopy (EM). Given that specific immuno-
labelling in the context of strong ultrastructural preservation is difficult to achieve using 
traditional immuno-EM approaches, we therefore generated a viperin expression 
construct with an APEX2 tag for EM purposes (Martell et al., 2012). We successfully 
created an expression plasmid encoding viperin-APEX2 and performed 
immunofluorescence analysis following transfection of this plasmid into Huh-7 cells, 
revealing that the APEX2 tag did not change the localisation of viperin on ER and LDs as 
the localisation pattern of viperin-APEX2 was similar to that of non-APEX2 tagged 
viperin (viperin-FLAG) (Figure 3.11). Visualisation of viperin-APEX2 following DAB 
staining by EM demonstrated that viperin induced LD accumulation. Interestingly it was 
also apparent that viperin frequently localised to the contact sites of LDs and 
mitochondria in a number of cells (Figure 3.14 and see additional EM image in Appendix 
XI). It is possible that viperin may contribute to the transfer of signals from these 
organelles to amplify innate antiviral responses, and this is further explored in chapters 5 
and 6. Moreover, we also observed that viperin induced the formation of crystalloid ER, a 
specialised smooth ER that consists of multiple membrane tubules packed in a hexagonal 
form (see EM image of cell no. 8 and 9 in Appendix XI) and this result supports the study 
by the Cresswell group in which overexpression of viperin was also shown to induce 
crystalloid ER (Hinson and Cresswell, 2009b). However, to date, the function of 
crystalloid ER and the mechanism underlying the ability of viperin to induce this 





Our results showed strong evidence that viperin increased the number of LDs in the 
context of viperin overexpression in Huh-7 cells (Figure 3.15), in addition to viperin’s 
ability to induce LDs accumulation and enlargement suggested by our EM analysis 
(Figure 3.14). In contrast, the study by the Cresswell group (Hinson and Cresswell, 
2009a) reported that viperin does not alter the number and size of LDs in bone marrow-
derived macrophages (BMM) isolated from WT and viperin knockout mice following 
treatment with oleic acid overnight. However, there were several notable differences 
between our study and others: 1) different species of viperin, 2) differences in the 
experimental set-up and 3) different cell types. In our study, human viperin was 
overexpressed in Huh-7 cells, while the other study assessed the effect of viperin on lipid 
droplet formation in BMM cells derived from WT and viperin
-/- 
mice. Although it is clear 
that viperin induced LD accumulation, dysfunction of LDs is associated with alterations 
in LD biogenesis (Wang and Sztalryd, 2011) which then may affect the viral life cycle. 
Therefore, the function of viperin-induced LD accumulation in the context of ectopically 
expressed viperin needs to be further investigated. 
 
The viperin-APEX2 tag offers a useful tool to investigate, at the ultrastructural level, how 
viperin interacts/associates with HCV RCs. However, due to complications of 
transfection of plasmids expressing viperin into HCV replicon cells, the HCV 
membranous web formation without viral replication system (Tai and Salloum, 2011) 
was employed to investigate the ability of viperin to alter membranous web formation. It 
is interesting that ectopic expression of viperin completely blocks membranous web 




once again in cells expressing viperin-APEX2, while typical virus-induced cellular 
membrane rearrangements to form membranous factories was clearly seen in cells 
expressing the APEX2 control (Figure 3.20). This suggests that viperin-induced LD 
accumulation may be a mechanism underlying antiviral activity. In addition, a previous 
report has shown that the C-terminus of viperin is a crucial domain that is responsible for 
its anti-HCV function (Helbig et al., 2011), therefore a series of viperin mutants, 
particularly C-terminal mutants, with an APEX2 tag would further enable investigation of 
which domain of viperin is responsible for inhibiting HCV RC/membranous web 
formation. 
 
In conclusion, viperin displays its antiviral action by inhibiting the formation of the 
membranous web, pivotal sites of HCV replication. Although the mechanism underlying 
its antiviral function is likely not through the disruption of VAP-A and OSBP, as both of 
these factors are important for cholesterol and lipids biogenesis, this raises the possibility 
that viperin-induced LD accumulation may alter cholesterol and lipid homeostasis in a 
manner related to the regulated interaction of VAP-A and OSBP. Moreover, several 
studies have reported that many host pro-viral proteins can bind to viperin, thus we 
reasoned that a number of host proteins remain to be discovered and this hypothesis will 






Identification of novel interacting partners of viperin  
 
4.1 Introduction 
Viperin has been reported to be a restriction factor for a broad range of viruses, however 
the molecular mechanism(s) that underpin this restriction are diverse and in some cases 
are still unclear. As an example, the radical SAM domain is critical for viperin’s anti-
TBEV activity while this domain is dispensable for its anti-HCV activity (Upadhyay et 
al., 2014, Helbig et al., 2011). Viperin can bind to a number of host and viral proteins 
including the host lipid metabolising enzyme FPPS, and the innate immune adaptor 
molecules TRAF6 and IRAK1 that are key in TLR7 and 9 signalling, the adaptor protein 
MAVS, and the cytosolic Fe/S Assembly Component 1 (CIAO1) (Wang et al., 2007, 
Saitoh et al., 2011, Hee and Cresswell, 2017, Upadhyay et al., 2014). Viperin also 
interacts with viral proteins from HCV (NS5A), DENV (NS3) and HCMV (vMIA) 
(Helbig et al., 2011, Helbig et al., 2013, Seo et al., 2011). This clearly suggests that 
viperin has a wide diversity of interacting partners, although to date a systematic 
investigation of viperin cellular interacting partners has not been conducted. It is likely 
that many of the interacting partners of viperin remain to be discovered and characterised 
and this represents a major gap in our understanding of the biology of this important host-
virus interaction. Therefore, the aim of this chapter was to identify and characterise novel 





In this study, the well-characterised yeast two-hybrid system (Y2H) was used to identify 
novel interacting partners of viperin. The Y2H system exploits the nature of the yeast 
Gal4 transcription factor. This Gal4 protein has 2 domains: a Gal4 DNA-binding domain 
(DNA-BD); and a Gal4 activation domain (AD). The Gal4 protein binds to an activating 
sequence (5’ to the gene) leading to initiation of gene transcription. In the Y2H system, 
the 2 domains of the Gal4 protein are divided with the Gal4 DNA-BD fused to a known 
protein of interest or “bait protein” which, in this study, is viperin. The Gal4-AD is fused 
to “prey proteins”, which are derived from a cDNA library of interest. When a bait 
protein (viperin-Gal4-BD) interacts with a prey protein (prey-Gal4-AD), the DNA-BD 
and AD are brought into close proximity that restores GAL4 activity and subsequently 
leads to transcriptional activation of a reporter gene (Figure 4.1) which in the case of the 
Y2H system is -galactosidase that results in blue yeast colonies. As there are four 
independent reporter genes (AUR1-C, ADE2, HIS3, and MEL1) under the control of 3 
promoters (G1, G2 and M1) in the Matchmaker Gold Yeast Two-Hybrid system 
(Clontech), the system generates significantly less false positives (Van Criekinge and 
Beyaert, 1999). Therefore, we used this Y2H system to identify novel interacting partners 
of viperin. A schematic of the main processes of the Y2H experiment at workflow is 







Figure 4.1: Schematic diagram of the yeast two-hybrid principle. 
A bait protein (protein of interest; viperin in this study) and prey protein are expressed 
separately in fusion with Gal4 DNA-BD and Gal4-AD, respectively. (A) The interaction 
of bait and prey protein results in the expression of reporter genes, while (B) no 









Figure 4.2: The main steps of Y2H experiments. 
 
  
5. Confirmation of the positive interactions 
4. Rescue of the prey vector to identify the interacting partners 
3. Screening by co-transformation method 
2. Construction of the cDNA library 




4.2 Construction and characterisation of the Y2H viperin bait plasmid (pGBKT7-
viperin) 
4.2.1 Cloning of viperin-coding cDNA sequence into a pGBKT7 plasmid 
In order to screen for novel interacting partners of viperin, full-length human viperin (that 
will act as the bait) was cloned into the plasmid pGBKT7 (see Appendix V for plasmid 
map). To achieve this, the human viperin cDNA was amplified by PCR using specific 
primers (Appendix I) and the pLenti6-viperin-Flag plasmid (Helbig et al., 2011) as a 
template and the PCR amplicon was subsequently cloned into the plasmid pGBKT7. Five 
bacterial transformants were randomly picked and double digested with BamHI and 
EcoRI to confirm the correct size of the inserted gene. The sizes of linear pGBKT7 
plasmid and viperin gene fragments are ~7.3 kb and 1,086 bp, respectively as shown in 
Figure 4.3. The sequences of the recombinant plasmids were confirmed by Sanger 
sequencing and all gene-inserts showed 100% identity to Homo sapiens radical S-
adenosyl methionine domain containing 2, or viperin, (Accession no. NM_080657.4). 
The pGBKT7-viperin plasmid was then transformed into competent Saccharomyces 
cerevisiae strain Y2H gold cells and plated on Tryptophan (Trp) dropout (SD/-Trp) 
selective medium to allow selection of Trp biosynthesis of transformant clones. Five 
colonies were randomly selected and lysed in 20 mM NaOH for further confirmation via 
colony PCR to verify the yeast cells contained the expected plasmid (pGBKT7-viperin). 







Figure 4.3: Viperin cDNA was successfully cloned into pGBKT7. 
Insertion of the viperin cDNA into the plasmid pGBKT7 was confirmed by 
BamHI/EcoRI digestion of plasmid DNA extracted from 5 bacterial transformants. 
Restriction digests were run on 1% agarose gel. Lane M, 1 kb DNA marker; lanes 1-5, a 








Figure 4.4: pGBKT7-viperin plasmid was successfully transformed into yeast cells. 
To test whether yeast cells (Saccharomyces cerevisiae strain Y2H Gold) contain the 
pGBKT7-viperin plasmid, five individual clones were randomly picked and lysed in 20 
mM NaOH prior to colony PCR to detect viperin cDNA. Lane M, 1 kb DNA marker; 
Lane 1-5, yeast cells carrying pGBKT7-viperin clone no. 1-5, respectively; lane 6: yeast 





4.2.2 Viperin expression in Saccharomyces cerevisiae strain Y2H gold cells 
Next, it was imperative to determine if viperin was expressed in transformed yeast cells. 
Five clones of the pGBKT7-viperin transformed Saccharomyces cerevisiae were grown 
to log-phase in SD/-Trp broth and whole cell protein lysates were extracted using 
cracking buffer (see section 2.2.4.2, Chapter 2). Viperin expression was detected by 
Western blot analysis using antibodies to Myc (Myc tag was incorporated in the original 
PCR cloning strategy) and viperin (Enzo life sciences). The result revealed that viperin 
was expressed in yeast cell transformants with a molecular mass of approximately 65 
kDa that represents viperin fused with the DNA-binding domain (Figure 4.5). Variability 
was noted in the level of expression between yeast clones, however maximal viperin 
expression was observed for clone # 3. Clone #3 was further selected for analysis of bait 
toxicity, auto-activation and was used for further experiments in this study. 
 
4.2.3 Toxicity and auto-activation testing of the bait protein 
As a first stage before performing the Y2H screen, it is imperative to confirm that the bait 
protein (viperin) does not autonomously activate the reporter genes in Saccharomyces 
cerevisiae strain Y2H Gold, in the absence of a prey protein. Moreover, it is also 
necessary to verify that a bait protein is not toxic when expressed in yeast cells. If a bait 
protein is toxic, this can be observed by both solid and liquid cultures growing more 
slowly. To determine whether viperin was toxic or had auto-activation ability, 
Saccharomyces cerevisiae (strain Y2H gold) was transformed with pGBKT7-empty or 
pGBKT7-viperin plasmids and plated on the SD/-Trp selective medium for toxicity 










Figure 4.5: Viperin expression in Saccharomyces cerevisiae strain Y2H gold. 
To investigate if viperin was expressed in yeast cells, clones were grown to log phase and 
whole cell lysates were extracted from yeast cells using a cracking buffer prior to Western 
blot analysis. (A) Viperin expression was detected by probing with anti-Myc (Millipore, 
clone 4A6) or (B) anti-viperin (Enzo life sciences) antibody. Lane 1-5: PGBKT7-viperin 





not toxic to the yeast cells as the size of yeast colonies transformed with the pGBKT7-
viperin plasmid was similar to that of the yeast cells carrying pGBKT7-empty plasmid 
(Figure 4.6A). Furthermore, expression of viperin did not result in auto-activation of 
reporter genes, as demonstrated by red colonies on SDO/X selective medium (Figure 
4.6B). Additionally, no colonies grew on the SDO/X/A medium indicating that viperin 
was not able to auto-activate the MEL1 gene (encodes for -galactosidase; enzyme for X-
-gal substrate) or the AUR1-C gene (encodes for aureobasidin A resistance). As 
expected, it was noticed that yeast colonies turned red when they were grown in medium 
containing a low concentration of adenine (SDO and DDO medium). The red pigment 
exhibited by ADE2 mutants is a purine precursor which accumulates in yeast ADE2 or 
ADE1 strains, from which the Y2H gold strain is derived. Collectively these results 
indicate that viperin is not toxic when expressed in yeast and does not have auto-
activation capacity. 
 
4.3 Construction of the IFN--stimulated Huh-7 cell cDNA library  
As viperin is an interferon-stimulated gene (ISG) that is upregulated following viral 
infection and IFN- stimulation, we postulated that interacting partner of viperin may 
also fall into the class of ISGs or be associated with ISGs upregulation. Hence, we 
generated a cDNA library from Huh-7 cells stimulated with IFN- for screening for 
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Figure 4.6: Viperin expression in yeast is not an auto-activator and is not toxic. 
To test if viperin expression in yeast is toxic or has auto-activator capability in the Y2H 
system, pGBKT7-empty and pGBKT7-viperin plasmids were introduced into 
Saccharomyces cerevisiae strain Y2H gold and plated on the SD/-Trp selective medium 





4.3.1 Determination of the IFN-α concentration and treatment time required for 
maximal viperin upregulation in Huh-7 cells. 
Before generating the cDNA library from IFN--stimulated Huh-7 cells, we first 
determined the concentration of IFN-α and time post-stimulation that resulted in optimal 
viperin and other ISG mRNA expression levels. To determine the optimal concentration 
of IFN-, Huh-7 cells were treated with IFN--2A (Peprotech) at 100, 250, 500 and 
1,000 U/ml for 24 hr. Quantification of mRNA abundance (real time RT-PCR) 
demonstrated that viperin mRNA was upregulated by all treatment concentrations of 
IFN- with maximum viperin mRNA levels being observed with 1,000 U/ml (Figure 
4.7A). Moreover, viperin expression was maximal at 8 hr following IFN- stimulation 
(1000 U/ml) of the Huh 7 cells (Figure 4.7B), after which mRNA rapidly declined. 
 
4.3.2 Amplification of cDNA using long-distance PCR 
Based on the results above (see Section 4.3.1), we next generated a cDNA library using 
the “Make Your Own “Mate & Plate” Library System” (Clontech) from Huh-7 cells 
treated with IFN- at 1,000 U/ml for 8 hr. Following IFN- stimulation, RNA was 
extracted from the Huh-7 cells and used for first strand cDNA synthesis using an oligo-
dT primer and MMLV reverse transcriptase. Long-distance PCR was performed to 
prepare the library cDNAs (ds-cDNA) using Advantage® 2 Polymerase Mix (Clontech). 
Analysis of amplified cDNA on a 1% agarose gel revealed that the resulting cDNAs 
ranged from 100 bp to 10 kb representing good recovery of intact mRNA (Figure 4.8). 
cDNA of size >200 bp was purified using column chromatography and the final quantity 







Figure 4.7: Dynamics of viperin mRNA expression in Huh-7 cells following IFN- 
stimulation. 
To assess viperin expression following IFN- stimulation, (A) Huh-7 cells were treated 
with IFN- at 100, 250, 500 and 1,000 U/ml. (B) Huh-7 cells were treated with IFN- 
1,000 U/ml for 4, 8, 16 and 24 hr for time course analysis of viperin upregulation. 
Viperin mRNA expression was analysed by real time RT-PCR and expressed as fold 







Figure 4.8: Long-distance PCR (ds cDNA) amplification. 
ds-cDNA was amplified using Advantage® 2 Polymerase Mix (Clontech). The cDNAs 





4.4 Proof of principle that the Y2H method can identify known interacting partners 
of viperin 
The first attempt to screen for novel interacting partners of viperin using an IFN- 
stimulated cDNA library (see Section 4.3) was unsuccessful, as screening more than 1 
million independent clones resulted in no blue colonies. There are a number of 
possibilities that may explain this result. Firstly, a weak or transient interaction of viperin 
with interacting partners may result in an excess of aureobasidin A, which is toxic to the 
yeast cells. Secondly, it is possible that viperin interactions may not occur in the nucleus 
and hence result in no transactivation. To investigate if either of these possibilities were at 
play and to validate our Y2H approach, known interacting partners of viperin were 
constructed in prey plasmids. It has been reported by our laboratory using 
immunofluorescence and fluorescence resonance energy transfer (FRET) analysis that the 
host factor VAP-A and NS5A interact with viperin within the HCV RC (Helbig et al., 
2011). Therefore, the interaction of viperin with VAP-A and HCV NS5A was assessed in 
yeast cells prior to conducting further screening experiments. VAP-A and NS5A were 
amplified using pLenti6-VAP-A-mCherry (Helbig et al., 2011) and pJc1 plasmid (Eyre et 
al., 2010) as templates (PCR products were of the expected size, as show in Figure 4.9), 
cloned into pGADT7 AD (prey) plasmid and transformed into α-Select Chemically 
Competent E. coli cells. Positive clones were tested by double digestion with NdeI and 
EcoRI (Figure 4.10) and confirmed by DNA sequencing. These plasmid constructs were 
then used to investigate the interaction of viperin with either VAP-A or NS5A in yeast 
cells and also used to titrate an appropriate concentration of aureobasidin A for screening 







Figure 4.9: NS5A and VAP-A amplicons. 
NS5A and VAP-A PCR products revealed by 1% agarose gel electrophoresis and Gel 
Red staining. Lane M, 1 kb DNA marker; lane 1, NS5A gene amplicon (1,401 bp) and 








Figure 4.10: Patterns of NdeI and EcoRI double digestion of recombinant 
NS5A/VAP-A pGADT7 AD plasmids. 
To confirm the positive clones, plasmid DNA was extracted from transformant clones 
and subjected to double digestion with NdeI and EcoRI. Lane M, 1 kb DNA marker; 
lanes 1-4, pGADT7 AD-NS5A recombinant plasmid clones no. 1-4, respectively; lanes 5-
8, pGADT7 AD-VAP-A recombinant plasmid clones no. 1-4, respectively; lane 9, 






appropriate plasmids were co-transformed into competent Saccharomyces cerevisiae 
strain Y2H gold and various concentrations of aureobasidin A were used as outlined in 
Table 4.1. After 3-5 days of incubation of the transformed yeast cells, viperin was found 
to interact with VAP-A as determined by the emergence of blue colonies, but not with 
NS5A. We also found that low concentrations of aureobasidin A (< 50 ng/ml) were 
required to observe the interaction between viperin with VAP-A (Table 4.1). This low 
concentration of aureobasidin A together with pale blue colonies suggests that the 
interaction between viperin and VAP-A is weak or transient that results in low expression 
of the reporter gene (Figure 4.11). It is intriguing as to why we did not observe a viperin-
NS5A interaction in our system. It is well-established that VAP-A interacts with NS5A 
and it may be possible that a prior VAP-A and NS5A interaction may be required to 
facilitate the interaction of viperin with NS5A. Alternatively, there may be other factors 
required for viperin-NS5A interaction that are not found in yeast cells (but are found in 
mammalian cells, where the interaction has been demonstrated). These experiments 
highlight one of the limitations of the Y2H system: the protein interactions that are 
observed in mammalian cells may not be observed in yeast cells (and vice versa). 
Nevertheless, we successfully identified that a viperin-protein interaction can occur in 
yeast cells verifying our approach. 
 
4.5 A second screen for novel interacting partners of viperin by co-transformation 
method in the Y2H system. 
In a second attempt to screen for novel interacting partners of viperin, pGBKT7-viperin 




Table 4.1: Aereobasidin A Titration 
 
Co-transformation DDO (SD/-Trp/-Leu)/X + aereobasidin A (ng/ml) 
 0 25 50 75 100 150 200 
pGBKT7-Viperin + pGADT7 AD-VAP-A +  (*) +  (*) +  (*) - - - - 
pGBKT7-Viperin + pGADT7 AD-NS5A + + + - - - - 
pGBKT7-Viperin + pGADT7 AD-empty plasmid + + + - - - - 
pGADT7 AD-VAP-A + pGBKT7-empty plasmid + + + - - - - 
pGADT7 AD-NS5A + pGBKT7-empty plasmid + + + - - - - 
 
+ (*): Pale blue colonies 
+     : White colonies 







Figure 4.11: Viperin interacts with VAP-A but not HCV NS5A in a Y2H system. 
To assess the interaction of known viperin interacting partners in the Y2H system, the 
plasmid pGBKT7-viperin was co-transfected with (A) pGADT7 AD-VAP-A or (C) 
pGADT7 AD-NS5A into competent Saccharomyces cerevisiae strain Y2H gold and 
incubated for 3-5 days. Note that blue colonies are present in (A) only. Co-transformation 
of pGBKT7-empty plasmid with (B) pGADT7 AD-VAP-A or (D) pGADT7 AD-NS5A 
and (E) pGBKT7-viperin with pGADT7 AD-empty plasmids were used as negative 




linearised pGADT7-Rec (prey) plasmid (Clontech) were combined and co-transformed 
into competent Saccharomyces cerevisiae strain Y2H Gold. The transformation reaction 
was spread onto 50 plates of DDO (SD/-Trp/-Leu)/XA medium (150 mm petri-dish size). 
After incubation for 3-5 days, 40 blue colonies were observed from 50 plates (Figure 
4.12A). All blue colonies were picked and re-streaked on DDO/X medium to separate 
any contamination of blue and white colonies. This process was repeated three times until 
there were pure blue colonies (Figure 4.12B). Plasmid DNA representing the bait cDNA 
was rescued from all blue colonies and subsequently transformed into bacterial cells and 
plated onto LB-Amp plates to select bacteria harbouring the prey plasmid. All extracted 
prey plasmids (40 in total) were analysed by DNA sequencing and sequence compared to 
the NCBI GenBank database. Seven plasmids were identified that contained full-length 
or truncated open reading frames (ORF) fused in frame to the GAL4 AD sequence in the 
prey plasmid. The coding sequences from each of the 7 plasmids were translated to 
amino acid sequence and compared to known sequences in the GenBank databases using 
the Basic Local Alignment Search Tool (BLAST) from the National Centre for 
Biotechnology Information (NCBI) (Table 4.2). The identified sequence above from the 
Y2H screen was validated by co-transformation of each of the rescued-prey plasmids 
with pGBKT7-viperin. This validation screen identified that there were two genuine 
positive interacting partners of viperin: peroxisome biogenesis factor 19 (PEX19); and 
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Figure 4.12: Screening of viperin’s interacting partners by co-transformation 
method. 
In order to screen the interacting partners of viperin, the pGBKT7-viperin (bait) plasmid, 
ds cDNA and linearised pGADT7-Rec plasmid were co-transformed into competent 
Saccharomyces cerevisiae strain Y2H Gold and spread onto 50 plates of DDO/XA 
medium. (A) Blue colonies were observed after 3-5 days incubation. (B) All blue 
colonies were re-streaked (x3) until pure blue colonies were present on selective medium 






Table 4.2: Validation, by co-transformation method, of viperin interacting partners 
identified in the Y2H screen 
 
Prey no. Protein 
Amino acid 




Amino acid residues 
of a candidate prey 
protein that fused in 









1-158 1-158 False positive 
Prey#7 Protein phosphatase 1, catalytic 
subunit, alpha isoform 
1-349 3-31 False positive 
Prey#55 Peroxisomal biogenesis factor 
19 (PEX19) 
1-299 1- 272 Genuine positive 
Prey#62 Apolipoprotein A1 1-267 104-267 Genuine positive 
Prey#16 F-box and leucine-rich repeat 
protein 6, isoform CRA_d 
  
1-300 19-300 False positive 
Prey#3 FAM46A (HBV X-
transactivated gene 11 protein) 
1-442 337-442 False positive 








Figure 4.13: Validation of viperin interacting partners by co-transformation 
method. 
To confirm the positive interaction of viperin and its novel interacting partners, 
pGBKT7-viperin and candidate prey plasmid were co-transformed into competent 
Saccharomyces cerevisiae strain Y2H gold and plated onto DDO/X and DDO/XA. The 
co-transformation of candidate prey plasmid and pGBKT7-empty plasmid was used as a 
control. (A, B) blue colonies appeared only for the co-transformation of the candidate 
prey plasmids and pGBKT7-viperin but not on the control plate representing a true 





4.6 Confirmation of viperin-interacting partners by other techniques 
It was somewhat disappointing that only such few true positive interacting partners were 
identified in the Y2H screen. However, this alleviated the need to rationalise or prioritise 
target proteins for analysis. To investigate the interaction of viperin with hits identified 
above, expression plasmids encoding cDNA representing PEX19 (pCMV6-PEX19, 
catalogue number RC201756) and APO-A1 (pCMV6-ApoA1, catalogue number 
RC210762) were obtained from Origene. These plasmids contain the complete ORF 
downstream of the CMV promoter and are fused in frame to a Myc and FLAG tag at the 
C-terminus. These plasmids were subsequently used to confirm the interaction of viperin 
with PEX19 or ApoA1 using immunoprecipitation and proximity ligation assays.  
 
4.6.1 Confirmation of viperin-interacting partners by proximity ligation assays  
In order to assess the interaction of viperin with PEX19 and ApoA1 in eukaryotic cells, 
proximity ligation assay (PLA) was employed. In brief, proximity ligation assay enables 
detection and visualisation of subcellular localisation of protein-protein interactions using 
immunofluorescence microscopy. The interacting proteins are detected using primary 
antibodies raised in different species to the proteins in question. The appropriate 
secondary antibodies are conjugated with oligonucleotides (PLA probe MINUS and PLA 
probe PLUS) and following binding to corresponding primary antibodies results in a 
close proximity of the two probes if there is an interaction between the 2 proteins in 
question. The fluorescently labelled probe generates a fluorescent signal following 
ligation and amplification of the two oligonucleotides or probes. Initially, it was 




the Myc tag as at the time we did not have a reliable viperin antibody (for IF) and all 
viperin expression constructs were FLAG-tagged. We generated PEX19-Myc and 
ApoA1-Myc by removing the FLAG tag using EcoRV and PmeI double digestion and 
then re-ligation of the digested plasmid. Removal of the FLAG tag was confirmed by 
transfection of the modified plasmids into Huh-7 cells and staining with mouse anti-
FLAG and mouse anti-Myc. As shown in Figure 4.14, the new constructs were stained by 
anti-Myc but not by anti-FLAG indicating the fusion of only the Myc tag for both 
constructs. Moreover, these plasmids were analysed by DNA sequencing and the results 
showed that they lacked the FLAG tag-coding sequence. These plasmids were further 
used in PLA. 
 
To investigate the interaction of viperin and the candidate interacting partners by PLA, 
Huh-7 cells were co-transfected with pLenti6-viperin-FLAG and pCMV6-PEX19-Myc or 
pCMV6-ApoA1-Myc for 24 hr and then PLA was performed using mouse anti-FLAG 
and rabbit anti-Myc. A combination of mouse isotype control and rabbit anti-Myc was 
used as a control for the assay. A fluorescent signal represented a protein-protein 
interaction in cells as shown in Figure 4.15, implying that viperin interacts with PEX19 
and ApoA1 in Huh-7 cells.  
 
4.6.2 Confirmation of viperin-interacting partners by co-immunoprecipitation 
The interaction of viperin and PEX19 and ApoA1 was next examined by co-






Figure 4.14: Generation of PEX19-Myc and ApoA1-Myc tag plasmids. 
The Myc-tagged plasmids were confirmed by staining with mouse anti-FLAG/mouse 
anti-Myc, followed by an Alexa Fluor 555-conjugated goat anti-mouse IgG (Red). Nuclei 
were counterstained with DAPI (blue). Cells were visualised using a Nikon TiE inverted 







Figure 4.15: Viperin associates with PEX19 and ApoA1 as determined by proximity 
ligation assays (PLA). 
To investigate whether viperin interacts with PEX19 and ApoA1, Huh-7 cells were 
transiently transfected with pLenti6-viperin-FLAG and pCMV6-PEX19-Myc or pCMV6-
ApoA1-Myc and cultured for 24 hr. PLA was performed using mouse anti-FLAG (to 
detect viperin) and rabbit anti-Myc (to detect either PEX19 or ApoA1). A combination of 
mouse isotype control and rabbit anti-Myc was used as a negative control and nuclei were 
counterstained with DAPI (blue). Red dots in cells were visualised using a Nikon TiE 





viperin-mCherry and pCMV6-PEX19-Myc/FLAG or pCMV6-ApoA1-Myc/FLAG, 
cultured for 24 hr and then a whole cell lysate was prepared. Viperin was 
immunoprecipitated from the cell lysate using anti-mCherry, while co-precipitation of 
PEX19 and ApoA1 with viperin was detected by Western blot analysis using anti-FLAG 
antibody. As shown in Figure 4.16, PEX19 co-precipitated with viperin and this was 
consistent with the PLA result indicating that PEX19 is an interacting partner of viperin. 
In contrast, ApoA1 was not detected by Co-IP with viperin. It is possible that the 
interaction of viperin with ApoA1 is weak or transient in nature, such that cell lysis may 
dissociate the interaction of these proteins, resulting in negative Co-IP results.  
 
4.7 Discussion  
It is clear from many published reports that viperin is a potent cellular antiviral factor 
against a broad range of viruses, however there is no unifying molecular mechanism that 
underpins this function. For example, the radical SAM domain is crucial for the antiviral 
function of viperin against TBEV but not HCV or DENV (Upadhyay et al., 2014, Helbig 
et al., 2011, Helbig et al., 2013). Moreover, viperin can bind to a number of host and viral 
proteins (see section 4.1). It has been shown to disrupt lipid rafts through its interaction 
with the host lipid metabolising enzyme farnesyl pyrophosphate synthase (FPPS), a 
mechanism that is specific for influenza and HIV (Wang et al., 2007, Nasr et al., 2012) 
and has also been shown to reduce cholesterol and sphingomyelin on cellular membranes, 
both of which are are the main components of lipid rafts and necessary for rabies virus 






Figure 4.16: Confirmation of the interaction of viperin and PEX19 or ApoA1 by co-
immunoprecipitation. 
To determine whether viperin interacts with PEX19 and ApoA1, Huh-7 cells were 
transiently transfected with pLenti6-viperin-mCherry and pCMV6-PEX19-Myc/FLAG or 
pCMV6-ApoA1-Myc/FLAG for 24 hr. The co-transfection of pLenti6-mCherry plasmid 
and pCMV6-PEX19-Myc/FLAG or pCMV6-ApoA1-Myc/FLAG plasmids served as a 
negative control. Whole cell lysates were then extracted and viperin was 
immunoprecipitated using anti-mCherry. Viperin immunoprecipitates were analysed by 






through interaction with the HCV NS5A protein and the HCV pro-viral cellular factor 
VAP-A. Furthermore, viperin seems to be involved in antiviral signalling as it was shown 
to be important in Toll-like receptor 7 (TLR7) and TLR9 signalling through its 
interaction with the adaptor molecules IRAK1 and TRAF6. Clearly, the domains of 
viperin cannot possibly account for its diverse range of biological functions and are most 
likely explained by its ability to interact with and modulate cellular protein function. 
While some host factors have been identified, they cannot account for the diverse nature 
of viperin function. We therefore hypothesise that cellular interacting partners of viperin 
remain to be discovered and characterised. This gap in knowledge led us to identify and 
characterise novel interacting partners of viperin in order to expand and fulfil our 
understanding of the diverse cellular biological functions of viperin. 
 
There are a number of methods to identify protein-protein interactions and the recent 
explosion of proteomic techniques such as affinity purification coupled with mass 
spectrometry has revolutionised identification of protein interacting partners. Initially, we 
entertained the idea of using co-immunoprecipitation-coupled mass spectrometry (MS) to 
identify novel interacting partners of viperin. However, this approach required a specific 
antibody to viperin that could be used in immunoprecipitation experiments. We therefore 
evaluated a number of commercial monoclonal and polyclonal antibodies against viperin 
and found that these were not robust in Western blot analysis, and were ineffective in 
immunoprecipitation experiments of either endogenous (following IFN- stimulation) or 
exogenous expression of viperin in multiple cell types (Huh-7, 293T and HeLa cells) 




transcription-based yeast two-hybrid (Y2H) experimental system that is a proven 
powerful method to identify of protein-protein interactions in living cells (yeast cells) that 
reflect an in vivo situation.  
 
In this study, we utilised the “Matchmaker Gold Yeast Two-Hybrid system (Clontech)” 
to identify novel viperin interacting partners. This system has advantages over previous 
versions of Y2H systems in that it consists of 4 reporter genes under the control of 3 
promoters which lead to reduce false positives. Initially, viperin cDNA (bait protein) was 
cloned into the bait vector (pGBKT7) and then toxicity and auto-activation of the reporter 
genes (AUR1-C, ADE2, HIS3, and MEL1) of the bait were tested. Viperin was clearly 
expressed in yeast cells with no effect on the viability of the yeast cells or auto-activation 
of the reporter genes. As previously described by our laboratory using 
immunofluorescence microscopy and FRET analysis it has been shown that viperin 
interacts with HCV NS5A protein and the pro-viral host factor VAP-A. This provided an 
excellent opportunity to not only confirm these observations by another method but to 
test the ability of viperin to interact with a viral or mammalian protein in the context of 
yeast cells. We therefore cloned HCV NS5A or VAP-A cDNA into the Y2H prey 
plasmid pGADT7 AD. Interestingly following transfection of the bait and prey plasmids 
into yeast and selection of tryptophan (Trp) and leucine (Leu) biosynthesis genes 
(provided in bait and prey plasmids, respectively) on DDO (SD/-Leu/-Trp)/XA selective 
medium, we noted transactivation of the 3 independent promoter (G1, G2, M1) only in 
the presence of VAP-A and not NS5A. The reasons why we see transactivation only in 




VAP-A interacts with NS5A and it may be that the association of viperin and NS5A may 
be solely mediated by the interaction between VAP-A and viperin at sites of HCV 
replication. Alternatively, as previously mentioned it is possible that the NS5A-viperin 
interaction is either too weak or transient to be identified in the Y2H assay. Clearly 
further studies are required to confirm or refute the NS5A viperin interaction. 
Nevertheless, the observation that VAP-A can interact with viperin in our Y2H system 
confirms the validity of the experimental system.  
 
Similar to many interferon-stimulated genes, viperin mRNA expression is significantly 
induced following IFN- stimulation often from a very low baseline expression. We 
therefore reasoned that possible viperin interacting partners may also fall within the ISG 
family. Therefore, the cDNA library to generate the prey library was subsequently 
generated from Huh-7 cells stimulated with IFN- and cloned in the linearised pGADT7-
Rec (prey) plasmid. Implementation of our Y2H screen using the above-mentioned 
plasmids revealed 40 blue colonies that represent a positive interaction between viperin 
and the prey protein, from a total of more than 1  10
6
 transformants. However, analysis 
of all 40 cDNAs by Sanger sequencing revealed that only 7 of the candidate prey proteins 
were fused in frame with the linearised pGADT7-Rec (prey) plasmid (Table 4.2) and are 
possible authentic viperin interacting partners. This represents a limitation of Y2H 
approach in which the system is prone to the identification of false positives hits which 
are defined as physical interactions identified in the screen that cannot be reproduced 
using independent assays. False positives can arise for a number of reasons and include; 




physiological compartment that does not correspond to their natural environment, 3) 
incorrectly folded proteins can lead to non-specific interaction and 4) auto-activation 
[reviewed in (Bruckner et al., 2009)]. It is possible that a number of the 40 identified hits 
in our screen fall into this category especially for those ORFs that are not fused in frame 
that would lead to aberrant protein expression. It was also intriguing that only a small 
number of interaction partners were identified and none of the previously identified 
viperin interaction partners were identified. This can be explained by a further limitation 
of Y2H false negatives that are defined as protein-protein interactions that cannot be 
detected due to the limitations of the assay. As above false negatives arise for a host of 
reasons, for example, protein interactions involving membrane proteins are mostly 
undetectable while it is possible that in some instances the fusion of bait or prey proteins 
may cause steric hindrance and block interaction. Furthermore, interactions must occur in 
the nucleus while post-translational modifications may be lacking in yeast while weak or 
transient interactions may go unnoticed [reviewed in (Bruckner et al., 2009)]. It is likely 
that a number of these factors (false positive) were at play in our Y2H screen as 
following confirmation of the co-transformation experiments using viperin (bait) and 
positive candidate prey proteins, we could only detect 2 genuine positive interacting 
partners of viperin namely PEX19 and ApoA1. The other candidate prey proteins gave 
false positive interactions as they auto-activated the reporter gene when expressed alone 
in the absence of interaction with the bait protein (Figure 4.13C). 
 
As indicated above, the propensity of Y2H screens to identify false positives means that 




interaction of novel viperin interacting partners PEX19 and ApoA1 we employed co-
immunoprecipitation (Co-IP) and proximity ligation assay (PLA) techniques. Both of 
these approaches require robust specific antibodies to the protein in question, however as 
described above, available commercial antibodies to viperin were unable to 
immunoprecipitate ectopic expression of viperin. To overcome this limitation, we utilised 
exogenous viperin expression in which viperin was tagged with either the FLAG epitope 
or fused in frame with mCherry. Interestingly we could only immunoprecipitate viperin 
from transfected cell lysates using a specific Ab to mCherry and not the FLAG epitope 
for reasons that are not immediately apparent. Therefore, the plasmid, pLenti6/V5-D-
TOPO expressing viperin-mCherry was used for Co-IP studies to confirm the interaction 
of viperin and its novel interacting partners.  
 
Using Co-IP and PLA approaches, we confirmed our Y2H results and revealed an 
interaction of viperin and PEX19. Interestingly, during the course of this thesis, our Y2H 
studies identifying PEX19, were confirmed in a study using liquid chromatography 
coupled to tandem mass spectrometry (LC-MS/MS) to identify cellular viperin 
interacting partners (Vonderstein et al., 2017). However, this was not the case for ApoA1 
in which we could only detect an interaction using PLA but not Co-IP. The reasons for 
this are not clear but could be related to a weak interaction between viperin and ApoA1 
that may not have survived the immunoprecipitation protocol. However, the PLA results 
suggest that indeed viperin and ApoA1 interact or are least in close proximity as a 
positive PLA can only be obtained when the proteins are within 40 nm of each other. 




as repeating immunoprecipitation experiments coupled with a confocal microscopy 
approach to visualise protein-protein interactions in a cellular context. Nevertheless, both 
PEX19 and ApoA1 are novel viperin interacting partners that require further 
investigation and for reasons that will become apparent in the following chapters of this 
thesis, we chose to further investigate the viperin-PEX19 interaction.  
 
It is interesting to speculate as to why using the Y2H system that we did not uncover 
more viperin interaction partners especially previously recognised partners such as FPPS, 
TFP, IRAK1, VAP-A, TRAF6, MAVS and CIAO1. This may be for a host of reasons, 
some of which have been alluded to above and may in part relate to weak or transient 
interactions with viperin and the possibility of interactions occurring in specific cell 
subsets as was noted for the interaction between viperin with TRAF6 and IRAK1 only in 
pDCs.  
 
In conclusion, we have identified two novel interacting partners of viperin, PEX19 and 
ApoA1. PEX19 is a key biogenesis factor in the formation of peroxisomes and given that 
peroxisomes are emerging as a key organelle in the host antiviral response, we have 
focused our efforts in the remainder of this thesis to investigate the interaction of viperin 
and PEX19 and determine how this interaction may mediate the cellular antiviral 





Viperin alters peroxisome biogenesis and localisation to augment innate 
immune signalling 
 
5.1 Introduction  
Work in Chapter 4 established using a Y2H approach that the peroxisomal biogenesis 
factor 19 (PEX19) and Apolipoprotein A1 (ApoA1) were novel viperin interacting 
partners. We decided to pursue the interaction between viperin and PEX19 based on the 
following: 1) recent reports suggest that the peroxisome plays an important role in innate 
immune signalling (Dixit et al., 2010, Odendall et al., 2014); 2) preliminary data from our 
laboratory suggests that viperin can modulate innate immune signalling  (Beard and 
Helbig unpublished data) and; 3) a number of viruses can interact with PEX19 and 
subvert innate immune signalling from peroxisomes (You et al., 2015, Magalhaes et al., 
2016). Collectively, this suggests that peroxisomes play a role in the innate immune 
response to viral infection and a PEX19/viperin interaction may impact this response. 
 
PEX19 is necessary for early peroxisome biogenesis and acts as a cytosolic chaperone to 
facilitate peroxisomal membrane protein (PMP) insertion into the peroxisome membrane. 
PEX19 shuttles between the cytoplasm and peroxisomes, although it is predominantly 
localised to the cytoplasm (Sacksteder et al., 2000, Jones et al., 2004) and PEX19 
interacts with multiple peroxisome biogenesis factors/peroxins (PEX) and peroxisomal 
membrane proteins (PMPs), including PEX3, PEX10, PEX11A, PEX11B, PEX12, 




Peroxisomes are cytoplasmic organelles involved in oxidative reactions and biochemical 
pathways and require a number of peroxisomal biogenesis factors or peroxin proteins 
(encoded by PEX gene) for their biogenesis. Mutation or deficiency of peroxins leads a 
defect of peroxisome biogenesis that results in a failure of peroxisomal metabolic 
function. Clinically, Zellweger syndrome (ZS) is the most severe type of peroxisome 
biogenesis disorder (PBD), and the related-PBD syndromes are groups of severe 
neurological disorders which can lead to life-threatening outcomes in childhood 
(Steinberg et al., 1993, Wanders, 2004). In addition to their metabolic function, several 
recent studies have suggested that peroxisomes promote MAVS-dependent innate 
immune signalling in response to viral infection (Odendall et al., 2014, Dixit et al., 2010, 
You et al., 2015). Further evidence highlighting the importance of peroxisomes in host 
antiviral responses comes from a recent study in which the Flaviviruses, DENV and 
WNV decreased the number of peroxisomes and altered peroxisome biogenesis through 
viral capsid protein-mediated PEX19 degradation and this may be a mechanism for which 
DENV and WNV evade the innate immune response (You et al., 2015). Furthermore, in 
human cytomegalovirus (HCMV) infection, the viral protein, vMIA, (mitochondria-
localised inhibitor of apoptosis) induces peroxisome fragmentation and limits antiviral 
signalling from peroxisomes. HCMV also evades the host antiviral response through an 
interaction of vMIA with PEX19, which interferes with the transport machinery of 
peroxisomes (Magalhaes et al., 2016). 
 
Collectively, the literature surrounding PEX19 and peroxisomes suggests that they are 




that viperin expression following viral infection is able to trigger a downstream signalling 
cascade through peroxisomes to perform a multifunctional role. Accordingly, the 
objective of this chapter is to define how viperin and PEX19 interaction initiates a role in 
the innate immune response via peroxisomes. 
 
5.2. Co-localisation of viperin and PEX19 
Previous work in Chapter 4 established that PEX19 and viperin interact as determined by 
Co-IP and PLA. To further determine this interaction, we investigated the cellular 
localisation of interaction between endogenous PEX19 and viperin. Initially, to 
investigate the normal cellular distribution of PEX19, we immuno-stained Huh-7 cells 
with rabbit anti-PEX19 (Abcam, ab95959) and visualised by IF analysis using Alexa 
Fluor 488-conjugated goat anti-rabbit IgG secondary antibody. However, this antibody 
displayed significant background staining during IF analysis (Figure 5.1). This led us to 
employ an alternative strategy in which we used a plasmid expressing PEX19 tagged 
with Myc/FLAG for further study. The localisation of exogenous PEX19 was first 
investigated by transfecting Huh-7 cells with pCMV6-PEX19-Myc/FLAG plasmid 
(Origene) and PEX19 was visualised using an anti-FLAG antibody. A staining pattern of 
PEX19 was observed as punctate intracellular compartments distributed throughout the 
cytoplasm of Huh-7 cells that represents peroxisomes (Figure 5.2). A weaker signal was 
also observed, most likely representing the cytoplasmic (and possibly ER) localisation of 
PEX19. This staining pattern result is consistent with previous studies (Jones et al., 







Figure 5.1: Endogenous PEX19 staining pattern. 
To investigate the localisation of endogenous PEX19, Huh-7 cells were stained with 
rabbit anti-PEX19 (Abcam, ab95959) and Alexa Fluor 488-conjugated goat anti-rabbit 
IgG secondary antibody (Ab). Nuclei were counterstained with DAPI (blue). A 
significant background of staining using anti-PEX19 (green) was observed in the nucleus 
and cytoplasm by immunofluorescence analysis using a Nikon TiE inverted fluorescent 







Figure 5.2: Exogenous expressed PEX19 localisation. 
To investigate the localisation of PEX19 by exogenous means, Huh-7 cells were 
transiently transfected with pCMV6-PEX19-Myc/FLAG for 24 hr followed by staining 
with mouse anti-FLAG and Alexa Fluor 555-conjugated goat anti-mouse IgG secondary 
Ab. Nuclei were counterstained with DAPI (blue). The staining pattern of PEX19 (red) 
was observed by immunofluorescence analysis using a Nikon TiE inverted fluorescent 




To further facilitate our studies of the PEX19 and viperin interaction, we generated a 
plasmid in which PEX19 was expressed with an N-terminal GFP tag. PEX19-encoding 
cDNA was amplified using pCMV6-PEX19-Myc/FLAG plasmid (Origene) as a template 
and cloned into pEGFP-C1 (Clontech). Positive clones were tested by double digestion 
with XhoI and SacII and confirmed by DNA sequencing. To further identify peroxisomes, 
we used an expression plasmid encoding the resident peroxisome protein, PEX11B 
[pCMV6-PEX11B (Cat no.#RC202018, Origene)] containing the complete ORF fused to 
a Myc and FLAG tag at the C-terminus, while endogenous peroxisomes were visualised 
with mouse anti-PMP70 (Sigma-Aldrich, SAB4200181). 
 
As mentioned previously PEX19 can shuttle between the cytoplasm and peroxisomes and 
therefore it was important to investigate whether PEX19 is present on peroxisomes or 
localised to the cytoplasm or both in Huh-7 cells. To investigate this, Huh-7 cells were 
co-transfected with a plasmid expressing PEX19-GFP and pCMV6-PEX11B-Myc/FLAG 
prior to staining with anti-FLAG. Additionally, localisation of PEX19 on native 
peroxisomes was also explored by transfecting Huh-7 cells with a plasmid expressing 
PEX19-GFP and staining with anti-PMP70. The majority of PEX19 distributed in the 
cytoplasm (and possibly ER), while a lesser proportion localised to peroxisomes as 
determined by co-localisation with peroxisome markers; PEX11B and PMP70 (Figure 








Figure 5.3: Localisation of PEX19 on peroxisomes. 
To investigate the distribution of PEX19 between peroxisomes and the cytoplasm, 
exogenous PEX11B expressed from pCVM6-PEX11B-Myc/Flag and endogenous 
PMP70 were used as markers of the peroxisome. (A) Huh-7 cells were transiently 
transfected with a plasmid expressing PEX19-GFP for 24 hr prior to staining with mouse 
anti-PMP70 and Alexa Fluor 555-conjugated goat anti-mouse IgG secondary Ab. (B) 
Huh-7 cells were additionally transiently co-transfected with a plasmid expressing 
PEX19-GFP and PEX11B-Myc/FLAG for 24 hr prior to PEX11B staining with mouse 
anti-FLAG and Alexa Fluor 555-conjugated goat anti-mouse IgG secondary Ab. Nuclei 
were counterstained with DAPI (blue). Serial (0.25-m) z-sections of 
immunofluorescence images were acquired using a Nikon TiE inverted fluorescent 
microscope and deconvoluted using the 3D AutoQuant Blind Deconvolution plug-in of 
NIS Elements Advanced Research v 3.22.14 software. Images are single representative z-
sections. Colocalisation of PEX19 (green) and peroxisome marker PEX11B/PMP70 (red) 
was observed using deconvolution fluorescence microscopy (60x magnification). Scale 
bars are 10 μm and 1 μm for main images and insets, respectively. Arrows indicate co-




The presence of PEX19 in both the cytoplasm and on peroxisomes raises the question as 
to the cellular sub-compartment where viperin interacts with PEX19. The co-localisation 
of viperin and PEX19 was therefore investigated by transiently transfecting Huh-7 cells 
with a plasmid expressing viperin-GFP and pCMV6-PEX19-Myc/FLAG prior to PEX19 
staining with anti-FLAG. It was immediately apparent that there was a significant co-
localisation between viperin and PEX19 (Figure 5.4). What was even more striking was 
the viperin-induced relocation of PEX19 from a homogenous cytoplasmic localisation to 
a region that surrounded circular structures with the cytoplasm (compare Figure 5.2 and 
5.4) that are reminiscent of LDs. It is well-established that viperin can locate to the LD 
(Hinson and Cresswell, 2009a, Helbig et al., 2011), and it is possible that the PEX19 and 
viperin interaction may direct PEX19 to the LD. However, we first investigated the 
relationship between PEX19 and LDs in the absence of viperin. Transfection of Huh-7 
cells with pCMV6-PEX19 Myc/FLAG and visualisation of PEX19 with anti-FLAG and 
LDs with the neutral lipid staining BODIPY 493/503 revealed no association of PEX19 
with the LD (Figure 5.5). On the other hand, expression of viperin alone results in its 
localisation to the LD, as has been previously described (Hinson and Cresswell, 2009a, 
Helbig et al., 2011). To further confirm that viperin is able to redistribute PEX19 to LDs, 
co-localisation of viperin and PEX19 on LDs was observed using BODIPY 493/503 as a 







Figure 5.4: Co-localisation of viperin and PEX19. 
To determine the cellular compartment in which viperin colocalises with PEX19, Huh-7 
cells were transiently transfected with a plasmid expressing viperin-GFP and pCMV6-
PEX19-Myc/FLAG for 24 hr followed by staining with mouse anti-FLAG and an Alexa 
Fluor 555-conjugated goat anti-mouse IgG secondary antibody. Nuclei were 
counterstained with DAPI (blue). Serial (0.25-m) z-sections of immunofluorescence 
images were acquired using a Nikon TIE inverted microscope and deconvoluted using the 
3D AutoQuant Blind Deconvolution plug-in of NIS Elements Advanced Research v 
3.22.14 software. Images are single representative z-sections. Strong co-localisation of 
viperin (green) and PEX19 (red) was seen at circular structures within cytoplasm using 
deconvolution fluorescence microscopy (60x magnification). Scale bars are 10 μm and 1 








Figure 5.5: PEX19 does not localise to lipid droplets. 
To determine the spatial localisation of PEX19 in relation to LDs in the absence of 
viperin, Huh-7 cells were transiently transfected with pCMV6-PEX19-Myc/FLAG for 24 
hr prior to staining with mouse anti-FLAG and Alexa Fluor 555-conjugated goat anti-
mouse IgG secondary antibody. LDs were detected by BODIPY 493/503 staining and 
nuclei were counterstained with DAPI (blue). No localisation of PEX19 (red) was 
observed on LDs (green) by immunofluorescence analysis using a Nikon TiE inverted 
fluorescent microscope (60x magnification). Scale bars are 10 μm and 1 μm for main 







Figure 5.6: Localisation of viperin and PEX19 on lipid droplets. 
To confirm that viperin and PEX19 interact at the LD interface, Huh-7 cells were 
transiently transfected with pLenti6-viperin-mCherry and pCMV6-PEX19-Myc/FLAG 
expression plasmids for 24 hr prior to staining with mouse anti-FLAG and Cy5-
conjugated goat anti-mouse IgG secondary antibody. LDs were stained with BODIPY 
493/503. Strong colocalisation of viperin (red) and PEX19 (blue) was observed (pink) in 
close proximity to LDs (green) by immunofluorescence analysis using a Nikon TiE 
inverted fluorescent microscope (60x magnification). Scale bars are 10 μm and 1 μm for 





5.3 Viperin redirects peroxisomes to lipid droplets. 
Our previous results indicate that following the interaction between PEX19 and viperin, 
there is a change in localisation of PEX19 away from the cytoplasmic compartment to an 
association with the LDs. However, the fact that PEX19 can shuttle between the 
cytoplasm and peroxisomes raises the question; does viperin interact with cytoplasm- or 
peroxisomal-PEX19? We therefore investigated co-localisation of viperin and the 
peroxisome markers, PMP70 and PEX11B. Huh-7 cells were transfected with a plasmid 
expressing viperin-GFP and peroxisomes were either identified by PMP70 (anti-PMP70) 
or PEX11B that was expressed following co-transfection with plasmids expressing 
viperin-GFP and pCMV6-PEX11B-Myc/FLAG. Viperin associated with both 
peroxisome markers as shown in Figure 5.7. Interestingly, peroxisomes associated with 
viperin in a similar staining pattern to that of PEX19 (see Figure 5.4), indicating that 
viperin redirects peroxisomes to LDs in a significant number of cases. However, we also 
noted that viperin interacted with peroxisomes distant to LDs. Consistent with the PEX19 
data in the absence of viperin, PMP70 (peroxisomes) did not localise in association with 
LDs (Figure 5.8), suggesting that this observation is mediated by an interaction of viperin 
with PEX19. 
 
To increase our resolution of the interaction between viperin, LDs and peroxisomes, three 
dimensional-structured illumination microscopy (3D-SIM) super-resolution imaging was 
used. 3D-SIM is a wide-field imaging technique with 2-fold increases in the lateral and 






Figure 5.7: Redistribution of peroxisomes to LDs in the presence of viperin. 
To determine whether viperin redirects peroxisomes to LDs, (A) Huh-7 cells were 
transiently transfected with viperin-GFP expression plasmid for 24 hr prior to staining 
with mouse anti-PMP70 followed by an Alexa Fluor 555-conjugated goat anti-mouse IgG 
secondary Ab to visualise peroxisomes. (B) In addition, Huh-7 cells were co-transfected 
with viperin-GFP and pCMV6-PEX11B-Myc/FLAG expression plasmids for 24 hr prior 
to PEX11B staining with mouse anti-FLAG and Alexa Fluor 555-conjugated goat anti-
mouse IgG secondary Ab. Nuclei were counterstained with DAPI (blue). Serial (0.25-
m) z-sections of immunofluorescence images were acquired using a Nikon TiE inverted 
fluorescent microscope and deconvoluted using the 3D AutoQuant Blind Deconvolution 
plug-in of NIS Elements Advanced Research v 3.22.14 software. Images are single 
representative z-sections. Co-localisation of viperin (green) and the respective 
peroxisome markers PEX11B/PMP70 (red) was observed using deconvolution 
fluorescence microscopy (60x magnification). Note the significant co-localisation of 
viperin and the peroxisomes at the LD interface and at sites distant to the LD. Scale bars 
are 10 μm and 1 μm for main images and insets, respectively. Arrows indicate co-







Figure 5.8: Localisation of peroxisomes with respect to LDs under resting 
conditions. 
To determine whether peroxisomes localise to LDs in the absence of viperin, Huh-7 cells 
were stained with mouse anti-PMP70 and Alexa Fluor 555-conjugated goat anti-mouse 
IgG secondary antibody. LDs were stained with BODIPY 493/503 and nuclei were 
counterstained with DAPI (blue). Peroxisomes (red) were not observed to associate with 
LDs (green) by immunofluorescence analysis using a Nikon TiE inverted fluorescent 







contrast. 3D-SIM was performed at the Microbial Imaging Facility (The University of 
Technology Sydney, in association with Lynne Turnbull and Cynthia Whitchurch). We 
initially confirmed the localisation of viperin with the LD through the use of an 
expression plasmid expressing the resident LD membrane marker ADRP fused to 
mCherry, while viperin was expressed tagged with GFP. As expected viperin localised to 
the LD interface as determined by co-localisation between ADRP and viperin in addition 
to ER localisation of viperin. It was also apparent that viperin and PEX19 located to the 
LD interface and also most likely at the ER (Figure 5.9). Consistent with results in Figure 
5.7, super-resolution 3D-SIM revealed that viperin presented at the LD in close 
association with peroxisomes (PMP70) (Figure 5.9). In some cases, viperin associated 
LDs are juxtaposed with the peroxisomes, while in some cases there was direct overlap of 
the signals. Collectively, this work suggests that viperin/PEX19 and the peroxisome 
interact in close association with the LD. 
 
5.4 Viperin enhances the numbers of peroxisomes.  
Given the nature of PEX19’s ability to facilitate peroxisome biogenesis, we next 
investigated the impact of viperin on peroxisome numbers. A recent study has shown an 
association between the innate immune response to viral infection and the number of 
peroxisomes (Odendall et al., 2014). Given that viperin binds PEX19, it is possible that 
viperin augments innate immune signalling by increasing or altering peroxisome 
biogenesis and/or function. To quantify cellular peroxisome content in the presence of 
viperin we used an Operetta high-content microscope as previously described in Chapter 






Figure 5.9: 3D-structured illumination microscopy (3D-SIM) super-resolution 
images. 
3D-SIM was used to investigate the relationship/interaction between viperin and LDs 
(ADRP), PEX19 and peroxisomes (PMP70). (A) Huh-7 cells were transiently co-
transfected with viperin-GFP and ADRP-mCherry expression plasmids which is LD 
marker. (B) Huh-7 cells were transiently co-transfected with viperin-GFP and PEX19-
Myc/FLAG expression plasmids prior to staining with mouse anti-FLAG and Alexa 
Fluor 555-conjugated goat anti-mouse IgG. (C) Huh-7 cells were transiently transfected 
with a plasmid expressing viperin-GFP and stained with mouse anti-PMP70 and Alexa 
Fluor 555-conjugated goat anti-mouse IgG. 3D-super-resolution images were generated 
by 3D-structured illumination microscopy which performed with a V3 DeltaVision OMX 
3D-SIM system fitted with a Blaze module (Applied Precision, GE Healthcare, USA). 
Images were deconvolved using SoftWorX software (Applied Precision, GE Healthcare) 
and rendered and presented using IMARIS software (v7.7 or above, Bitplane Scientific).  
  




viperin, Huh-7 cells were transiently transfected with plasmids expressing viperin-GFP or 
GFP alone (as a control) prior to staining with mouse anti-PMP70 and Alexa Fluor 555-
conjugated goat anti-mouse IgG. Images were obtained in non-confocal mode and 
analysed using Harmony software (Perkin Elmer) to quantitate absolute PMP70 positive 
fluorescence. Cells from each transfection experiment were counted and averaged, and 
the mean of Alexa Fluor 555 intensity (i.e. PMP70 content) was analysed per cell. A total 
number of approximately 4,000 cells was counted per group and transfection efficiency 
was approximately 34% and 55% for the transfection with viperin-GFP and GFP control, 
respectively (see raw data in Appendix X). The intensity of Alexa Fluor 555, an estimate 
of peroxisome content per cell was significantly higher in viperin expressing cells 
compared to GFP control-transfected cells, whereas no difference in Alexa Fluor 555 
intensity was observed in the untransfected cell populations for samples transfection with 
viperin-GFP and GFP control plasmids (Figure 5.10). 
 
Our results above suggest that the number of peroxisomes is increased in the presence of 
viperin expression. However, to confirm this observation, we investigated peroxisome 
biochemical activity through measurement of catalase enzyme levels. Peroxisomes 
contain catalase, an enzyme that converts hydrogen peroxide (H2O2) to H2O and O2 to 
protect against oxidative damage/stress. Consequently, to observe an alteration of 
peroxisome function induced by viperin, Huh-7 cells were transiently transfected with 
pLenti6-viperin-FLAG or an empty plasmid control, prior to catalase enzyme detection 






Figure 5.10: Viperin enhances peroxisome accumulation. 
To investigate whether viperin enhances peroxisome accumulation, Huh-7 cells were 
transfected with plasmids expressing viperin-GFP or GFP alone (control), as indicated. 
Peroxisome content was quantified by staining with mouse anti-PMP70 and Alexa Fluor 
555-conjugated goat anti-mouse IgG and cells were imaged using an Operetta high-
content microscope in non-confocal mode. 25-fields were taken per well, covering 
approximately 50% of the well. 12 replicates were performed per condition and image 
analysis was performed using Harmony software. Cell counts were determined via 
automated enumeration of DAPI stained nuclei. Mean Alexa Fluor 555 intensity was 
determined for each cell. The Alexa Fluor 555 intensities of viperin-transfected cells 
were approximately two-fold higher when compared to GFP control-transfected cells. 2-





in Figure 5.11A, there is an increase in catalase content of the cell in the presence of 
viperin. While only a modest increase in quantification of the immunoblot indicated an 
increase of catalase (approximately 35%) in the presence of viperin expression following 
normalisation to –actin expression.   
 
To further confirm an increase in catalase in the context of viperin, catalase enzyme 
detection using high-throughput microscopy (Operetta high-content microscope) was 
performed. Huh-7 cells were transiently transfected with plasmids expressing viperin-
GFP or GFP control and were stained with goat anti-catalase prior to Alexa Fluor 555-
conjugated rabbit anti-goat IgG. A total number of cells from each transfection condition 
were counted and averaged, and the mean of Alexa Fluor 555 intensity per cell was 
analysed using the Operetta high-content microscope and Harmony software as described 
above. Approximately 6,800 cells were analysed and approximately 32% and 57% 
transfection efficiencies were obtained for viperin-GFP and GFP control transfections, 
respectively (see raw data in Appendix X). The intensities of Alexa Fluor 555 labelling of 
catalase enzyme in viperin-transfected cells were significantly higher than those of GFP 
control-transfected cells, while there was no significant difference in the signal intensities 
of catalase staining in untransfected cells for both viperin-GFP and GFP control 
expressing cells (Figure 5.11B). These results suggest that viperin expression enhances 






Figure 5.11: Viperin enhances peroxisome’s catalase enzyme. 
To investigate whether viperin enhances peroxisome’s catalase enzyme, (A) Huh-7 cells 
were transfected with pLenti6-viperin-FLAG or empty plasmid control for 24 hr prior to 
cell harvesting and whole cell lysate preparation. Catalase enzyme was detected by 
Western blot analysis using goat anti-catalase. The band intensity of catalase enzyme was 
normalised to the internal control -actin and represented in a bar graph. An 
approximately 35% increase in catalase was noted in the presence of viperin compared to 
control. (B) Huh-7 cells were transfected with plasmids expressing viperin-GFP or GFP 
alone (control), as indicated. The content of the peroxisomes was quantified by staining 
with goat anti-catalase and Alexa Fluor 555-conjugated rabbit anti-goat IgG and cells 
were imaged using an Operetta high-content microscope in non-confocal mode as 
described above. 6 replicates were performed per condition in this experiment. The Alexa 
Fluor 555 intensities of viperin-transfected cells were approximately double when 





5.5 Viperin augments innate immune responses. 
While a direct antiviral role of viperin against a diverse array of viruses is well-
documented, it is also emerging that viperin can augment various aspects of innate 
immune signalling. There are a number of reports to suggest viperin controls both innate 
and adaptive immune responses. In viperin deficient mice (viperin
-/-
), IgG1 levels were 
significantly decreased following challenge with ovalbumin, and the expression of Th2 
cytokines IL-4, IL-5 and IL-13 were reduced in response to T cells stimulation with anti-
CD3/CD28 (Qiu et al., 2009). This observation indicated that viperin may regulate Th2 
response, although no mechanism underlying this investigation was proposed. In 
plasmacytoid dendritic cells (pDCs) deficient for viperin, type I IFN production was 
abrogated in response to TLR7 and TLR9 ligands (Saitoh et al., 2011). Moreover, 
knockdown of viperin resulted in a reduction of NF-κB in carcinoma cells and a decrease 
in IRF7-mediated induction of IFN-β gene expression (Moschonas et al., 2012). These 
results support a role for viperin in modulation of the immune response to pathogens, 
although further work is required to characterise this interaction.  
 
Preliminary data from our laboratory also suggest that viperin can modulate the cellular 
response to poly I:C, a viral dsRNA mimic that activates RLR response in cells. To 
determine whether viperin modulates innate immune signalling, IFN-β mRNA abundance 
was observed in viperin
-/-
 mouse embryonic fibroblast cells (MEFs) following activation 
of the RIG-I pathway by either poly I:C or Sendai virus (SeV) infection. MEFs were 
isolated from day 13.5-14.5 viperin
-/-
 and WT C57BL/6 mouse embryos (Van der Hoek et 
al., 2017). IFN-β mRNA levels were significantly reduced in viperin
-/-




to poly I:C stimulation and SeV infection (a well-known inducer of the cytoplasm RLR 
innate immune response) (Figure 5.12). To confirm a role for viperin in IFN-β 
production, we determined IFN-β promoter activity following transfection of Hela cells 
with the viperin expressing plasmid (pLenti6-viperin-FLAG) and a plasmid in which the 
luciferase reporter gene is driven by the IFN-β promoter. The ability of viperin to 
promote IFN-β production was considerably increased in response to poly I:C stimulation 
(Figure 5.13). These results suggest that viperin can augment innate immune signalling 
pathways. 
 
5.6 A central domain of viperin is required for the interaction with PEX19. 
5.6.1 Generation of a series of viperin mutants  
Viperin is comprised of three distinct domains; an N-terminal domain that contains an 
amphipathic -helix that is required for localisation to the ER and LDs (Hinson and 
Cresswell, 2009a, Helbig et al., 2011), a highly conserved central region that contains a 
radical SAM domain, and a C-terminal domain that contains no structural motifs but has 
been shown to be responsible for antiviral activity against a number of viruses (Helbig 
and Beard, 2014). A more comprehensive description of the domains of viperin is 
described in section 1.3.1, Chapter 1; we therefore investigated the domains responsible 
for the interaction with PEX19. A panel of viperin mutants (Figure 5.14) was created by 
PCR amplification and cloning into pLenti6/V5-D-TOPO with an N-terminal FLAG tag 
for detection. Positive clones were tested by double digestion with BamHI and SacII and 
confirmed by DNA sequencing. All of 5’ and 3’ viperin mutants were successfully 





Figure 5.12: Viperin promotes IFN-β production in response to poly I:C and Sendai 
virus infection. 
To assess the ability of viperin to regulate IFN-β production, WT and viperin
-/-
 MEFs 
were (A) stimulated with poly I:C or (B) infected with SeV for 24 hr. IFN-β mRNA 
levels were quantified using  real time RT-PCR. IFN-β message was significantly 
decreased in viperin
-/-







Figure 5.13: The ability of viperin to promote innate immune responses. 
To investigate the ability of viperin to augment innate immune response by inducing the 
IFN-β production, HeLa cells were co-transfected with pLenti6-viperin-FLAG, IFN-β-
luciferase and pRL-TK plasmids for 24 hr prior to stimulation with poly I:C for 24 hr. 
pLenti6/V5-empty plasmid was used as a control. Cell lysates were collected for 
luciferase activity by measuring on a GloMax
TM
 96 Microplate Luminometer (Promega). 
Data were analysed using GraphPad Prism 7 software. Viperin is able to enhance poly 


















Figure 5.15: Construction of 5’ viperin mutants. 
To generate a series of 5’ viperin mutants, (A) PCR products of each mutant were 
amplified with primers encoding a FLAG tag at the N-terminus and cloned into 
pLenti6/V5-D-TOPO. (B) To confirm the positive clones, plasmid DNA was extracted 
from transformant clones and subjected to double digestion with BamHI and SacII. Lane 











Figure 5.16: Construction of 3’ viperin mutants. 
To generate a series of 3’ viperin mutants, (A) PCR products of each mutant were 
amplified with primers that encode FLAG tag at the N-terminus and cloned into 
pLenti6/V5-D-TOPO. (B) To confirm the positive clones, plasmid DNA was extracted 
from transformant clones and subjected to double digestion with BamHI and SacII. Lane 







expression of viperin mutants, Huh-7 cells were transfected with a panel of mutants and 
stained with anti-FLAG and Alexa Fluor 555-conjugated goat anti-mouse IgG. Deletion 
of 33 amino acids from the N-terminal domain, resulted in viperin redistribution from the 
LDs and ER to a nuclear localisation and a homogeneous cytoplasmic pattern (Helbig et 
al., 2011, Hinson and Cresswell, 2009a). This was not surprising as the amphipathic- 
helix at the N-terminal domain allows peripheral membrane proteins to embed into the 
ER and bind LD surfaces (Guo et al., 2009). However, all of 3’ viperin mutants retain 
their localisation to the LD and ER, as is to be expected considering that these mutants 
retain their amphipathic--helix and their ability to localise to the LD (Figure 5.17). 
 
5.6.2 The interaction of viperin mutants and PEX19 
To determine which domain of viperin is required for binding to PEX19, Huh-7 cells 
were transiently co-transfected with each of the viperin mutants (FLAG-tagged) 
described previously and the PEX19-Myc expression plasmid (section 4.7.1, Chapter 4) 
prior to proximity ligation assay (PLA) analysis. PLA showed that all of the 3’ and 5’ 
viperin mutants were able to interact with viperin (Figure 5.18). This was certainly 
unexpected and suggests that the interaction is not dependent on viperin localisation. This 
is particularly evident in viperin mutants that contain a deletion of the N-terminal 
amphipathic--helix, that loose the ability to associate with the LD but still interact with 
PEX19. The ability of viperin to still bind to PEX19 in the absence of the 5’ and 3’ 
domains implies that a central radical-SAM domain may be responsible for PEX19 
interaction. This observation was not pursued, but requires further investigation to 






Figure 5.17: Viperin deletion mutants. 
To determine the expression and localisation of viperin mutants, Huh-7 cells were 
transiently transfected with each of viperin mutant prior to staining with anti-FLAG and 
Alexa Fluor 555-conjugated goat anti-mouse IgG. Nuclei were counterstained with DAPI 
(blue). Expression and localisation of (A) 5’viperin and (B) 3’viperin (red) mutants 
were observed by immunofluorescence analysis using a Nikon TiE inverted fluorescent 







Figure 5.18: A panel of viperin deletion mutants associates with PEX19 as 
determined by proximity ligation assay (PLA). 
To investigate whether viperin mutants interact with PEX19, Huh-7 cells were transiently 
transfected with pLenti6-viperin-FLAG (WT and mutants) and pCMV6-PEX19-Myc 
expression plasmids for 24 hr. PLA was performed using mouse anti-FLAG and rabbit 
anti-Myc. A combination of mouse isotype control and rabbit anti-Myc was used as a 
negative control and nuclei were counterstained with DAPI (blue). Red dots in cells were 





5.7 Localisation on LDs and a C-terminal domain of viperin are required for 
viperin’s ability to augment IFN- promoter activity. 
As described in section 5.5, viperin is able to promote a dsRNA (poly I:C)-induced innate 
response and we were therefore interested in the functional domains of viperin that may 
be responsible for their augmentation. To this end, we transfected Huh-7 cells with a 
plasmid in which the IFN-β promoter drives luciferase and a panel of plasmids that 
express viperin truncations as previously described. As expected WT viperin enhanced 
IFN-β promoter activity, however following deletion from the 5’ terminus their 
enhancement progressively decreased. While the 5’10 mutant showed a decrease trend, 
this was not significant compared to WT, and it was not until the 5’21 that a statistical 
significant difference was observed. In contrast, none of the 3’ deletion mutants retained 
their ability to augment the IFN-β promoter (Figure 5.19). This suggests that localisation 
of viperin to the LD (as determined by the 5’mutants) and the C-terminal domain are 
important in mediating this effect. 
 
5.8 Viperin requires PEX19 for its ability to modulate innate immune signalling. 
Our results above established that viperin promotes IFN-β promoter activity in response 
to dsRNA (see section 5.4). We, therefore, postulated that viperin requires the interaction 
with PEX19 and hence the peroxisome to enhance IFN-β promoter activation. To 
investigate this hypothesis, we required knockdown or knockout of PEX19. Initial 
attempts to delete the locus PEX19 using a CRISPR/Cas9 approach were unsuccessful. 
This is most likely due to the crucial requirement for peroxisomes in the cell and has been 






Figure 5.19: A critical domain is required for IFN-β production. 
To investigate which domain is responsible for IFN-β production, HeLa cells were co-
transfected with pLenti6-viperin-FLAG (WT and mutants), IFN-β-luciferase and pRL-
TK plasmids for 24 hr prior to stimulation with poly I:C for 24 hr. pLenti6/V5-empty 
plasmid was used as a negative control. Cell lysates were collected for measurement of 
luciferase activity. Data are means  SD (n=3).  With the exception of 5’10 and 5’21, 





approach of PEX19 using ON-TARGET plus SMART pool siRNA PEX19 (Dharmacon, 
GE Healthcare, USA) (see Appendix IX for target sequence). Huh-7 cells were 
transiently transfected with a pool of siRNAs directed to mRNA PEX19 for 48 hr prior to 
viperin expression for 24 hr and subsequent poly I:C stimulation for 24 hr. Knockdown 
of PEX19 was tested by Western blot analysis using rabbit anti-PEX19 that revealed an 
approximate 50% knockdown of PEX19 (Figure 5.20A). While not ideal, this degree of 
knockdown was the best that we could achieve. IFN-β mRNA levels were determined by 
real time RT-PCR analysis, and the result showed that in the presence of viperin 
expression and knockdown of PEX19, there was a trend in reduction of IFN-β mRNA 
compared to the siRNA control (Figure 5.20B). This indicated that viperin-PEX19 
interaction facilitates/augments innate immune signalling in response to poly I:C.  
 
5.9 Discussion 
It is well-documented that viperin interacts with a broad range of host and viral proteins 
and our work in Chapter 4 using a Y2H approach now adds PEX19 to the list of viperin 
interacting partners. It is not immediately apparent as to the biological significance of 
viperin binding to PEX19. PEX19 is a cytosolic chaperone protein that plays a role in the 
early peroxisome biogenesis pathway by facilitating the insertion of peroxisomal 
membrane proteins (PMP) into the membrane of the peroxisome. Peroxisomes are 
significant dynamic organelles with a diverse function mainly in lipid metabolism and 
degradation of harmful hydrogen peroxide, however, most recently it is emerging that the 
peroxisome plays a key role in the innate antiviral response. While we have provided 






Figure 5.20: Interaction with PEX19 is required for the ability of viperin to augment 
innate immune signalling. 
To test if viperin requires the interaction with PEX19 to modulate immune signalling, 
knockdown of PEX19 was achieved using a pool of siRNAs targeting PEX19 
(Dharmacon). Huh-7 cells were transiently transfected with the PEX19-specific siRNA 
pool or non-targeting control (NTC) siRNA pool for 48 hr prior to viperin overexpression 
for 24 hr followed by poly I:C stimulation for 24 hr. (A) knockdown of PEX19 was 
analysed by Western blot analysis using rabbit anti-PEX19 and HRP-conjugated goat 
anti-rabbit. An approximately 50% knockdown of PEX19 was obtained using this 
approach. (B) IFN-β mRNA levels were determined by real time RT-PCR analysis and 
was reduced in response to poly I:C induction following viperin expression, in the 





further characterise the PEX19-viperin interaction in a cellular context.  PEX19 has been 
shown previously to shuttle between the ER and peroxisomes and in the process 
chaperones, proteins essential for peroxisome biogenesis and hence we were therefore 
interested in the cellular distribution of PEX19 in our Huh-7 cells (Sacksteder et al., 
2000, Jones et al., 2004). We initially used an antibody directed toward PEX19 to 
observe endogenous PEX19 in Huh-7 cells, however this resulted in significant 
background fluorescence.  To this end, we expressed exogenous PEX19 (GFP tagged) 
and visualised peroxisomes using an antibody directed towards PMP70 (resident 
peroxisomal marker) and expression of PEX11B (Flag-tagged, also a resident 
peroxisomal marker). As expected PEX19 localised to the peroxisome as determined by 
overlapping immunofluorescence for both PMP70 and PEX11B but was also localised 
independent of the peroxisome in what was presumed to be the ER (Figure 5.3). This 
distribution of PEX19 raises the question as to whether viperin interacts with PEX19 at 
the ER or the peroxisome. To answer this question we initially expressed viperin-GFP 
and PEX19-Myc/Flag and confirmed that not only do PEX19 and viperin co-localise but 
that the cellular distribution of PEX19 is significantly altered in the presence of viperin. 
This is evident in Figure 5.3 in which PEX19 is distributed homogenously throughout the 
cytoplasm at the ER and peroxisomes, while in Figure 5.4 in the presence of viperin, 
PEX19 assumes a more peri-nuclear localisation in association with viperin in what 
seems to be at the surface of circular structures. These circular structures are most likely 
to be lipid droplets as it is well-documented that viperin can localise to the surface of the 
LD via an interaction of its N-terminal amphipathic helix with the LD membrane. 




LD, however in the presence of viperin, PEX19 can be found in association with viperin 
at the LD interface. Most importantly we also show that this interaction occurs at the 
level of the peroxisome as there is a strong association between viperin and the 
peroxisomal markers PMP70 and PEX11B. To further resolve the interaction of viperin 
and PEX19 and the peroxisome we used 3D-SIM super-resolution imaging. 3D-SIM 
allows for the imaging of several cellular components and the mapping of their relative 
positions in macromolecular complexes, enabling the study of their spatial relationship 
within the cell over and above that of standard confocal microscopy. We confirmed our 
previous observation showing that viperin indeed interacts at the LD interface (ADRP 
positive) and that PEX19 also interacts with viperin at the same location. Interestingly, 
while we also noted direct overlap of signals suggesting an interaction between viperin 
and PMP70, we also observed PMP70 positive peroxisomes juxtaposed to viperin 
positive LDs. Collectively, this work provides evidence that viperin interacts with PEX19 
at the peroxisome and recruits the peroxisome to a close association with the LD.  
 
Preliminary data from our laboratory has shown that viperin can augment the innate 
immune response to RNA viral infection and poly I:C. Furthermore, the recent reports 
that MAVS is localised to and can signal from the peroxisome suggests that the ability of 
viperin to bind PEX19 and redistribute the peroxisome may somehow be linked to innate 
immune signalling from the peroxisome. As discussed above, the biogenesis of the 
peroxisome requires PEX19 and previous reports have linked peroxisome number with 





It is therefore conceivable that viperin augments innate immune signalling by enhancing 
peroxisome biogenesis and/or function to maximise the antiviral response. Quantification 
of total cellular peroxisome content in the absence or presence of viperin using an 
operetta high content imager, found that peroxisome content (as determined by PMP70 
accumulation) was significantly increased in the presence of viperin. Concomitant with 
this observation, we also found that the peroxisomal enzyme, catalase, was significantly 
enhanced in expression in the presence of viperin. Hence, the ability of viperin to 
increase peroxisome number or alter their localisation could possibly be a mechanism to 
augment the innate antiviral response. Interestingly, the capsid proteins of WNV and 
DENV can also bind PEX19, resulting in a significant loss of peroxisomes and 
corresponding IFN- production, that highlights the importance of the peroxisome in the 
host innate response to viral infection (You et al., 2015). 
 
Preliminary data from our laboratory has implicated viperin expression in augmentation 
of the innate immune response to viral infection. To further explore this observation we 
made use of MEFs isolated from a viperin
-/-
 KO mouse generated in our laboratory using 
CRISPR/Cas9 technology, and either transfected the MEFs (WT were used as a control) 
with poly I:C or infected them with SeV, both of which are well-documented to activate a 
RIG-I response. Consistent with our preliminary data, a lack of viperin resulted in a 
significant decrease in IFN- mRNA, implicating viperin as a positive regulator of the 
innate response to viral infection. As we have outlined previously, viperin exerts its 
antiviral activity through a number of specific domains, however there is not a common 




example the radical SAM and C-terminal domains play a crucial role in viperin’s anti-
TBEV, while the N-terminal amphipathic helix is important for viperin’s anti-DENV 
activity, and both the N- and the C-terminal domain are important for its anti-HCV 
activity (Helbig et al., 2011, Helbig et al., 2013, Upadhyay et al., 2014). We reasoned that 
similar domains of viperin would play a role in its ability to bind PEX19 and hence 
impact the innate immune response. We therefore used a panel of viperin mutants and 
firstly investigated their interaction with PEX19 using PLA (Figure 5.18). To our 
surprise, we noted that all viperin mutants, both N- and C- terminal, retained their ability 
to bind to PEX19 suggesting that either the central or the radical SAM domain may play 
a role in the interaction with PEX19. We did not investigate the role of the radical SAM 
domain through mutagenesis and it will be of interest to further investigate the role of this 
domain in the interaction with PEX19. The ability of all viperin mutants to bind to 
PEX19 suggests that viperin’s capacity to augment innate immune signalling is most 
likely a function of the cellular localisation of viperin and not its ability to bind PEX19. 
This was certainly the case as viperin with a truncation of the first 21 AA retained the 
ability to augment innate immune signalling while truncation beyond this point and hence 
removal of the amphipathic helix and LD localisation significantly abrogated viperin’s 
innate immune stimulation ability. Furthermore, all 3’ deletion mutants significantly 
abrogated innate immune activation. Collectively, this work suggests that the ability of 
viperin to move to the LD is essential for its ability to modulate innate immune signalling 





Our results to date have demonstrated that viperin expression can induce peroxisome 
accumulation and re-localisation that most likely underpins viperins’ ability to augment 
the innate immune response. However, to conclusively determine the role of PEX19 in 
this process, we attempted to knockout PEX19 in Huh-7 cells using a CRISPR/Cas9 
approach, however, this was unsuccessful. The fact that the peroxisome is an essential 
organelle to control and stabilise lipid metabolism and cellular homeostasis is most likely 
the reason as to why we could not create PEX19 knockout cells. This is consistent with 
the study from the Bartenschlager laboratory (Bender et al., 2015) in which similar 
studies were attempted. Accordingly, transient knockdown PEX19 was achieved through 
a siRNA approach in which Huh-7 cells were transfected with a Dharmacon smart pool 
targeting PEX19. Even though we could only achieve an approximately 50% decrease in 
PEX19 expression, these cells showed a decrease in viperin induced innate immune 
augmentation (Figure 5.20), implying that viperin requires PEX19/peroxisomes to trigger 
innate immune signalling. Obviously complete knockout of PEX19 would be ideal, 
however there are challenges associated with this approach as discussed above. However, 
a human fibroblast cell line defective in PEX19, isolated from a patient with Zellweger 
syndrome is available (Odendall et al., 2014) and could be used to further study the 
effectiveness of viperin to promote an innate immune response in the complete depletion 
of peroxisomes. 
 
Previous studies demonstrated that the Flaviviruses, DENV and WNV have evolved a 
strategy to evade the MAVS-dependent innate antiviral response via degradation of 




reduction of peroxisome number, most likely through direct interactions of PEX19 and 
the DENV or WNV viral capsid proteins (You et al., 2015). Therefore, it is conceivable 
that the interaction of viperin and PEX19 may reverse the effect of virus-mediated 
degradation of peroxisome by either protecting peroxisomes from degradation or 
initiating peroxisome biogenesis. Clearly further studies are warranted. 
 
In summary, viperin physically interacts with PEX19 and redirects peroxisomes to LDs, 
and it is possible that the radical SAM domain plays a principle role in this interaction. 
Moreover, PEX19, and hence peroxisomes are required for viperin to augment innate 
immune signalling in response to viral infection. A recent study has shown that viperin 
interacts with the innate immune adaptor protein MAVS (Hee and Cresswell, 2017) that 
is localised to the mitochondria, mitochondria-associated membrane (MAM) and 
peroxisomes and that maximal signalling requires the coming together of these organelles 
into an immune synapse (Dixit et al., 2010, Horner et al., 2011). This raises the question 
as to how viperin interacts with MAVS and the peroxisome to modulate an innate 
antiviral response in the formation of the immune synapse. The association of viperin, 
MAVS, and other cellular organelles (peroxisomes, LDs, mitochondria) will be 






Viperin augments innate immune response through the interaction with 
MAVS at mitochondria and peroxisomes 
 
6.1 Introduction   
It is well-established that mitochondrial antiviral signalling protein (MAVS), also named 
VISA/IPS-1/Cardif, is an indispensable adaptor protein for innate immune signalling. 
Anchoring of MAVS via its C-terminal domain to the outer membrane of mitochondria 
(Seth et al., 2005) engages and activates the downstream RLR signalling pathway that 
results in the expression of type I IFN (see Figure 1.8, Chapter 1). Localisation of MAVS 
to mitochondria is essential for innate immune signalling. MAVS engineered to a 
cytosolic localisation abrogates the innate antiviral signalling (Dixit et al., 2010) and 
moreover, cleavage of MAVS from the mitochondria by the HCV protease NS3/4a 
abolishes RIG-I signalling (Li et al., 2005b, Meylan et al., 2005, Foy et al., 2005). Recent 
studies have shown that in addition to the mitochondrial outer membrane, MAVS also 
localises to mitochondrial-associated membranes (MAM), a specialised subdomain that 
physically connects the ER to the mitochondria, and to peroxisomes (Horner et al., 2011, 
Dixit et al., 2010). Interestingly, in one study the selective localisation of MAVS to 
specific organelles such as mitochondria and peroxisomes generated a diverse and 
specific immune response upon viral infection (Odendall et al., 2014). However, this was 
not the case with studies from Bender et al. in which both mitochondrial and peroxisomal 
MAVS activated, the expression of type I and III IFNs with comparable efficiency upon 




shown using a biochemical and microscopy approach that there is an interaction between 
mitochondria, peroxisomes and the MAM upon viral infection that constitutes the 
formation of a signalling innate “immune synapse” following RIG-I activation in 
response to viral infection (Horner et al., 2011, Vazquez and Horner, 2015). This 
suggests some sort of coordination of signalling from these organelles (Horner et al., 
2011, Vazquez and Horner, 2015), however the spatial and temporal dynamics of these 
interactions are not understood. 
 
Our previous results showing an interaction of viperin with the peroxisome, and 
subsequent shift in localisation of the peroxisome suggests that viperin (expressed in 
response to viral infection) may regulate the signalling of the immune synapse; at least 
from the peroxisome. Thus, we hypothesise that viperin is a regulator of innate immune 
signalling from the peroxisomes. Accordingly, the aim of this chapter is to define of how 
viperin controls MAVS signalling from different organelle compartments. 
 
6.2 Viperin associates with MAVS, peroxisomes and lipid droplets. 
Previous studies have identified the localisation of MAVS to the mitochondria, MAM 
and to peroxisomes (Horner et al., 2011, Dixit et al., 2010). However, to confirm 
localisation of MAVS to the mitochondria and peroxisomes in our culture model we 
investigated MAVS expression in association with various organelles in Huh-7 cells 
using a monoclonal Ab directed towards MAVS. Indirect immunofluorescence revealed 
as expected, a significant proportion of MAVS on the mitochondria (Mitotracker) and 




clearly indicated that MAVS localised to both the mitochondria, (and possibly MAM) 
and peroxisomes in Huh-7 cells. 
 
Given our previous results showing viperin can interact with peroxisomes and the 
presence of MAVS on peroxisomes, we next investigated the association of viperin and 
MAVS. Spatial co-localisation of these proteins was investigated by transiently 
transfecting Huh-7 cells with a plasmid expressing viperin-GFP and staining with rabbit 
anti-MAVS followed by Alexa Fluor 555-conjugated goat anti-rabbit IgG. While there 
were areas of viperin that did not interact with MAVS, viperin-positive LDs were 
surrounded by MAVS positive mitochondria and in numerous instances there was an 
obvious overlap of fluorescent signal indicating possible interaction between viperin and 
MAVS (Figure 6.2). This result is consistent with a recent study that has shown an 
interaction of viperin and MAVS at the MAM (not mitochondria), however in this study 
interactions with the peroxisomes were not investigated (Hee and Cresswell, 2017).  
 
As mentioned above, viperin interacts and directs peroxisomes in close proximity to LDs, 
and together with the data above that viperin does colocalise with MAVS, prompted us to 
investigate the association between viperin, the peroxisome and MAVS. The co-
localisation of viperin, MAVS and peroxisomes was assessed by transiently transfecting 
Huh-7 cells with a plasmid expressing viperin-GFP prior to staining the endogenous 
MAVS (using rabbit anti-MAVS and Alexa Fluor 555-conjugated goat anti-rabbit) and 






Figure 6.1: Localisation of MAVS to both mitochondria and peroxisomes. 
To investigate MAVS localisation to mitochondria, Huh-7 cells were incubated with a 
permeable probe for mitochondrial labelling (MitoTracker
®
 Red CMXRos, Cell 
Signalling Technology) for 30 min prior to staining with rabbit anti-MAVS and Alexa 
Fluor 488-conjugated goat anti-rabbit IgG secondary Ab. In addition, to observe the 
localisation of MAVS on peroxisomes, Huh-7 cells were stained with rabbit anti-MAVS 
and mouse anti-PMP70 followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG and 
Alexa Fluor 555-conjugated goat anti-mouse IgG secondary Ab. Nuclei were 
counterstained with DAPI (blue). MAVS (green) is predominantly found on (A) 
mitochondria, with a lesser extent on (B) peroxisomes, which observed by 
immunofluorescence analysis using a Nikon TiE inverted fluorescent microscope (60x 
magnification). Scale bars are 10 μm and 1 μm for main images and insets, respectively. 







Figure 6.2: Co-localisation of viperin and MAVS. 
To investigate if viperin does colocalise with MAVS, Huh-7 cells were transiently 
transfected with a plasmid expressing viperin-GFP prior to staining with rabbit anti-
MAVS and Alexa Fluor 555-conjugated goat anti-rabbit IgG. Nuclei were counterstained 
with DAPI (blue). Serial (0.25-m) z-sections of immunofluorescence images were 
acquired using a Nikon TiE inverted fluorescent microscope and deconvoluted using the 
3D AutoQuant Blind Deconvolution plug-in of NIS Elements Advanced Research v 
3.22.14 software. Images are single representative z-sections.  Obviously co-localisation 
of viperin (green) and endogenous MAVS (red) was obviously seen using deconvolution 
immunofluorescence microscopy (60x magnification). Scale bars are 10 μm and 1 μm for 




Analysis of micrographs revealed that in Huh-7 cells not expressing viperin, there was 
some association of peroxisomes with MAVS (Figure 6.1), however as indicated above 
this was not a common occurrence. However, in the presence of viperin, we noted 
significant co-localisation between viperin (surrounding the LDs), MAVS and 
peroxisomes. In some cases, it seemed that viperin was acting as a connector or bridge 
between the peroxisomes and mitochondria (Figure 6.3). It has been suggested that the 
localisation of MAVS to the MAM-mitochondria interface is important for antiviral 
signalling function. However, how MAVS signalling from the peroxisome is orchestrated 
has not been addressed. These results suggest that at least in Huh-7 cells, viperin 
relocates MAVS positive peroxisomes in close proximity to MAVS present on 
mitochondria and the MAM to enhance antiviral signalling. 
 
6.3 Differential localisation of MAVS creates a different innate immune signalling. 
Selective localisation of MAVS on mitochondria/MAM or peroxisomes has established 
that peroxisomes are an important site of antiviral signal transduction. Studies from the 
Kagan laboratory revealed that peroxisomal-MAVS (MAVS-pex) induces a rapid 
interferon-independent antiviral effect, whereas mitochondrial-MAVS (MAVS-mito) 
activates the IFN dependent effect. Furthermore, MAVS-pex was responsible for type III 
IFN (IFN-) induction (Odendall et al., 2014). However, this is controversial as work 
from Bender et al. showed that MAVS-pex could equally induce both type I and III IFN 
expression (Bender et al., 2015). Nevertheless, peroxisomal localised MAVS is important 






Figure 6.3: The association of viperin, MAVS, and peroxisomes. 
To determine whether viperin is in close connection with MAVS and peroxisomes, Huh-
7 cells were transiently transfected with a plasmid expressing viperin-GFP prior to 
staining with rabbit anti-MAVS and mouse anti-PMP70 following by a combination of an 
Alexa Fluor 555-conjugated goat anti-rabbit IgG and Cy5–conjugated goat anti-mouse 
IgG. Nuclei were counterstained with DAPI. Serial (0.25-m) z-sections of 
immunofluorescence images were acquired using a Nikon TiE inverted fluorescent 
microscope and deconvoluted using the 3D AutoQuant Blind Deconvolution plug-in of 
NIS Elements Advanced Research v 3.22.14 software. Images are single representative z-
sections. A close association between viperin (green), endogenous MAVS (red) and 
peroxisome/PMP70 (blue) was obviously seen using deconvolution immunofluorescence 
microscopy (60x magnification). Scale bars are 10 μm and 1 μm for main images and the 
inset, respectively. Arrows indicate viperin (on LDs), MAVS (mitochondria, MT) and 






determine which MAVS subcellular compartment is under the regulation of viperin to 
augment antiviral innate immune signalling. 
 
To address this experimentally, we adopted the approach of Dixit et al. in which MAVS 
was targeted to specific organelles by engineering specific organelle localisation signals 
to the C-terminus of MAVS. However, prior to generation of organelle specific MAVS 
cell lines, it was necessary to knockout endogenous MAVS in Huh-7 cells. MAVS 
knockout (MAVS-KO) in Huh-7 cells was successfully generated using CRISP/Cas9 
technology (see section 2.3.7.5, Chapter 2) with immunofluorescence microscopy and 
Western blot analysis confirming deletion of the MAVS locus (Figure 6.4A, B). The 
functionality of these MAVS-KO cells to an innate immune response was tested by 
transfection of poly I:C, a known activator of the RIG-I pathway, followed by an 
assessment of the induction of IFN- and IFN-1 mRNA by real time RT-PCR. As 
expected, IFN- and IFN-1 mRNA levels were significantly reduced in MAVS-KO 
cells compared to the parental Huh-7 cells (Figure 6.4C), indicating successful knockout 
of MAVS and associated signalling.  
 
To generate a stable Huh-7 cell line expressing MAVS with specific localisation to either 
the mitochondria, peroxisomes or both compartments, expression plasmids expressing 
MAVS-WT (addgene#52135), MAVS-pex (addgene#44557) and MAVS-mito (addgene 
#44556) were introduced into Huh-7 MAVS-KO cells using a retroviral transduction 







Figure 6.4: Generation of MAVS knockout (MAVS-KO). 
To create MAVS-KO cells, Huh-7 cells were transduced with lentivirus containing 
LentiCRISPR v2 encoding the MAVS sgRNA for 5 hr and subsequently replaced with 
fresh complete media. A monoclonal population of each potential knockout colony was 
obtained under puromycin selection. MAVS-KO cells were tested by (A) 
immunofluorescence analysis using a Nikon TiE inverted fluorescent microscope (20x 
magnification, scale bars are 50 m) and (B) Western blot analysis. (C) To determine the 
function of MAVS-KO cell line, this cell was stimulated with poly I:C for 24 hr, and 
IFN- and IFN-1 mRNA level were assessed by real time RT-PCR. The IFN- and 




replaced with a set of targeting sequences to direct MAVS to a single compartment 
(Figure 6.5). The plasmids also contain GFP that can be used to select for MAVS 
expressing cells. Following selection of GFP expressing cells by FACS at the single cell 
level, stable cell lines expressing MAVS were expanded and tested by immunoblotting 
and immunofluorescence microscopy analysis for MAVS expression and localisation 
(Figure 6.6). Expression levels between MAVS-WT and MAVS-mito were similar, 
however MAVS-pex expression was considerably lower and most likely reflects the 
differential localisation of MAVS expressed on peroxisomes compared to the 
mitochondria. Selectively expression of MAVS on distinct subcellular compartments was 
confirmed by immunofluorescence microscopy analysis using a specific marker of 
mitochondria (Mitotracker) and peroxisomes (PMP70). As expected, with parent Huh-7 
cells, MAVS localised predominantly to the mitochondria with a lesser amount to the 
peroxisomes (Figure 6.7 and 6.8, respectively). MAVS-WT localised predominantly to 
mitochondria with a marginal amount on peroxisomes, while MAVS-mito and MAVS-
pex are expressed on the specific subcellular compartments, mitochondria and 
peroxisomes respectively (Figure 6.7 and 6.8, respectively). For downstream studies, it 
was important to check that organelle specific MAVS still retained the capacity to signal.  
We therefore stimulated parent Huh-7 cells, Huh-7 MAVS-KO and organelle targeted 
MAVS cells with poly I:C (transfected) for 24 hr and assessed IFN- and IFN-1 mRNA 
induction by real time RT-PCR. Stable cells expressing MAVS on both compartments 
i.e., Huh-7 (parent) and MAVS WT significantly induced expression of IFN- and IFN-







Figure 6.5: Schematic diagram of WT and engineered MAVS alleles targeting to a 
specific organelle. 
The transmembrane domain (TM) of MAVS was replaced with Fis1 and Pex13 
sequences to direct MAVS to mitochondria (MAVS-mito) and peroxisomes (MAVS-







Figure 6.6: Generation of stable cell lines expressing MAVS allele. 
To create stable cell lines expressing MAVS transgenes, MAVS-KO cells were 
transduced with retroviral containing MAVS alleles for 5 hr and subsequently replaced 
with fresh complete media for 3 days. A monoclonal stable cell expressing each MAVS 
allele was obtained by GFP positive cell sorting (BD FACSAria
TM
 II). The expression of 
MAVS in each stable cell lines was tested by (A) immunofluorescence analysis, using a 
Nikon TiE inverted fluorescent microscope (20x magnification, scale bars are 50 m) and 






Figure 6.7: Stable cell lines expressing MAVS transgenes on mitochondria. 
To determine the localisation of stable cell lines expressing MAVS transgenes on 
mitochondria, cell lines were incubated with permeable probes for mitochondrial 
labelling (MitoTracker
®
 Red CMXRos, Cell Signalling Technology) for 30 min prior to 
cell fixation and staining with rabbit anti-MAVS antibody and Alexa Fluor 488-
conjugated goat anti-rabbit IgG. Nuclei were counterstained with DAPI. Co-localisation 
of MAVS (green) and mitotracker (red) was obviously seen in Huh-7, MAVS-WT, 
MAVS-mito cell lines, whereas no co-localisation was found in MAVS-KO and MAVS-
pex cell lines. All IF images were obtained by immunofluorescence analysis using a 
Nikon TiE inverted fluorescent microscope (60x magnification). Scale bars are 10 μm 






Figure 6.8: Stable cell lines expressing MAVS transgenes on peroxisomes. 
To determine the localisation of stable cell lines expressing MAVS transgenes on 
peroxisomes, cell lines were stained with rabbit anti-MAVS antibody and mouse anti-
PMP70 (peroxisome marker) prior to staining with a combination of Alexa Fluor 555-
conjugated goat anti-mouse IgG and Alexa Fluor 488-conjugated goat anti-rabbit IgG. 
Nuclei were counterstained with DAPI. A partial co-localisation of MAVS (green) and 
peroxisomes (red) was observed in Huh-7, MAVS-WT, while a perfectly co-localisation 
was obviously seen in MAVS-pex cell lines. No co-localisation was found in MAVS-KO 
and MAVS-mito cell lines. All IF images were obtained by immunofluorescence analysis 
using a Nikon TiE inverted fluorescent microscope (60x magnification). Scale bars are 10 
μm and 1 μm for main images and insets, respectively. Arrows indicate the localisation of 




IFN-1 mRNA that was less than that for MAVS present on both compartments (Figure 
6.9). This suggests that MAVS localisation to both organelles may be important for a 
maximal type I interferon response to viral infection.  
 
6.4 Viperin mediates a MAVS signalling through mitochondria and peroxisome 
compartments. 
Having established selective expression of MAVS on both the mitochondria and 
peroxisomes (MAVS-WT), mitochondria (MAVS-mito) and peroxisomes (MAVS-pex) 
and shown that these cell lines all respond to poly I:C, we are now in a position to 
investigate the impact of viperin on MAVS signalling from selected organelles. Selective 
MAVS expressing cell lines were transfected with a plasmid expressing viperin and 24 hr 
post-transfected cell were stimulated with poly I:C, and IFN- and IFN-1 mRNA 
expression quantitated by real time RT-PCR. 
 
As we have shown previously, expression of viperin in Huh-7 cells revealed a statistical 
increase in IFN- and IFN-1 mRNA, while as expected, viperin or dsRNA (poly I:C) 
had no effect on mRNA expression in MAVS-KO cells. To our surprise, we noted no 
impact of viperin expression on IFN- and IFN-1 expression in cells with selective 
expression of MAVS on either the mitochondria or peroxisomes. This was somewhat 
confusing as we anticipated that the trafficking of peroxisomes by viperin would be a 
contributing factor in innate immune augmentation. However, we did see a significant 
increase in both IFN- and IFN-1 mRNA expression in MAVS-WT cells in which 






Figure 6.9: Induction of IFN- and IFN-1 expression in a panel of stable cell lines 
expressing MAVS alleles. 
To assess the signalling capacity of stable cell lines expressing MAVS alleles, all cell 
lines were stimulated with poly I:C for 24 hr prior to IFN- and IFN-1 mRNA level 
quantification by real time RT-PCR. Selective MAVS expression on mitochondria and 
peroxisomes or both respond to poly I:C stimulation to produce (A) IFN- and (B) IFN-
1. Data are means  SD (n=3). 2-way ANOVA, ****p<0.0001, *** p=0.0004. 
  
IFN-         
                    





marked with IFN-1 expression (Figure 6.10). This suggests that while MAVS can signal 
from either the mitochondria or peroxisomes, in the presence of viperin, optimal 
signalling occurs when MAVS is present on both the mitochondria and peroxisomes. It is 
not inconceivable to envisage that while signalling can occur from specific organelles, 
optimal signalling requires MAVS to be present on the mitochondria, peroxisomes and 
MAM to form the innate immune synapse, and that viperin may facilitate movement of 
the peroxisome to facilitate maximal innate immune induction. 
 
6.5 Discussion 
We have demonstrated previously in Chapter 5 that viperin promotes peroxisome 
biogenesis and positions peroxisomes in close association with LDs through an 
interaction with PEX19. However, the question remains as to what the biological 
significance of this interaction. It is possible that the ability of viperin to increase 
peroxisome numbers may facilitate innate immune signalling and downstream IFN and 
ISG expression as have been previously postulated. However, a second possibility is that 
the ability of viperin to redirect the peroxisome may help in the formation of the innate 
immune synapse to maximise innate immune signalling in response to infection. Elegant 
work by Horner et al. established that recognition of RIG-I following viral infection 
signals through MAVS that is present at the MAM-mitochondrial interface in what has 
been termed the “innate immune synapse”, however in this model antiviral signalling 
from MAVS present on the peroxisome is not considered even though the literature 
strongly supports their role in the antiviral innate response (Horner et al., 2011). We 






Figure 6.10: Viperin is required for MAVS signalling. 
To determine the effectiveness of viperin to regulate MAVS signalling in the selectively 
MAVS localisation to mitochondrial and peroxisomes or both, all cell lines were 
transiently transfected with a plasmid expressing viperin-FLAG or plasmid control for 24 
hr prior to poly I:C stimulation for 24 hr. IFN- and IFN-1 mRNA level were quantified 
by real time RT-PCR. (A) IFN- and (B) IFN-1 messages were drastically increased in 
MAVS-WT overexpressing of viperin in response to poly I:C stimulation while viperin is 
not able to enhance MAVS signalling in specific localisation of MAVS on mitochondria 





drive the peroxisome in close association with the innate immune synapse to augment the 
cellular response to viral infection. With this in mind, we investigated the interaction of 
MAVS, viperin, peroxisomes and mitochondria at the cellular level and furthermore 
investigated the impact of viperin on activation of MAVS selectively expressed from 
either mitochondria, peroxisomes or both. 
 
Initially, we assessed MAVS localisation to mitochondria and peroxisomes in our Huh-7 
cells using immunofluorescence microscopy. Consistent with previous studies, we 
revealed that MAVS is primarily localised to mitochondria, while to a lesser extent on 
peroxisomes (Figure 6.1). This corroborates with the previous work from Bender and 
colleagues in which approximately 80% of MAVS was localised to the mitochondria and 
20% to peroxisomes (Bender et al., 2015). As we established that viperin can bind to the 
peroxisome, the next logical step was to determine if there was an interaction between 
viperin and MAVS. As expected, immunofluorescence analysis in cells expressing 
viperin-GFP and stained for endogenous MAVS revealed an obvious co-localisation 
between the two proteins. It is unclear at this stage if there is a direct interaction between 
viperin and MAVS, however this co-localisation is most likely a function of the viperin-
PEX19 interaction. Interestingly, this interaction seems to be at the interface between 
viperin present at the LD interface and MAVS positive mitochondria or peroxisomes, 
however from these images the role of the peroxisome cannot be deduced. To resolve this 
issue we further investigated the interaction between viperin, MAVS and the peroxisome 
using immunofluorescence microscopy. As in Chapter 5, in which we revealed an 




we now reveal an interaction between viperin, peroxisomes and MAVS in which it seems 
that viperin facilitates the interaction between the peroxisome and MAVS (Figure 6.3). 
While these images represent deconvolution microscopy of z-stacks, the resolution 
precludes detailed analysis. Future experiments should include super-resolution 
microscopy to further resolve these interactions. Interestingly, our viperin-APEX2 EM 
micrographs presented in Chapter 3 revealed viperin in close association with the LD and 
in many cases in close association with the mitochondria (Figure 3.14). Future 
experiments should extend these EM studies to identify the localisation of the peroxisome 
and possibly MAVS in this complex. The experiments outlined above clearly place 
viperin in association with the peroxisome at the mitochondrial interface (and possibly 
the MAM) and with the LD. This also suggests that the LD is also involved in playing a 
role as a scaffold in innate immune signalling. Together with the emerging evidence that 
the peroxisome is a platform for antiviral signalling (Dixit et al., 2010), we hypothesise 
that viperin interacts with the peroxisome to augment the innate antiviral response from 
this organelle. 
 
To further investigate the role that viperin may have on innate signalling from the 
peroxisome we adopted an approach developed by the Kagan laboratory in which 
selective expression of MAVS to either the mitochondria, peroxisome or both, was 
achieved through engineering specific organelle targeting sequences to the carboxy 
terminal end of MAVS (Dixit et al., 2010). However, prior to generating selective 
localisation of MAVS, it was necessary to knockout endogenous MAVS (KO) 




7 MAVS-KO cell line did not express MAVS as determined by immunoblot and 
immunofluorescence analysis. Furthermore, the production of IFN- and IFN-1 mRNA 
was significantly reduced compared to the parental Huh-7 cells (Figure 6.4C), following 
stimulation with transfected poly I:C to activate cytosolic PRR recognition. This indicates 
that we have successfully generated a MAVS-KO cell line that is refractory to 
stimulation with poly I:C. We next generated stable Huh-7 cell lines expressing MAVS 
with specific localisation to either the mitochondria, peroxisomes or both compartments 
by retroviral delivery of MAVS cDNA expressing selective localisation of MAVS 
including MAVS-WT, MAVS-pex and MAVS-mito (Dixit et al., 2010). We successfully 
generated the selective expression of MAVS to distinct subcellular compartments, and as 
expected MAVS-WT localised predominantly to mitochondria (and possibly the MAM) 
with a lesser amount on peroxisomes, while MAVS-mito and MAVS-pex were 
selectively expressed on their target subcellular compartments, respectively (Figure 6.7 
and 6.8). It was necessary to confirm that organelle specific MAVS maintained its 
capacity to signal. We found that following transfection of poly I:C, IFN- and IFN-1 
mRNA was significantly induced from all MAVS expressing lines, however the greatest 
expression was observed in MAVS-WT cells, followed by MAVS-mito and then MAVS-
pex cells (Figure 6.9). This observation is consistent with that of Dixit et al., and may be 
reflective of lower expression of MAVS proteins in MAVS-pex cells (Figure 6.6B) (Dixit 
et al., 2010) or alternatively may reflect the fact that only a finite amount of MAVS can 
be loaded onto peroxisomes compared to the mitochondria. We attempted to select for 
clones of Huh-7 cells that expressed increased MAVS-pex by FACS, however all clones 




IFN- and IFN-1 in MAVS-WT compared to MAVS-mito and -pex suggests that 
MAVS localised to both organelles is required for maximal innate immune activation. 
Although it is well-documented that MAVS can signal from both the mitochondria and 
the peroxisome, there is some controversy as to the relative roles of each organelle in this 
process. Studies from the Kagan laboratory indicated that peroxisomal MAVS activation 
triggers a rapid antiviral effect in an interferon-independent manner and is responsible for 
type III IFN (IFN-) production, while mitochondrial MAVS activates a late type I IFN 
dependent antiviral effect (Odendall et al., 2014). However, Bender et al. revealed that 
activation of peroxisomal MAVS could equally promote expression of type I and III IFN 
(Bender et al., 2015). There were a number of reasons for this discrepancy, the most 
significant being the use of different MAVS organelle targeting constructs and the 
sensitivity of read-out systems that used to measure IFN production. Bender et al. fused 
MAVS with the targeting sequences at aa 514, while the constructs engineered by Dixit 
et al. retained MAVS only up to aa 500, that may affect the signalling capacity of the 
MAVS fusion proteins. In our study, we have used the selective MAVS expression 
constructs from the Kagan laboratory and we found that activation of peroxisomal MAVS 
can result in expression of both IFN- and IFN-1 mRNA. This contradicts the 
conclusions from the Kagan laboratory, and while we have only investigated mRNA 
expression, suggests that like the Bender et al. study, activation of peroxisomal MAVS 
can result in IFN- and IFN-1 mRNA. This of course may be a moot point, as in a 
biological context, MAVS will always be expressed associated with mitochondria/MAM 





Having established a system to evaluate MAVS activation in a selective manner we were 
now in a position to define the impact of viperin expression on MAVS signalling from 
the peroxisome, mitochondria or both. Given our previous data showing that viperin 
binds to the peroxisome (via PEX19) and alters its cellular localisation, we postulated 
that viperin would impact MAVS signalling from the peroxisome. However, to our 
surprise this was not the case. We noted that viperin did not augment MAVS-pex (or 
MAVS-mito) activation but unexpectedly did result in a significant increase in IFN- and 
IFN-1 only when MAVS was present on both the peroxisome and mitochondria. This 
suggests that while it is possible for MAVS to signal from either mitochondria or 
peroxisomes alone, the enhancing function of viperin only occurs in the presence of 
MAVS on both organelles. However, our results were in contradiction to a recent study 
from Hee and Cresswell in which they demonstrated viperin mediates inhibition of the 
IFN response through physically interacting with MAVS specifically localised to the 
MAM (Hee and Cresswell, 2017). This discrepancy can be explained by the use of 
different cell lines (Hee and Cresswell used BMM) and possibly a different species of 
viperin as mouse viperin (not human as in this thesis) was utilised in the aforementioned 
report.  
 
While it is well-established that MAVS localises to a diverse set of membranes, including 
at peroxisomes and mitochondria as well as the mitochondrial-associated membrane 
(MAM), the regulatory factors that mediate these different localisations are completely 
unknown. Furthermore, following viral infection the three intracellular membranes that 




during activation of the RIG-I pathway (Horner et al., 2011), suggesting that signalling 
from these organelles is co-regulated in a process that is also completely unknown. Based 
on evidence provided in this thesis it is not inconceivable to envisage that viperin 
expression following viral infection may indeed act in part to regulate MAVS-mediated 
antiviral signalling. In this model, recognition of viral RNA by RIG-I in the cytosol 
followed by RIG-I oligomerisation and RIG-I translocation to the MAM activates MAVS 
at the mitochondria and the MAM followed by recruitment of downstream signalling 
factors to form a MAVS signalling complex or the “innate immune synapse” (Horner et 
al., 2011, Vazquez and Horner, 2015). This early activation of the RIG-I pathway results 
in IRF3 independent gene expression, of which viperin is one, with viperin expression 
noted as early as 4 hours post infection (Dixit et al., 2010, Odendall et al., 2014). This 
viperin and PEX19/peroxisome interaction would function as a molecular chaperone in 
which it would help position peroxisomes via an interaction at the LD in close proximity 
to the innate immune synapse, resulting in an augmentation of innate immune signalling.  
 
It should be noted in this study, we assessed the induction of both type I and III IFN 
mRNA in response to transfection of a synthetic dsRNA, poly I:C that is a potent 
activator of RIG-I. Future studies should confirm these observations at both the activation 
level and the cellular level using viral infection such as Sendai virus (SeV) or Newcastle 
disease virus (NDV) that are well-known activators of the RLR response. Interestingly it 
has been noted as mentioned above, that following viral infection (SeV) the known 
MAVS cellular compartments interact to maximise antiviral signalling. In addition, it 




activation by MDA5, a PRR that is thought to be activated late in viral infection such as 
in WNV and Tulane virus infection (Fredericksen et al., 2008a, Errett et al., 2013, 
Chhabra et al., 2017).  
 
In summary, our original hypothesis was that viperin would enhance innate immune 
signalling from the peroxisome using a selective model of MAVS expression to this 
organelle. However, this was not the case and we only noted an augmentation of the 
innate response when MAVS was present on both the peroxisome and the mitochondria, 
and possibly the MAM. This suggests that for the induction of a maximal innate 
response, MAVS is required at the peroxisome, mitochondria and the MAM and that 
viperin facilitates this activation by redirecting the peroxisome to the innate immune 
synapse. Clearly, MAVS expression at multiple sites within the cell is dynamic and must 
be coordinated to place all players in close vicinity for maximal expression. We therefore 
postulate that viperin is a strong candidate for augmenting the innate antiviral response 






Conclusions and Future Directions 
 
Viral infection results in the activation of viral recognition pathways that trigger the 
induction of cytokines and predominately type I interferon (IFNs) expression to establish 
a host antiviral state (Sen, 2001). Binding of IFNs to their specific receptors initiates the 
production of hundreds of interferon-stimulated genes (ISGs). Many of these ISGs are 
uncharacterised, however there are a growing number that possess antiviral activity 
(Schoggins and Rice, 2011). One such ISG is viperin (RSAD2) that exerts a broad 
antiviral activity against a number of RNA viruses including hepatitis C virus (HCV) 
(Helbig et al., 2005, Wang et al., 2012), dengue virus (DENV) (Fink et al., 2007, Helbig 
et al., 2013), influenza virus (Tan et al., 2012, Wang et al., 2007), HIV (Nasr et al., 
2012), respiratory syncytial virus (RSV) (McGillivary et al., 2013) and Tick-borne 
encephalitis virus (TBEV) (Upadhyay et al., 2014). The mechanisms responsible for its 
diverse antiviral activity are not well understood and seem to be specific for different 
viruses, including closely related viruses of the Flaviviridae family; HCV, DENV and 
TBEV. For example, the C-terminal domain plays a crucial role in antiviral activity 
against HCV and DENV, while the radical SAM domain is responsible for anti-TBEV 
activity (Helbig et al., 2011, Helbig et al., 2013, Upadhyay et al., 2014). This selective 
antiviral activity is in part related to well-conserved protein domains and the ability of 
viperin to bind and modulate several host factors. However, this does not fully explain 




activity. Furthermore, the full repertoires of the host interacting partners of viperin 
remain to be uncovered.  
 
It has been reported that viperin interacts with VAP-A and the HCV non-structural 
protein NS5A, and could interfere with the interaction of VAP-A and NS5A at sites of 
HCV replication (Helbig et al., 2011, Wang et al., 2012). HCV can induce extensive 
intracellular membrane remodelling to form RC or membranous webs where RNA 
amplification takes place (Gosert et al., 2003, Ferraris et al., 2010, Romero-Brey et al., 
2012). Several host and viral proteins are essential for the formation of membranous 
webs such as VAP-A, OSBP, PI4KA, NS4B, NS5A (Chukkapalli and Randall, 2014), 
however the precise molecular mechanism of host-virus interactions within the RC is not 
understood. The host pro-viral protein, VAP-A has been shown to bind to OSBP, the 
cholesterol recruiting protein oxysterol-binding protein that is essential for cholesterol 
traffic and exchange and as such plays a role in HCV replication by modification of 
intracellular membranes for the formation of the HCV RC (Wyles et al., 2002, Amako et 
al., 2009, Wang et al., 2014). Interestingly, the antiviral effector protein and also an ISG, 
interferon-inducible transmembrane protein 3 (IFITM3), has been shown to disturb the 
interaction of VAP-A and OSBP to inhibit viral entry (Amini-Bavil-Olyaee et al., 2013). 
Taken together, this raises the question of whether an association between viperin and 
VAP-A disrupts the interaction of VAP-A and OSBP to impact the function of OSBP in 
the formation of HCV RC to ultimately inhibit HCV replication. We therefore 
hypothesised that viperin binding to VAP-A can alter the interaction of VAP-A and 




To our surprise, our results in Chapter 3 revealed that viperin did not co-localise with 
OSBP and also did not disturb the interaction of VAP-A and OSBP as VAP-A 
maintained its co-localisation with OSBP. However, it is interesting that these 
interactions presented at different sites, with viperin interacting with VAP-A at LD 
interface, while the binding of VAP-A and OSBP is likely at the ER-Golgi contact sites, 
as expected (Amako et al., 2009). Our results also revealed that in the presence of 
viperin, the VAP-A localisation pattern was shifted from its typical ER localisation 
(Skehel et al., 2000, Prosser et al., 2008) to LDs where viperin accumulates, suggesting 
that viperin alters VAP-A localisation which may later impact HCV RC formation. 
However, as this was observed in uninfected cells, we therefore cannot rule out the 
possibility that extensive HCV-induced cellular membrane rearrangements to form 
membranous webs (Romero-Brey and Bartenschlager, 2014) may alter the localisation of 
host pro-viral proteins such as VAP-A and OSBP, such that altered interactions of viperin 
with these pro-viral factors can occur in the RC. Therefore, it will be of interest to further 
determine the association/interaction of these viral and host cellular proteins (HCV 
NS5A, viperin, VAP-A and OSBP) in the context of HCV-induced membrane 
rearrangements.  
 
As indicated previously, the diverse functions of viperin cannot be explained by its 
intrinsic functions alone and it is likely that its effect is mediated at least in part through 
interaction with host proteins. While a number of viperin interacting partners have been 
identified including both viral (HCV NS5A, DENV NS3, HCMV vMIA) (Helbig et al., 




TFP, IRAK1, VAP-A, TRAF6, MAVS and CIAO1) (Wang et al., 2007, Seo et al., 2011, 
Saitoh et al., 2011, Helbig et al., 2011, Wang et al., 2012, Hee and Cresswell, 2017, 
Upadhyay et al., 2014), we reasoned that more remain to be discovered. Understanding 
the repertoire of viperin interacting partners will help in elucidating the role of this 
enigmatic protein as an antiviral and in cellular functions. Therefore, a central aim of this 
thesis was to identify and characterise novel cellular interacting partners of viperin. In 
this thesis, a yeast two-hybrid approach was employed to identify novel interacting 
partners of viperin. As described in Chapter 4, we identified and confirmed that the 
peroxisomal biogenesis factor 19 (PEX19) and apolipoprotein A1 (ApoA1) are novel 
viperin interacting partners. Surprisingly, among 115 identified viperin interactomes 
using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), PEX19 
has been reported as a potential viperin interacting partner (Vonderstein et al., 2017), and 
thus confirms our findings. However, it was somewhat disappointing in that we could 
only reliably identify 2 viperin interaction partners. The reasons for this are outlined in 
Chapter 4 and highlight the limitations of the Y2H system for recovery of protein 
interaction partners. It is highly likely that the repertoire of viperin interaction partners 
extends beyond PEX19 and ApoA1 identified in this thesis and cellular and viral protein 
identified elsewhere. Therefore future experiments should use a more robust and sensitive 
system to recover interacting partners as such affinity purification coupled with Mass 
Spectrometry. 
 
The significance of viperin binding to either of these proteins was not immediately 




innate immune signalling to RNA viral infection (Dixit et al., 2010, Odendall et al., 2014) 
and preliminary data from our laboratory implicating viperin in augmentation of innate 
immune signalling focused our efforts to investigate this interaction further. PEX19 is 
important for the peroxisome biogenesis pathway by facilitating the insertion of the 
peroxisomal membrane protein (PMP) into peroxisome membranes. Most importantly for 
this thesis is that recent work has implicated the peroxisome as a key organelle in innate 
immune sensing of viral RNA infection through the presence of the signalling adaptor 
protein MAVS on the peroxisome outer membrane in addition to its presence on 
mitochondria and mitochondrial-associated membranes (MAM) (Dixit et al., 2010). This 
raises important questions about the biological impact of the PEX19-viperin interaction 
on both peroxisome biology and innate immune signalling from peroxisomes. While the 
role of the peroxisome in innate immune signalling is in its infancy, the interaction of a 
number of viruses with peroxisomes provides evidence that peroxisomes are important 
organelles in the host innate response to viral infection (You et al., 2015, Magalhaes et 
al., 2016). Interestingly, a recent study has shown that WNV and DENV capsid proteins 
can bind and sequester PEX19 resulting in a significant loss of peroxisomes and a 
corresponding decrease in IFN- production (You et al., 2015). This could be a possible 
mechanism whereby the flaviviruses, WNV and DENV abrogate antiviral signalling from 
peroxisomes. Furthermore, the HCMV vMIA protein binds to PEX19 resulting in 
peroxisome fragmentation and downstream blockade of peroxisome-dependent antiviral 
signalling (Magalhaes et al., 2016). Collectively these observations in which viruses have 
evolved mechanisms to selectively evade peroxisomal MAVS-dependent antiviral 




infection. Clearly an improved understanding of the biology of innate immune signalling 
from peroxisomes and the cellular factors that dictate this is warranted. 
 
The current model by Horner and colleagues regarding antiviral MAVS signalling 
postulates that upon RIG-I sensing of viral RNA in the cytosol and RIG-I 
oligomerisation, RIG-I translocates to the MAM-mitochondrial interface where MAVS 
becomes activated by CARD-CARD interactions between MAVS and RIG-I. This 
interaction results in MAVS oligomerisation for subsequent recruitment of downstream 
signalling factors to form the MAVS signalling complex that ultimately results in IRF3 
phosphorylation and transcription of IFN- and IRF3-dependent gene expression and 
initiation of the antiviral state.  In this way, it is postulated that to initiate signalling there 
is formation of an innate immune synapse that brings together all relevant players at the 
MAM-mitochondrial interface (Horner et al., 2011, Vazquez and Horner, 2015). 
However, in this model the role of MAVS-dependent signalling from the peroxisome is 
neglected even though we know that the peroxisome plays an important role in the 
antiviral response. While some MAVS positive peroxisomes are in close proximity to the 
mitochondria as shown by others and us in this thesis, there is a significant proportion 
that is distant to the proposed innate immune synapse. This raises a question that to date 
has not been addressed or has been neglected; can MAVS positive peroxisomes signal 
independently of the innate immune synapse? This would seem somewhat 
counterintuitive, as this would require a complete complement of signalling and adaptor 




that following viral infection the peroxisome repositions itself to the innate immune 
synapse to initiate MAVS dependent peroxisome signalling.  
 
How then do peroxisomes distant from the innate immune synapse position themselves in 
a context for maximal signalling? Based on the results from this thesis (Chapter 5), we 
propose that viperin acts as a chaperone to reposition the peroxisome at the innate 
immune synapse. This is supported by a number of lines of independent investigation.  
Firstly, the ability of viperin to interact with PEX19 and hence the peroxisome provides 
the first clue that viperin may play a role in peroxisome-mediated innate immune 
signalling. This is further reinforced by the fact that exogenous expression of viperin or 
the lack thereof in MEFs isolated from viperin
-/-
 mice resulted in enhancement or 
suppression of the innate response to poly I:C or SeV infection, respectively. Clearly, 
viperin expression plays a role in modulation of the innate response to RNA viral 
infection. While the antiviral properties of viperin are well-documented, its ability to 
modulate innate immunity is less well understood. Work from Saitoh and colleagues 
reported that viperin promoted TLR7 and TLR9 mediated production of type I IFN in 
pDCs that was mediated by the interaction of viperin with the signal mediators IRAK1 
and TRAF6 (Saitoh et al., 2011). Interestingly and relevant to this thesis, viperin 
recruited the adaptor molecules IRAK1 and TRAF6 to lipid droplets, that placed them in 
the correct environment for signalling. It is not surprising that viperin directed IRAK1 
and TRAF6 to the lipid droplet as it is well-documented by our laboratory (including this 
thesis) and others that viperin can localise to the outer membrane of the lipid droplets, 




Cresswell, 2009a, Helbig et al., 2011). Indeed, we also observed that viperin can also 
reposition peroxisomes in close association with lipid droplets. In the absence of viperin 
expression peroxisomes do not associate with the lipid droplets, however in contrast, in 
its presence, there was a close association of peroxisomes (PEX19, PMP70 and PEX11B 
positive foci) with lipid droplets as determined by wide-field immunofluorescence 
deconvolution microscopy. Super-resolution microscopy further defined this interaction 
revealing that peroxisomes are juxta-opposed to viperin-laden lipid droplets. 
Furthermore, using deconvolution microscopy we also demonstrated that there is 
significant co-localisation between viperin (present on the lipid droplets) and MAVS 
present on mitochondria and peroxisomes suggesting that viperin may redirect the 
peroxisomes in close proximity to the mitochondria and the MAM and hence the innate 
immune synapse. This raises the question as to the importance of the lipid droplet in this 
process. Mutational analysis of viperin in which the N-terminal amphipathic -helix has 
been removed such that it can no longer locate to the lipid droplets also results in a 
significant decrease in viperin’s ability to augment the cellular response to poly I:C. 
Interestingly, it is emerging that the lipid droplets can play a role in cellular signalling 
events and in unpublished results we have shown that in cells depleted of lipid droplets 
there is a significant decrease in the innate immune response to viral infection (Helbig K., 
unpublished data). In this regard, future studies should focus to determine if viperin can 
still augment the innate immune response to viral infection in the context of lipid droplet 
depletion. One could envisage that lipid droplet may not be essential for MAVS-





Having established that viperin can augment innate immune signalling and its role in 
repositioning peroxisomes prompted us to investigate MAVS-dependent signalling from 
peroxisomes independent from that of the mitochondria and the MAM. This was 
achieved using a strategy developed by the Kagan laboratory in which selective 
expression of MAVS was achieved by first deleting endogenous MAVS from the cell 
followed by exogenous targeted MAVS expression to either the mitochondria, 
peroxisome or both (Dixit et al., 2010). In this way, we could investigate the impact of 
viperin expression on MAVS signalling from either the peroxisome or mitochondria or 
both. Given our previous data, we hypothesised that viperin would have the most impact 
on MAVS located on the peroxisome, however this was not the case as viperin 
expression had no impact on either MAVS signalling from the mitochondria or the 
peroxisome. However, we did see an enhancing effect of viperin on the expression of 
both IFN- and IFN- mRNA when MAVS was expressed on both organelles. This 
suggests that viperin can only drive a maximal innate antiviral response when MAVS is 
present on the peroxisome and the mitochondria including the MAM. Based on our 
observations, we propose that following RNA virus infection recognition of RNA by 
RIG-I and subsequent activation of MAVS is achieved at the innate immune synapse that 
includes MAVS present on the outer mitochondrial membrane and the MAM. This 
results in IRF3 dependent gene expression and immediate expression of viperin. 
However, maximal signalling is not achieved until MAVS positive peroxisomes are 
redirected the innate immune synapse in a process that is facilitated by viperin interacting 
with PEX19 on the peroxisome. In this way all the appropriate adaptor molecules 




efficient downstream signalling. This process is summarised in Figure 7.1. While all of 
our studies have relied on exogenous expression of viperin, it is pertinent to note that 
viperin expression is induced rapidly following viral infection by both IFN-independent 
and -dependent mechanisms (protein expression as early as 4 hr) that would result in a 
rapid enhancement of the antiviral response following viral infection (Dixit et al., 2010, 
Odendall et al., 2014). Furthermore, under interferon stimulation, viperin mRNA 
expression is tightly regulated with maximal expression at 8 hr post stimulation after 
which it rapidly declines (Figure 4.7). This suggests that viperin may be responsible for 
an early rapid enhancement of innate immune activation from MAVS present on 
peroxisomes that decreases over time as viperin expression is regulated. Ultimately a 
heightened innate response to viral infection would result in a more robust cellular 
antiviral response with the overall goal to control or limit viral replication. 
 
In summary, we have demonstrated that PEX19 is a novel interacting partner of viperin 
and their interaction is crucial for recruiting peroxisomes to the lipid droplet surface and 
in a close proximity to mitochondria. In addition, the close association of viperin and 
MAVS at both mitochondria and peroxisomes augments the innate antiviral response. 
Collectively, the studies conducted in this thesis provide valuable insights into the 
association of viperin, MAVS and the peroxisomes for augmentation of the innate 
immune response and highlight a central role of viperin in both direct antiviral activity 
and acting as a molecular bridge within the innate immune synapse. Hence, an improved 
understanding of the molecular mechanisms involved in viperin’s innate antiviral activity 





Figure 7.1: Schematic representation model of viperin interacting with MAVS in an innate immune synapse. 
Upon RNA viral infection, activation of RIG-I signalling cascade results in the expression of viperin that subsequently interacts with 
PEX19 on peroxisomes and recruits peroxisomes in a close proximity to lipid droplets and mitochondria to form an innate immune 












Appendix I: Primer sequences used in this study 
Gene name Forward primer ( 5’ to 3’) Reverse primer ( 5’ to 3’) 
Primers for cloning into mammalian expression plasmid 
OSBP  






Human viperin  






Human viperin 5’10 





Human viperin 5’21 





Human viperin 5’33 





Human viperin 5’42 





Human viperin 3’33 
(N-terminal Flag tag) 
Use * CGCCGCGGCTAACCAACAT
CCAGGATGGA  
Human viperin 3’50 
(N-terminal Flag tag) 
Use * CGCCGCGGCTACAGAAAGC
GCATATATTC  
Human viperin 3’72 
(N-terminal Flag tag) 
Use * CGCCGCGGCTACAAGCAGG
ACACTTCTTT 
Human viperin 3’100 













Mouse viperin  






Mouse viperin  

















Primers for cloning into yeast expression plasmid 
Human viperin 































Human viperin GTGAGCAATGGAAGCCTGATC GCTGTCACAGGAGATAGCG
AGAA 














Murine IFN- β AGAAAGGACGAACATTCGGAAA CCGTCATCTCCATAGGGATC
TT 
Murine IFN-2 CCACATTGCTCAGTTCAAGTCTCT TCCTTCTCAAGCAGCCTCTT
CT 
Sequencing primers( 5’ to 3’) 
T7 TAATACGACTCACTATAGGGC - 
CMV  CGCAAATGGGCGGTAGGCGTG  - 
V5 reverse  ACCGAGGAGAGGGTTAGGGAT  - 
EGFP FP1 TACCTGAGCACCCAGTCC - 
DNA-BD  TTTTCGTTTTAAAACCTAAGAGTC - 





Appendix II: General Solutions and Buffers 
The following solutions were obtained from the Central Services Unit (CSU) and 
Tissue Culture Services Unit (TSU), School of Biological Sciences, The 
University of Adelaide. 
 0.85% saline solution 
 10x GTS buffer 
 10x TBS buffer 
 1x and 20x PBS (phosphate buffered saline) solutions 
 20% Glucose solution 
 4M NaCl solution 
 Ampicillin 1 mg/ml 
 EDTA (different concentration and pH) 
 Kanamycin 1 mg/ml 
 L-Agar + ampicillin plates 
 Luria agar plates 
 Luria Broth 
 SDS 
 SOC media 
 Tris solutions (different concentration and pH) 
 G418 
 Penicillin/streptomycin 
 Trypan blue 
 Trypsin-EDTA 
 FCS (Foetal Calf Serum) 






Cell lysis RIPA Buffer  (40 ml) 
 
150mM NaCl (1.5ml of 4M NaCl) 
0.5% deoxych = 0.2g  
0.1% SDS (0.4ml of 10% SDS) 
1% NP-40 (0.4 ml  of NP-40) 
50mM Tris (2 ml of 1M Tris) 
dH2O 35.7 ml 
Cell lysis NP-40 Buffer  (40 ml) 
 
50 mM Tris-HCL (2 ml of 1M Tris-HCL,pH8) 
150mm NaCl (1.5 ml of 4M NaCl) 
1% NP-40 (0.4 ml  of NP-40) 
dH2O 36.1 ml  
5X Laemmli Buffer 5% β-Mercaptoethanol  
0.02% Bromophenol blue  
30% Glycerol  
10% SDS  
0.25 mM Tris-Cl (pH 6.8) 
SDS PAGE Running Buffer 2.9% Trisma Base 
14.14% glycine 
1% SDS 
SDS PAGE Transfer Buffer 0.3% Trisma Base 
1.44% glycine 
20% (v/v) methanol 
TBS-T washing solution 
(Western blot) 
1x TBS buffer in dH2O 
0.1 % Tween® 20 
Acetone:Methanol 50% acetone 
50% methanol 
4% Paraformaldehyde (100 ml)  4g of paraformaldehyde (PFA)  
10ml of 10x PBS  
dH2O up to a final volume of 100 ml 
Gel-Red Solution 30 μl Gel-Red  
2.5 ml 4M NaCl 




Redsafe solution 5 μl Redsafe  
100 ml of melted-agarose gel  
1% Agarose 1g Agarose  
100ml 1xTAE buffer 
1% BSA 1 g of Bovine serum albumin (BSA) 
100 ml of 1X PBS 
5% BSA 5 g of BSA 
100 ml of 1X PBS 
EM fixative solution 4% paraformaldehyde  
1.25% glutaraldehyde (EM grade)  
4% sucrose (w/v) in PBS (pH 7.2) 
2x Freezing medium (10 ml) 
 
50% complete DMEM medium (5 ml) 
30% FCS (3 ml) 
20% DMSO (2 ml) 
 
Competent Cells: 
The E.coli α-Select Chemically Competent Cells used for bacterial transformation 
was: 














Appendix III: Antibodies 
Antibody dilution for Western blot analysis 
  
Primary antibody  Dilution  Incubation  Supplier 
Mouse anti-FLAG 1:1,000 O/N, 4°C Sigma Aldrich 
Rabbit anti-FLAG 1:1,000  O/N, 4°C Sigma Aldrich 
Mouse anti--actin 1:10,000  O/N, 4°C Sigma Aldrich  
Rabbit anti-viperin 1:1,000  O/N, 4°C Enzo life sciences 
Rabbit anti-OSBP 1:1,000 O/N, 4°C Proteintech 
Rabbit anti-mCherry 1:1,000 O/N, 4°C BioVision 
Mouse anti-PMP70 1:1,000  O/N, 4°C Sigma Aldrich 
Rabbit anti-PEX19 1:1,000  O/N, 4°C Abcam  
Rabbit anti-MAVS 1:2,000  O/N, 4°C Enzo Life Sciences 
Goat anti-catalase 1:500 O/N, 4°C Santa Cruz Biotechnology 
Mouse anti-cMyc (clone 4A6) 1:1,000 O/N, 4°C Millipore 
Secondary Antibody    
Goat anti-mouse IgG (H+L), 
peroxidase conjugated 
1:10,000  1 hr, RT Thermo Fisher Scientific 
Goat anti-rabbit IgG (H+L), 
peroxidase conjugated 
1:10,000  1 hr, RT Thermo Fisher Scientific 
Rabbit anti-goat IgG (H+L), 
peroxidase conjugated 




Antibody dilution for Immunofluorescence labelling 
 
  
Primary antibody  Dilution Incubation Supplier 
Mouse anti-FLAG 1:200 1 hr, RT Sigma Aldrich 
Rabbit anti-FLAG 1:200 1 hr, RT Sigma Aldrich 
Mouse anti-PMP70 1:200 1 hr, RT Sigma Aldrich 
Rabbit anti-PEX19 1:200 1 hr, RT Abcam 
Rabbit anti-MAVS 1:200 1 hr, RT Enzo Life Sciences 
Goat anti-catalase 1:50 1 hr, O/N Santa Cruz Biotechnology 
HCV patient antisera 1:50 1 hr, RT Pooled patient serum 
(genotype 2) 
Secondary Antibody    
Anti-mouse/Alexa 488 1:200 1 hr, RT Invitrogen 
Anti-mouse/Alexa 555 1:200 1 hr, RT Invitrogen 
Anti-mouse/Cy5 1:200 1 hr, RT Invitrogen 
Anti-rabbit/Alexa 488 1:200 1 hr, RT Invitrogen 
Anti-rabbit/Alexa 555 1:200 1 hr, RT Invitrogen 
Anti-goat/Alexa 555 1:200 1 hr, RT Abcam 
BODIPY 493/503                                   
(lipid droplet marker) 




Appendix IV: Media and reagents for yeast two-hybrid system 
Table IV: Components of Yeast Media Set 2 & Yeast Media Set 2 Plus 
Yeast Media Pouch  Volume of Media Each Pouch Makes 
Rich Media (Routine Yeast Culturing) 
YPDA Broth  




Minimal Media Single Dropouts (SDO) 
SD/–Leu Broth 
SD/–Leu with Agar 
SD/–Trp Broth 






Minimal Media Double Dropouts (DDO) 
SD–Leu/–Trp Broth 




Minimal Media Quadruple Dropouts (QDO) 
SD–Ade/–His/–Leu/–Trp Broth 




Additional Components in Yeast Media and other reagents 
X-alpha-Gal 250 mg - 
Aureobasidin A 1 mg - 
Cracking buffer stock solution (100 ml) 
 
8 M Urea  
5% w/v SDS   
40 mM Tris-HCl [pH6.8]  
0.1 mM EDTA 
0.4 mg/ml Bromophenol blue  
dH2O to a final volume of 100 ml 
Complete cracking buffer (working solution) 1 ml of Cracking buffer stock solution  
10 l of β-mercaptoethanol  





Appendix V: Yeast plasmid maps 
Yeast plasmids were provided in Matchmaker Gold Yeast Two-Hybrid System 
(Clontech, catalogue number 630489). 
 



















Appendix VI: Mammalian expression plasmid maps 
 


































Appendix VII: Plasmid constructs in this study 
 















Appendix VIII: Target sequences of shRNA OSBP  
 
A gene set of GIPZ OSBP shRNA (6 clones) target to human OSBP (accession# 
NM_002556) were obtained in E. coli glycerol stocks from Thermo Scientific (USA). 
The target gene sequence of each human GIPZ lentiviral shRNAmir individual clone is 
listed below: 
 











Appendix IX: Target sequences of siRNA PEX19 
A SMARTpool of ON-TARGETplus PEX19 siRNA (5 nmol) containing a mixture of 
foure siRNA target to human PEX19 (accessions NR_036493, NM_001193644, 
NM_002857, and NR_036492) was obtained as dry pellet from Dharmacon (part of GE 
Healthcare, USA, catalogue number L-012594-00-0005). The target gene sequences are 
listed below: 






ON-TARGETplus Non-targeting pool (5 nmol, catalogue number D-001810-10-05) was 










Appendix X: Raw data output of the quantification of fluorescence signal using an 
Operetta high-content microscope and analysed with Harmony software.  
1. Huh-7 cells transfected with viperin-mCherry/mCherry control followed by LD 
staining using BODIPY 493/503. 
 
well# 
The number of 
Transfection 
efficiency (%) 










Transfection with viperin-mCherry 
1 2878 760 2118 26.41 3.45 1.06 
2 3828 953 2875 24.90 2.61 0.74 
3 4570 1200 3370 26.26 2.06 0.62 
4 4544 1141 3403 25.11 2.46 0.69 
5 4453 1118 3335 25.11 2.70 0.74 
6 4982 1244 3738 24.97 2.33 0.66 
7 5124 1348 3776 26.31 2.26 0.67 
8 5170 1332 3838 25.76 2.27 0.65 
9 4771 1295 3476 27.14 2.30 0.70 
10 3774 938 2836 24.85 2.94 0.80 
11 3454 860 2594 24.90 2.91 0.82 
12 4280 972 3308 22.71 2.32 0.57 
Average 4319 1097 3222 25.37 2.55 0.73 
Transfection with mCherry control 
1 3500 1718 1782 49.09 1.33 1.22 
2 4749 2317 2432 48.79 1.03 0.94 
3 4891 2340 2551 47.84 1.04 0.92 
4 5037 2406 2631 47.77 1.05 0.92 
5 5164 2570 2594 49.77 1.16 0.97 
6 4795 2247 2548 46.86 1.09 0.92 
7 5122 2411 2711 47.07 1.02 0.85 
8 5235 2655 2580 50.72 0.97 0.95 
9 5193 2523 2670 48.58 0.99 0.90 
10 5052 2428 2624 48.06 0.98 0.86 
11 4890 2309 2581 47.22 1.11 0.94 
12 5141 2373 2768 46.16 0.98 0.80 





2. Huh-7 cells transfected with viperin-GFP/GFP control followed by peroxisome 
staining using mouse anti-PMP70 and subsequently Alexa Fluor 555–conjugated 
goat anti-mouse IgG. 
 
well# 
The number of 
Transfection 
efficiency (%) 










Transfection with viperin-GFP 
1 2572 857 1715 33.32 2.29 0.83 
2 3938 1395 2543 35.42 1.32 0.53 
3 4540 1493 3047 32.89 1.18 0.44 
4 3797 1287 2510 33.90 1.42 0.55 
5 4557 1556 3001 34.15 1.18 0.46 
6 3687 1306 2381 35.42 1.42 0.57 
7 3592 1211 2381 33.71 1.51 0.56 
8 3365 1103 2262 32.78 1.66 0.59 
9 4435 1616 2819 36.44 1.13 0.48 
10 4247 1432 2815 33.72 1.57 0.65 
11 2896 977 1919 33.74 1.89 0.73 
12 3016 1035 1981 34.32 1.98 0.75 
Average 3720 1272 2448 34.15 1.55 0.59 
Transfection with GFP control 
1 3149 1807 1342 57.38 0.90 1.02 
2 4124 2348 1776 56.94 0.67 0.76 
3 4275 2381 1894 55.70 0.67 0.70 
4 4359 2398 1961 55.01 0.67 0.71 
5 4731 2766 1965 58.47 0.59 0.69 
6 4134 2299 1835 55.61 0.71 0.75 
7 4040 2146 1894 53.12 0.75 0.70 
8 4132 2178 1954 52.71 0.72 0.68 
9 4063 2269 1794 55.85 0.70 0.74 
10 3214 1681 1533 52.30 0.91 0.84 
11 3306 1785 1521 53.99 0.83 0.82 
12 3517 1973 1544 56.10 0.90 0.93 






3. Huh-7 cells transfected with viperin-GFP/GFP control followed by catalase 
enzyme staining using goat anti-catalase and subsequently Alexa Fluor 555–
conjugated goat anti-mouse IgG 
 
well# 
The number of 
Transfection 
efficiency (%) 










Transfection with viperin-GFP 
1 8423 2864 5559 34.00 0.54 0.22 
2 6903 2125 4778 30.78 0.70 0.26 
3 6257 1902 4355 30.40 0.83 0.30 
4 6810 2216 4594 32.54 0.71 0.28 
5 6230 2022 4208 32.46 0.85 0.33 
6 6407 1913 4494 29.86 0.91 0.31 
Average 6838 2174 4665 31.67 0.76 0.28 
Transfection with GFP control 
1 6313 3465 2848 54.89 0.40 0.40 
2 6282 3482 2800 55.43 0.40 0.42 
3 6296 3505 2791 55.67 0.41 0.43 
4 6860 3962 2898 57.76 0.36 0.40 
5 7141 3996 3145 55.96 0.37 0.38 
6 7625 4534 3091 59.46 0.34 0.40 






Appendix XI: Additional EM figures  
X-I. Huh-7 cells were transfected with a plasmid expressing viperin-APEX2 following DAB staining. 
 
Viperin-APEX2 (Cell#3) 



















































































































X-II. Huh-7 cells were transfected with a plasmid expressing APEX2 control following DAB staining. 
 























APEX2 control (Cell#4) 













X-III. Huh-7 stably expressing T7 RNA polymerase cell line was transfected with a plasmid expressing viperin-APEX2 and 
pTM1(NS3-5B)/NS5A-GFP following DAB staining. 
 
Huh-7/T7 + viperin-APEX2 (Cell#2) 






Huh-7/T7 + viperin-APEX2 (Cell#3) 





Huh-7/T7 + viperin-APEX2 (Cell#4) 
 Zoom in 
  
 







X-IV. Huh-7 stably expressing T7 RNA polymerase cell line was transfected with a plasmid expressing APEX2 control 
pTM1(NS3-5B)/NS5A-GFP following DAB staining. 
 
Huh-7/T7 + APEX2 control (Cell#2) 






Huh-7/T7 + APEX2 control (Cell#3) 
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